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FORENSIC TOXICOLOGICAL SCREENING AND CONFIRMATION OF  
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by 
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Professor Anthony DeCaprio, Major Professor 
 Novel psychoactive substances (NPS) represent a great challenge to toxicologists 
because of the ability of illicit drug manufacturers to alter NPS chemical structures 
quickly and with ease to circumvent legislation regulating their use.  Each time a new 
structure is introduced, there is a possibility that it has not been previously recorded in 
law enforcement or scientific databases.  Many toxicology laboratories use targeted 
analytical methods that rely on libraries of known compounds to identify drugs in 
samples.  However, these libraries do not include large numbers of NPS, which could 
result in non-identification or detection.   
 High-resolution mass spectrometry (HRMS) has been suggested as a method for 
screening a wide variety of analytes because of its high sensitivity and mass accuracy as 
compared to some other forms of mass spectrometry.  The technique can generate 
characteristic MS/MS spectral data for use in compound identification.  The main goal of 
x 
   
this research was to create a high-resolution mass spectrometry (HRMS) library of NPS 
and metabolites, as well as to validate a method for screening and confirmation of these 
substances.  The study consisted of three main tasks which included; 1) the development 
of a large high-resolution MS/MS spectral library and database, 2) validation of a method 
for screening and confirmation of over 800 NPS and metabolites, and 3) screening of 
blind-spiked and authentic urine specimens to determine real-world applicability of the 
HRMS library and method. 
During validation, several isomeric and structurally related NPS were observed 
which could not be adequately separated using traditional LC methods.  A fourth task 
was therefore added to investigate improved separation using two-dimensional liquid 
chromatography (2D-LC).  Increased resolving power is achieved in 2D-LC through the 
coupling of multiple orthogonal separation systems.  Ultimately, an on-line, 
comprehensive method was developed using orthogonal reversed-phase columns in each 
dimension (RP x RP) for improved separation of isomeric and structurally similar 
synthetic cannabinoids. 
This work can aid laboratories in the identification of NPS through the use of a 
validated LC-QTOF-MS method for screening and confirmation and HRMS spectral 
library.  In instances where isomeric and structurally related NPS are not sufficiently 
separated, RP x RP methods can be explored. 
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1. INTRODUCTION 
1.1 Statement of the Problem 
The emergence of many novel psychoactive substances (NPS) has caused great 
concern in the areas of public health and law enforcement.  NPS include a wide variety of 
diverse compounds such as synthetic cannabinoids, designer opioids, designer 
hallucinogens, and synthetic stimulants for which multiple reports of overdoses and even 
fatalities are available.1-4  These compounds are mainly created with the purpose of 
circumventing existing drug laws.  Manufacturers achieve this goal by simply altering the 
existing structures of NPS and other drugs (i.e., adding or removing a functional group, 
moving a functional group, etc.).  When changes are made to the structures, the new 
compounds no longer match the illegal structure and therefore do not fall under the 
regulation of controlled substance laws.5  As a result, there exist thousands of these 
compounds whose effects can range from having no pharmacological effect to exhibiting 
significant toxicity. 
Changing the chemical structures of these compounds can also make existing 
methods of detection unreliable, since these methods are generally designed to identify 
specific functional groups or structures.6  In the fields of clinical and forensic toxicology, 
the changing structures can especially cause issues when trying to identify which 
compound was used in instances of overdose and emergency department cases in order to 
properly treat patients.  To combat the public health issue of NPS, a reliable method for 
detection and identification of the multitude of NPS potentially present in biological 
specimens must be available.  
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One solution for detecting and identifying NPS that might be missed by other 
screening methods involves the creation of drug libraries for chromatographic and mass 
spectrometric data.  These libraries contain characteristic spectral information generated 
using mass spectrometry (MS) that can help identify NPS in specimens.  Currently, there 
exist a number of libraries for gas chromatography (GC) generated via electron ionization 
(EI) methods, but fewer for liquid chromatography (LC) and electrospray ionization 
(ESI) methods.  For example, Ojanpera, Broecker, and Rosano have all created libraries 
for LC, but they are either mostly theoretical or do not contain many NPS which can 
hinder identification efforts during screening and confirmation.7-9 
The lack of suitable screening methods and support libraries has hindered the 
ability of forensic and clinical laboratories to quickly and reliably identify NPS.  
Typically, these compounds are not detected and identified until there are incidences of 
mass-intoxications or a series of deaths in a singular region.  To rapidly identify such 
incidents as they occur, laboratories need to have access to constantly updated mass 
spectral databases that consist of accurate precursor mass and fragmentation data.10 
1.2 Rationale for Research 
In most toxicology laboratories, drug screening typically involves the use of 
immunoassays.  While these methods are fairly effective in screening for common drugs 
of abuse, they are not well suited for the screening of specimens containing NPS.6,10-12  A 
major goal of the present work was to develop a reference standard-based spectral library 
containing high resolution mass spectrometry (HRMS) data for more than 800 NPS and 
related compounds for use with an LC-quadrupole time-of-flight (QTOF)-MS based 
screening method.  The developed library will help enable the rapid detection and 
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identification of NPS in biological specimens such as urine.  The library can also be used 
with retrospective data searching in order to detect and identify previously unreported 
NPS in specimens.  
Following validation of the LC-QTOF-MS method, blind-spiked urine specimens 
were screened in order to establish the applicability of the method for use with real-world 
specimens.  The specimens used for this part of the research were created in a “blind” 
manner, meaning that they were designed and made by a third party directly involved 
with the analysis. 
It was also important to develop a comprehensive screening and confirmation 
method capable of detecting and identifying several hundred NPS in a single analytical 
run with high specificity at minimal (i.e. low ng/mL) concentrations.  In order to 
accomplish this goal, a rapid, sensitive, and specific LC-QTOF-MS based analytical 
method was developed and validated in conjunction with the compound database and 
HRMS libraries.  In some cases, however, it can be extremely difficult to 
chromatographically separate certain NPS to facilitate identification via mass 
spectrometry, such as in the case of chemically similar and isobaric compounds which 
have the same or significantly related chemical formulae.  This lack of separation can be 
especially problematic when attempting to identify a previously unknown or unreported 
NPS using its mass spectra alone.  To address the challenge presented by lack of 
separation, a two-dimensional (2D)-LC separation system was investigated to separate 
isobaric and non-isobaric co-eluting SC. 
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1.3 Significance of Study 
The body of work presented herein has applicability to forensic science, 
toxicology, law enforcement, and even pharmaceutical development.  The research 
provides a large HRMS library for the identification of over 800 common and uncommon 
NPS, metabolites, and related compounds, generated using ESI.  A validated, 
comprehensive LC-QTOF-MS method for screening and confirmation was also 
developed in conjunction with the library and tested using blind-spiked urine specimens 
to ensure applicability.  A possible solution to the separation challenge presented by the 
co-elution of some NPS, both isobaric and non-isobaric, was also investigated through 
2D-LC analysis of mixes containing co-eluting synthetic cannabinoids (SC). 
The NPS used in the research were identified and selected on the basis of the 
reference standards available from commercial suppliers, as well as citations in 
government documents, peer-reviewed literature, and online drug-user forums.  In order 
to complete this research, the work was divided into three major tasks. 
1.3.1 Task 1 – Development of database and spectral library 
Comprehensive libraries are widely used in analytical toxicology for the 
identification of analytes present in specimens, however, these libraries often do not 
contain many NPS.  In order to identify NPS, a database and library containing 
characteristic spectra of these compounds must be developed.  This report details the 
creation of a database containing over 800 NPS, metabolites, and related compounds, as 
well as the generation and collection of tandem mass spectrometry (MS/MS) data for 
each compound using commercially available reference standards.  The database and 
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library were then used to qualitatively screen blind-spiked urine specimens to ensure 
applicability to real-world samples. 
1.3.2 Task 2 – Comprehensive LC-QTOF-MS method validation 
In order to detect and identify NPS and related compounds in biological 
specimens, a comprehensive LC-QTOF-MS method for screening and confirmation of 
said compounds was developed and validated according to accepted analytical method 
development guidelines. 
1.3.3 Task 3 – Investigation of a 2D-LC method  
Chemically related and isobaric NPS are not uncommon and can present 
challenges to identification using mass spectral data alone.  Throughout the development 
of the library and LC-QTOF-MS method, several such compounds were identified which 
demonstrated similar chromatographic retention times by standard 1D-LC.  
Consequently, 2D-LC was investigated as a possible approach for separation of co-
eluting, chemically related and isobaric SC in order to analyze each compound 
individually.  
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2. BACKGROUND 
2.1 Novel Psychoactive Substances 
Novel psychoactive substances (NPS), also known as “designer drugs”, are 
compounds that have been created to circumvent controlled substance laws.  When the 
Comprehensive Drug Abuse Prevention and Act, also known as the Controlled 
Substances Act (CSA), was passed into legislation in 1970, it created a protocol for 
regulating substances depending on their potential for abuse, potential for addiction, and 
accepted medical usage.  Compounds that had high potentials for abuse and addiction, 
but with no or limited accepted medial use were classified as Schedule I or II substances, 
respectively.13   
Typically, NPS have been synthesized to be structurally or pharmacologically 
comparable to substances that have been identified as Schedule I or II drugs by the U.S. 
Drug Enforcement Administration (DEA).5,10  In the late 1980s, an addition to the CSA, 
known as the Federal Analogue Act, was made to allow for the scheduling of NPS that 
were structurally and pharmacologically “substantially similar” to Schedule I or II 
substances under DEA control.14,15   In order to get around these legal controls, illicit 
laboratories turn to a variety of sources to guide the synthesis of new compounds that are 
not yet under government control.  These sources may include scientific journal articles, 
patents, and books published by pharmaceutical companies, academic or research 
institutions, and other organizations as part of the legitimate scientific process.15   
For classification purposes, NPS are generally divided according to their chemical 
structure.  These classes include, but are not limited to, piperazines, phenethylamines, 
tryptamines, cathinones, opioids, and synthetic cannabinoids.16,17  With the rise of 
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internet access over the past two decades, not only has synthesis information become 
more widely available, but the ability to market and traffic these compounds has resulted 
in an explosion of new, untested NPS on the market.  In addition to the issues with 
legality, NPS also represent a significant risk to public health, given the untested nature 
of these compounds and the potential for adverse effects associated with their usage as 
compared with more traditional drugs of abuse.5,17,18 
One example involves the emergence of illicit fentanyl and its derivatives as part 
of the on-going opioid crisis in the United States.  Fentanyl is a synthetic opioid that is 
approximately 100 times as potent as morphine.  When the analog α-methylfentanyl was 
classified as a Schedule I drug by the DEA in 1981, it took just a few years for another 
analog, α-acetylfentanyl, to appear in 1984, demonstrating the efficiency with which 
illicit drug manufacturers have historically been able to introduce new compounds.5  New 
fentanyl derivatives now appear on the street in a time frame of weeks to months rather 
than years. 
More recently, numerous synthetic cannabinoids have been scheduled, only to 
have analogues appear on the market shortly thereafter.  The synthetic cannabinoid JWH-
018 was sold as a component of herbal incense products such as ‘Spice’ and ‘K2,’ and 
was labeled “not for human consumption” in order to avoid regulation.  However, JWH-
018 exhibits effects at a higher potency than Δ9-tetrahydrocannabinol (THC), which is the 
psychoactive component in cannabis.19  As a consequence of these effects, the DEA 
temporarily placed JWH-018 on the Schedule I list in 2011.  That very same year, 
NutraGenomics, a company that sold synthetic cannabinoids, stopped selling JWH-018 
products.  Instead, they began selling analogs of JWH-018 such as AM-2201, whose 
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structure differs only by the substitution of a fluorine for a hydrogen at the end of the 
alkyl chain.  It was not until 2012 that AM-2201 was controlled as a Schedule 1 
substance.20,21 
Synthetic cannabinoids are not the only class of NPS that have been subjected to fast 
turn-around times by illicit manufacturers.  The phenethylamine compound 4-methyl-N-
methylcathinone, also known as mephedrone, was placed on the temporary Schedule 1 
list in October 2011 because it can cause seizures, increase blood pressure and heart rate, 
result in delusions, and even cause death.22  After permanent scheduling occurred in July 
2012, the compound 4-fluoro-N-methylcathinone (4-FMC) appeared exhibiting similar 
effects after substitution of a fluorine for the para-position methyl group of the benzene 
ring.  This compound was not placed on a schedule by the DEA until March 2014.23 
2.2 Analysis of Drugs in Biological Specimens 
The analysis of drugs of abuse, including NPS, in biological specimens represents 
a large challenge for toxicologists.  Methods for such analyses need to take into account 
not only the analytes of interest, but also any potential interferences or sample 
preparation issues that arise as a result of biological matrices and any endogenous or 
naturally occurring compounds within the specimen. 
The most common matrices encountered in forensic toxicological analyses 
include blood and urine.6,24  Drug concentrations in both matrices can provide valuable 
information about a person’s exposure to a drug, including the identity of the compound 
and, in some cases, an approximate time since exposure.  Analysis of urine also presents 
the option of detecting and identifying metabolites, providing another option for targeted 
analysis in cases when the parent compound cannot be detected using current methods.  
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For example, synthetic cannabinoid metabolites are the most prevalent in urine with 
minimal or even no parent compound present.  The presence of any one of these 
metabolites can then indicate exposure to the parent drug.25   
Both urine and blood are fairly easy to obtain, however, urine collection is much 
less invasive and is thus a very common specimen collected for analyses, especially those 
for antemortem toxicology.  Larger volumes of urine than blood may also be collected at 
any one time, providing a significant advantage in the ability for multiple analyses and 
re-analyses to be conducted on a single specimen.8,26  These benefits make urine a good 
option for screening in clinical and forensic toxicology, including cases such as 
compliance monitoring, workplace drug testing, drug rehabilitation, child welfare, doping 
control, drug-facilitated crime (DFC), driving under the influence (DUI), and more.27   
In clinical and forensic toxicological analyses, urine is an important matrix for 
several other reasons.  A major advantage of conducting analyses with urine is that there 
is a much longer window of detection for drug compounds in the matrix.  This window 
can extend to several days after exposure, as opposed to blood concentrations which 
typically dissipate after a few hours.  Both parent drug and metabolites can often be 
detected in urine providing more targets to analyze to indicate extent and timing of 
exposure.   
Another key advantage to using urine is that drug compounds and their 
metabolites tend to be more concentrated.  As substances are metabolized, they 
accumulate in the bladder and when excreted in urine produce a specimen in which the 
analytes of interest are present at higher concentrations, even if the user was exposed to 
only a low dose of the compound.28  Concentrated samples present a huge benefit for 
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qualitative analysis, however, quantitation for the purposes of correlation to levels of 
intoxication is much more difficult as compared to blood specimens.   
From a sample preparation standpoint, urine is much easier to work with than 
blood since many analyses can be conducted simply by diluting the urine specimen with 
water, as opposed to the sometimes laborious extraction procedures required for the 
analysis of blood (i.e., solid-phase extraction).  Liquid-liquid extraction (LLE), which 
involves several steps in order to selectively remove acidic and basic compounds, can 
also be applied to urine, but for purposes of simplicity, dilution of the specimen is a valid 
technique for urinalysis.29-32  
Consequently, while there are some drawbacks to urine analysis, including the 
inability to correlate drug concentration with levels of intoxication, urine is a very 
valuable matrix for the qualitative analysis of small molecules and drug substances in 
both clinical and forensic toxicology settings.33  
Presumptive screening tests are the first step in the detection and identification of 
analytes of interest in biological specimens.  These screening methods are needed for fast 
delineation of negative samples from positive ones, and to also generate preliminary 
information as to what analytes might be present in any positive specimens.34  Screening 
techniques look for selected analytes present at concentrations above a specific level 
known as the “cutoff” concentration.  A predetermined set of analytes to be searched, or 
screened for, in a single run is known as a drug “panel”.  One of the most commonly used 
panels for drug screening, particularly in workplace drug monitoring, is known as the 
Substance Abuse and Mental Health Services Administration (SAMHSA) Five.  This 
panel includes tests for five common categories of drugs: amphetamines, cocaine, 
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marijuana, opiates, and phencyclidine (PCP).  Other categories that might be included are 
barbiturates, benzodiazepines, hydrocodone, methylenedioxy-methamphetamine 
(MDMA), and methadone.35  However, screening tests typically include few, if any, NPS.  
The need for accurate screening methods cannot be understated, especially since many 
current screening methods are not reliable for use in detecting NPS; oftentimes 
generating a negative result when NPS are actually present.36,37  
The type of screening method used depends on the matrix being analyzed, but 
typical methods for urine specimens include immunoassays to determine which class of 
drugs or NPS may be present, as well as liquid chromatographic (LC) and gas 
chromatographic (GC) methods coupled with mass spectrometry (MS).  Screens that 
result in positive results then undergo confirmatory testing in order to accurately identify 
the compound(s) present and provide quantitation when required.  However, this process 
of screening and confirmation can only be followed if compounds are known and if the 
immunoassay is capable of detecting NPS.36,38 
Immunoassays are a type of immunochemical technique which can provide a 
simple answer to whether or not a specific drug or drug class is present above cut-off 
concentrations.  These assays represent a relatively quick, inexpensive, and user-friendly 
method to determine which drug or class of drug is present, if any at all.12,39,40  When a 
compound is detected and tentatively identified using the results of the immunoassay 
screen, a more selective confirmatory technique, such as mass spectrometry, is then used 
for specific identification.  However, immunoassays use antibody-antigen interactions 
with the analytes of interest serving as the antigen.  The antibodies employed by the 
assays are engineered to detect specific chemical structures characteristic of one or more 
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drug classes. As a result, the slight structural alterations present in NPS can be enough to 
cause a negative result, or no cross-reactivity, regardless of whether the NPS has been 
previously identified or not.12,41  In these instances, specimens are determined to be 
“negative” for drugs and are not submitted for further analyses.39  For example, 
mephedrone and methylenedioxy pyrovalerone (MDPV) are two of the most common 
illicit stimulant-type substances.  When immunoassays were used to try and screen for 
these compounds, there was little to no cross-reactivity demonstrated, meaning that these 
samples would be determined to be negative and likely discarded.41 
A published work by Swortwood et al. sought to determine the level of cross-
reactivity present when 16 commercial immunoassay kits were used to screen for 30 NPS 
from the phenethylamine, piperazine, and tryptamine classes of compounds in human 
serum.  The kits chosen included some designed to detect amphetamine and/or 
methamphetamine-like compounds, as well as a few more specific kits such as one solely 
for the detection of mephedrone and methcathinone.  Ultimately, the commercial kits 
demonstrated little to no cross-reactivity with the NPS chosen for evaluation.  Those that 
demonstrated minimal cross-reactivity did so at concentrations too high to be practical for 
forensic or clinical applications.6   Results from such studies have shown that 
immunoassays, as they currently exist, cannot be reliably used as a presumptive detection 
method for NPS within the same drug class, let alone comprehensively.  While some 
newer immunoassay kits have been designed for the presumptive identification of a few 
NPS classes, specific immunoassays are not widely available for many NPS or their 
derivatives.   
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As the structures of NPS are constantly changing, it is not feasible to create the 
specific antibodies needed for immunoassays rapidly enough to keep pace with 
introduction of new varieties of NPS.  In addition, existing kits cannot be expected to 
demonstrate cross-reactivity with newer NPS as they emerge on the market.  Therefore, 
different methods must be employed for comprehensive screening of NPS in biological 
specimens to account for the lack of reliable detection with immunoassay-type methods. 
2.3 Liquid Chromatography Mass Spectrometry  
In order to overcome some of the limitations of screening with immunoassays, 
and to increase specificity, methods involving GC or LC coupled to MS have been used 
for both targeted and non-targeted screening purposes of analytes in biological 
specimens.  Targeted screening occurs when the presence of a specific known compound 
or set of compounds is searched for in the sample matrix and only MS data associated 
with the selected compound(s) are collected.  Non-targeted analyses involves the use of 
broad screening methods in which all MS data are collected and then analyzed afterwards 
to identify any compounds that might be present.  Non-targeted methods are ideal for 
unknown screening, since analytes that might be of interest are not unintentionally 
excluded during data collection as they might be in targeted methods.28,40   
Both targeted and non-targeted methods involve the chromatographic separation 
of compounds from the specimen matrix, as well as from other compounds that may be 
present in a mixture, before detection by MS.  Within the mass spectrometer, analytes are 
ionized and can be detected as the original molecule, or can be subjected to an energy 
source and broken into fragments.  These fragmentation patterns are characteristic of the 
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original molecule and can then be used for the structural elucidation and identification of 
analytes present.42-45  
When using MS-based techniques in conjunction with either GC or LC separation 
to identify an analyte, mass spectral libraries are required.  Typically, ion fragmentation 
patterns are generated via GC- or LC-MS and these patterns are then compared with 
those present in existing libraries which can contain information for several thousand 
different compounds.42,46,47  
Gas chromatography with mass spectrometry (GC-MS) has been described as the 
“gold standard” for drug screening and identification.  As an established and well-
understood technique, GC-MS is used by many labs for the detection and identification of 
NPS and many other compounds in both toxicological and seized material analyses.  
Large spectral libraries containing tens of thousands of spectra have been built over the 
course of 40+ years using electron ionization (EI) techniques; a hard ionization technique 
which typically produces fragment-rich, characteristic spectra.42,48  In the 2017 iteration 
of the EI mass spectral library released by the National Institute of Standards and 
Technology (NIST), over 260,000 unique compounds are represented by over 300,000 EI 
spectra.49   
While there exist large databases of reproducible spectral data generated through 
the use of EI sources, the use of GC-MS is not without its restrictions, particularly in the 
types of analytes that can be evaluated with this technique.  In order to generate spectra 
using EI sources, compounds of interest must be volatile, non-polar, and thermally stable.  
Lengthy sample preparation processes such as derivatization are sometimes required to 
make some compounds suitable for analysis using EI, while the above suitability criteria 
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for analysis might prevent some analytes from being detected at all.50  The lengthy 
sample preparation restriction is especially true for the analysis of urine specimens that 
require cleavage of the glucuronic acid or sulfonate acid conjugates of the phase I 
metabolites that may be present during analysis via GC.8 
In contrast, liquid chromatography with mass spectrometry (LC-MS) is suitable 
for the analysis of non-volatile, polar, and thermally labile compounds and does not 
mandate that specimens undergo derivatization or other chemical modifications prior to 
analysis.8,36,38,42,47,51  Electrospray ionization (ESI), commonly used in LC-MS, is a soft 
ionization technique that is effective in ionizing analytes contained in aqueous specimens 
without requiring the derivatization often needed in GC-MS.  As a result, LC-MS 
screening has increased in popularity for clinical and forensic toxicological case work 
because of the increasing polarity and low volatility of many new relevant substances 
which are difficult, if not impossible, to analyze via GC-MS.   
2.3.1 Electrospray Ionization Spectral Libraries  
 Since the use of LC-MS for screening is much newer than the use of GC-MS, the 
spectral libraries that have been created are not as extensive.  The very nature of the 
ionization techniques used with LC-MS are also not as reproducible as those used with 
GC-MS, and require complete standardization of source parameters in order for libraries 
to be used across different laboratories and instruments.42,50,52  Additional work is 
required in the development of large, comprehensive mass spectral libraries to support 
the identification of compounds using LC-MS methods and their corresponding 
ionization techniques, particularly electrospray ionization (ESI).25,28,45,53 
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Techniques using LC-MS for identifying and quantifying NPS require the use of 
libraries with known compounds and their known masses, spectral data, or ion 
transitions.18,54  If a NPS has not been previously included in such a database or library 
then detection may be possible with a non-targeted analytical method, however, 
identification and thus quantification will not be achievable.10,18  Lack of analyte 
detection due to absence in a database or library is also true for NPS metabolites, which 
are of particular interest in forensic toxicological analyses, especially those from the 
synthetic cannabinoid classes which can be abused in the same manner as the parent 
compound.55  
 Electrospray ionization (ESI) is a soft ionization technique commonly used with 
LC-MS to generate ions detectable by the MS detectors.  Libraries created using ESI 
coupled to tandem mass spectrometry (ESI-MS/MS) have been shown to be much more 
reproducible than those created with “in-source” collision induced dissociation (CID), 
such as with methods utilizing a single mass analyzer, so long as collision energy and 
collision gas pressure are consistent.47,53,56,57  This is because the first mass analyzer can 
be used as a filter to isolate a particular range of masses and exclude ions from 
background contaminants and matrix components before CID fragmentation occurs.  
Selective ion fragmentation then occurs in the collision cell placed after the first mass 
analyzer.  The resultant product ions then move through the second mass analyzer where 
they are analyzed using mass-to-charge (m/z) ratios.53,56,58  The first mass analyzer can 
also be used to detect analytes before undergoing a mass dependent scan which provides 
the MS/MS spectra needed for identification via a library search.38  The use of ESI-
MS/MS has the added benefit of virtually always revealing the molecular ion (i.e., the 
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ionized original compound) in resultant spectral data, leading to increased confidence in 
identification from library searching.42,54 
Libraries for ESI-MS/MS techniques are typically generated using triple 
quadrupole (QqQ) or hybrid quadrupole time-of-flight (QTOF) mass analyzers with 
fragmentation patterns collected at more than one collision energy to account for 
differences between mass analyzers and brands.42,47,53,58  Most ESI libraries exist in-
house, but there have been published works creating reproducible and shareable 
libraries.8,9,28,34,36,38,50,57,59,60   
The poor availability of reference standards for many NPS and metabolites 
presents a large challenge to forensic toxicology laboratories when trying to detect and 
identify both known and unknown NPS and other xenobiotics.  In an attempt to address 
this issue, the Ojanperӓ group created a database containing theoretical monoisotopic 
masses for over 7,500 toxicologically relevant compounds and metabolites.  Their 
database was then used in conjunction with a method for LC-TOF-MS and applied to 
postmortem human urine specimens.  Each search of the database resulted in no more 
than three potential elemental formulas which resulted in a significantly more 
manageable list of possible identifications.  The greatest asset to this database was that it 
could be updated with new formulas and theoretical masses as soon as they appear in the 
literature or are noted by law enforcement and/or public health officials.27  While this 
approach simplified the list of possible identification significantly, the use of accurate 
mass data alone was not enough to explicitly identify the compounds present.  Retention 
data could have been used to corroborate identifications, but reference standards would 
have been needed in order to acquire those data.8   
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Another approach to theoretical databases was employed by Polettini et al. when 
they developed a screening procedure utilizing a subset of compounds curated from those 
available in PubChem.  The PubChem database contained accurate masses for over 
50,000 toxicologically relevant compounds including pharmaceutical and illicit drugs, 
pesticides, poisons, and over 6,000 metabolites.  The database was then used to screen for 
compounds present in a variety of postmortem biological specimens.  The resulting 
number of possible identifications from this work ranged from one to 39 per analyte.60  
While Polettini’s work indicated the potential of a theoretical database to help narrow 
down possible identifications, unambiguous identifications could not be generated for 
each analyte.  Other information that would assist in improving the confidence of an 
identification include chromatographic retention data, isotope patterns, and/or 
fragmentation patterns.60,61   
Another possible way to address the issue of the lack of available reference 
standards, especially of NPS metabolites, involves the use of in silico methods to predict 
metabolites of certain compounds and what their characteristic fragmentation patterns 
might be.  For example, Pelander et al. used metabolite prediction software to predict the 
phase I metabolites of the anti-psychotic drug quetiapine.  Using another software tool, 
fragmentation patterns of these metabolites were also predicted.  The resulting data were 
used to screen authentic urine specimens in which several of the predicted major 
metabolites were detected, however, there were several metabolites detected that had not 
been predicted, particularly the hydroxylated metabolites.  The predicted fragmentation 
patterns were also helpful in differentiating between isobaric metabolites, but the work 
was not conclusive enough to serve as a reliable substitute for identification using CID 
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spectral profiles collected from reference standards.62  Predicted fragmentation patterns 
would not be suitable for use in forensic cases as they would not meet standards for 
admissibility in court. 
In a recent paper by Colby et al., the efficiency of using certain workflows for 
screening via LC-QTOF-MS was evaluated when using databases and/or spectral 
libraries to identify compounds of interest.  Four different workflows were assessed in the 
identification of 170 drugs and metabolites: one targeted and three involving “suspect 
screening.”  The first involved analysis of a reference standard followed by targeted 
searching of the sample.  In contrast, suspect screening does not utilize a reference 
standard but instead bases identification on predicted and/or intrinsic characteristics such 
as accurate mass, isotope pattern, and product ion spectrum.  The study focused on which 
combination of these three characteristics carried the most weight when identifying 
compounds without direct use of a reference standard.  It was found, unsurprisingly, that 
the most effective methods included the use of product ion spectra that had been 
previously collected from reference standards and included in a searchable library.  When 
product ion spectra were utilized, in addition to accurate mass and isotope patterns, over 
80% of the drugs in human urine specimens were correctly identified with a minimal 
number of false identifications.  These results, combined with the fact that retention times 
were not required, indicated the potential of building large screening methods and 
libraries for screening of toxicologically relevant compounds, including NPS.63   
The utility of spectral libraries for identification of compounds in screening 
procedures has been demonstrated in other works as well.  Lee et al. created a screening 
method for toxicologically relevant compounds present in urine which utilized a spectral 
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library developed with the use of reference standards.  Spectral data were collected using 
ultra performance liquid chromatography (UPLC) coupled to a TOF MS then searched 
against a library containing spectra for 300 compounds, 102 of which were metabolites.  
The substances in the library originated from pure reference standards, pharmaceutical 
materials, and from metabolites present in authentic urine specimens.  The library was 
created using retention data, exact mass, and fragmentation patterns collected at two 
collision energies (10 and 45 eV) for each of the compounds.  The inclusion of spectra 
containing a pseudomolecular ion in addition to one CID fragmentation pattern provided 
additional confidence in the identification of the compounds present in the samples and 
improved the specificity of the method.50 
The largest MS library, containing CID mass spectral data for over 2,500 
toxicologically relevant substances, was created by Broecker et al.  A hybrid quadrupole 
time-of-flight mass spectrometer (QTOF-MS) was used to collect the CID fragmentation 
patterns generated in the collision cell located between the quadrupole and the TOF 
analyzer.  Substances were subjected to three different collision energies (10, 20, and 40 
eV) and the data were then curated and checked for suitability before being added to an 
existing database of theoretical fragment masses and molecular formulas for 7,500+ 
additional toxicologically relevant substances.  The compounds in the combined spectral 
library and database represented substances such as illicit and therapeutic drugs, 
pesticides, alkaloids, and other toxic chemicals and metabolites.7  However, there was not 
a significant presence of NPS and NPS metabolites as is true for many other existing ESI-
MS/MS libraries and databases.  This lack of NPS representation in existing libraries can 
hinder the detection and identification of such substances in systematic clinical and 
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forensic toxicological analyses.  Thus the development of larger, more comprehensive 
libraries that include NPS is needed to improve detection and identification of 
compounds during screening efforts.   
Historically, QqQ-MS, a unit resolution technique, is more often used for drug 
screening than HRMS because of its lower cost of operation and its robustness.  
However, since the mass spectra generated are of low resolution, compounds must be 
known prior to analysis.  Libraries for QqQ-MS are built by collecting data generated 
from multiple reaction monitoring (MRM), which is suitable for use with targeted 
screening methods.7,37,54  High resolution MS methods, such as those utilizing QTOF-MS 
are recognized as having higher resolution and allowing for the collection of all ion 
spectra, an approach that is ideal for non-targeted screening.  High-resolution mass 
spectra can also be collected for the screening of known targets using data-dependent 
acquisition methods.7,36,40,64  Compounds are then identified using corresponding libraries 
through the comparison of accurate masses or the characteristic spectral data.8,65  
 Methods using QTOF mass analyzers are recognized as having high mass 
accuracy and high-resolution capabilities, meaning that collected data have mass 
accuracy better than 5 ppm and resolution greater than 20,000 full width half maximum 
(FWHM), respectively.  However, high mass accuracy is not required for a method to be 
considered high-resolution.28  These qualities are vital in building HRMS libraries to 
ensure the collection of accurate masses, as well as the ability to resolve isobaric 
compounds or those with very similar chemical formulas and similar product ion 
fragmentation patterns.  An added benefit of using QTOF mass analyzers is that the 
accurate masses of analytes can be recorded over a wide range of abundances.  The 
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ability to record over a wide abundance range is especially important for conducting both 
targeted and non-targeted analyses, which enables scientists to conduct screening for 
known analytes and also to collect ion data that can be retroactively searched for 
previously unknown substances as libraries are updated.18,28,66  The ability to conduct 
non-targeted analyses and collect data that can be searched later on are crucial to the 
future of forensic toxicological analysis of NPS, as the potential to create new drug 
compounds within synthetic chemistry is practically unlimited.67,68 
Employing QTOF mass analyzers also enables users to search for common 
fragments or use mass-defect filtering to investigate unknown compounds that share 
common functional groups or structural components with known NPS.69  When such 
collected spectra are searched against a library, a “hit list” of possible compound 
identities is generated.  These lists are comprised of “scores” which reflect the likelihood 
that the collected spectra and the library spectra are from the same compound.42,43,47  In 
instances where the collected spectrum is from a compound not yet included in the 
library, modern algorithms will include library compounds on the “hit list” that may 
differ by a simple insertion, deletion, or replacement of a structural group.  These 
“nearest neighbor” identifications are extremely useful when screening unknown NPS 
and are much more impactful when using HRMS spectra.44  
There are two main search methods used when comparing collected spectra and 
library spectra: forward and reverse searching.  Forward searching involves comparing 
the collected spectrum of an unknown with spectra contained in a library.  The base mass 
peak or each ion within the spectrum is identified and then compared to those contained 
in the library for potential matches.  Reverse searching is essentially the same technique 
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except that the collected spectrum is searched through using spectra in the library.  More 
simply, in forward searching, the collected spectrum is searched for in the library spectra 
and in reverse searching library spectra are searched for in the collected spectrum.7,48 
2.4 Co-elution Challenges 
Even with the increased resolving power of HRMS, there may still be instances in 
which isobaric compounds or those that are too structurally related to be identified solely 
by mass spectral data are present in specimens.  This is particularly true with NPS as 
many are simple variations on existing compounds with minor or novel structural 
alterations.  In cases of mixtures or true unknown substances, resolution of compounds 
using spectral data alone may not be possible.   
Typically, chromatographic separation systems are employed to isolate individual 
compounds prior to MS analysis.  However, there are instances in which the structural or 
physiochemical differences between NPS are so slight that they cannot be separated using 
traditional chromatographic techniques (i.e. LC or GC) and will therefore not be detected 
as individual compounds.70-72  To resolve this issue, two-dimensional liquid 
chromatography (2D-LC) has been proposed as a method to improve separation and 
resolution of complex mixtures prior to further mass spectral analysis.73,74  
2.4.1 2D-LC 
When conducting toxicological analyses that rely on searching MS library data, 
screening for unknown or previously unreported NPS can be problematic because of the 
large number of isomers and chemically related compounds that exist with similar 
accurate masses, fragmentation patterns, and/or chromatographic retention times.  The 
alteration of a single functional group may result in the inability to separate such 
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compounds using traditional chromatographic methods which can further hinder proper 
detection and identification of each as an individual substance.  As more and more NPS 
are added to an analytical method in order to keep up with the growing number of 
possible analytes and the increasing complexity of mixtures, more separation issues are 
likely to arise.  These challenges to separation and thus identification will only increase 
as more NPS are synthesized and introduced to the illicit market.12,70,72,75,76  In these 
instances, it is important to perform an effective initial separation so that each substance 
may be analyzed via MS individually.45,77  One proposed solution to issues of coelution is 
the use of two-dimensional liquid chromatography (2D-LC).    
 Two-dimensional LC combines the separation and resolving power of two 
independent, orthogonal LC dimensions in order to improve chromatographic separation 
of analytes from matrices and/or each other and to increase the maximum number of 
peaks that can be equally resolved in a separation space, also known as peak capacity.78  
The two dimensions can consist of several columns, but typically each dimension 
contains a single column with different selectivity, or orthogonality, than the other.71,79,80  
There have been various applications of 2D-LC ranging from analysis of proteins and 
peptides, determination of pesticides, separation of chiral compounds, and the separation 
of pharmaceuticals and other small molecules.  Several of these applications also include 
using the improved separation and resolving powers to differentiate analytes of interest 
from toxicologically relevant biological matrices such as urine, whole blood, serum, and 
saliva.72,76,78,79,81-84 
 The ability of a chromatographic system to separate constituents of a mixture is 
commonly described by its peak capacity, which is a measure of the theoretical maximum 
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number of peaks that can be equally resolved within a separation space.  Traditional 1D-
LC systems generally achieve peak capacities of only a few hundred, whereas 2D-LC can 
achieve maximums over 1000.  As peak capacity increases, so too does the resolution of 
the separation system.78,85,86   
The most basic model for calculating peak capacity is for the “comprehensive” 
2D-LC approach (discussed below), where the peak capacities of each dimension are 
multiplied as demonstrated in Equation 1, where nc,tot is the theoretical peak capacity of 
the 2D-LC system, and 1nc and 2nc represent the peak capacities of the first and second 
dimensions, respectively.87  
 
nc,tot ≈ 1nc x 2nc     (1) 
 
However, there is no general consensus as to how peak capacity can be best calculated, 
since the ideal capacity values are never fully realized as a consequence of the unique 
designs and applications of each 2D-LC system.78,86  In contrast, “heart-cutting” 2D-LC 
techniques (discussed below) do not require peak capacity calculations since the only 
relevant chromatographic fraction is the targeted one, and thus calculations of peak 
capacity, which are employed to determine the maximum number of peaks that can be 
resolved in a separation window, hold no significant value.79 
 In addition to the increased power of separation, one of the greatest advantages of 
2D-LC is the decreased amount of time needed for sample preparation.  The potential 
loss of analytes during preparation can also be minimized by using 2D-LC techniques in 
which the first dimension is used to separate analytes of interest from complex matrices, 
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as well as from other analytes present which can also be particularly useful when 
removing endogenous compounds from the biological matrices relevant to toxicological 
analyses.88-91  Using a dimension in which both cleanup and initial separation can be 
conducted also minimizes the amount of time required for sample preparation prior to 
analysis.92   
 There are two main modes of operation for 2D-LC: heart-cutting (LC-LC) and 
comprehensive (LC x LC).  Heart-cutting is a method which involves taking selected 
fractions or peaks of the effluent from the first dimension (1D) and subjecting these to 
additional separation in the second dimension (2D) with the remaining effluent going to 
waste.  Heart-cutting is useful for conducting targeted analyses of analytes in complex 
matrices and biological specimens, since the known analytes or peaks eluting from 1D are 
the only fractions subjected to further separation by 2D.93-96   
 Heart-cutting methods are commonly used in pharmaceutical laboratories to help 
separate target compounds and any possible impurities of a developed drug compound.  
Sandra et al. used a multiple heart-cutting (mLC-LC) system for the characterization of 
antibody-drug conjugates (ADCs) consisting of monoclonal antibodies, cytotoxic small 
molecule drugs, and linkers which are used in the treatment of tumor cells.94,97  The 
mLC-LC configuration involved using multiple sample loops, or parking decks, between 
the dimensions where up to 12 fractions from 1D could be stored before transfer to 2D for 
analysis.  Multiple heart-cutting was a very effective method, but the fractions that were 
selected to go to the “parking decks” had to be known or expected prior to analysis.97  
Because peaks of interest must be known in order to be transferred to 2D in LC-LC, it is 
extremely difficult to automate a heart-cutting 2D system.  Another potential issue is that 
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if the incorrect fraction is collected, peaks of interest could be lost between 
dimensions.86,98  
 Pandohee et al. used a heart-cutting method with two RP columns in order to 
separate the constituents of cannabis/hemp plants.  This matrix is extremely complex, 
which complicates work in pharmacological settings where isolation of the pure 
compounds is important.  Fractions of 200 µL were collected after they eluted from 1D 
before injection into 2D.  Once the sample had gone through separation in both 
dimensions, another sample could be injected.  However, this process resulted in a total 
analysis time of 12 h, which is not conducive to routine screening, nor does it lend itself 
to automation.99 
 The separation of samples containing illicit drugs has been improved through the 
use of LC-LC.  Andrighetto et al. used an in silico technique to optimize a 2D separation 
system with C18 columns in both dimensions in order to differentiate ephedrine and 
pseudoephedrine-based methamphetamine in seized samples.  Following optimization, 
authentic samples were analyzed and co-eluting peaks were transferred to the second 
dimension.82  However, selection of the peaks to be transferred to the second dimension 
used simulation data, which presents the risk of missing potential peaks of interest should 
the simulation be incorrect. 
 Heart-cutting 2D-LC can be a very valuable tool for improving separation of 
compounds from complex matrices and mixtures.78  The potential peak capacities that 
can be achieved through heart-cutting methods are impressive, however, there are some 
clear drawbacks which do not make it an ideal choice for all multi-dimensional 
separation applications.  In particular, LC-LC is not the best choice for the separation of 
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mixtures in which there may be unknown targets or in situations where automation is 
desired.  Long analysis times are also common with heart-cutting methods which can 
slow down productivity.78,86,100-102  
 Alternatively, comprehensive 2D-LC, referred to as LC x LC, offers greatly 
improved peak capacities as compared to 1D-LC while also allowing for full automation 
and analysis of the entire sample.  Comprehensive 2D-LC methods involve the complete 
transfer of the 1D effluent to 2D for separation, which is ideal for non-targeted analyses 
and samples with low concentrations of analytes, since the entire effluent from the first 
dimension undergoes separation in the second dimension, thus preventing the loss of any 
sample that might occur when sampling only certain fractions and/or peaks as in LC-
LC.85,98,103,104  Another key benefit to transferring the entire effluent from 1D to 2D is 
observed when separating extremely complex mixtures such as plant material associated 
with pharmaceutical or therapeutic samples.  In these instances, constituents that are 
considered to be the target fractions could be even more difficult to isolate because of 
interferences from endogenous compounds or other interfering analytes in the sample.105  
The potential for contamination is also minimized in a comprehensive system since 
samples do not leave the system once injected; typically going from the injection, through 
the first dimension then into sample loops before elution on to the second dimension.78,85  
The ability to easily combine LC x LC systems with conventional LC detectors 
such as MS and UV is also an important advantage over LC-LC methods.  Many LC x 
LC systems include a reversed-phase (RP) column in the second dimension which uses 
mobile phases conducive to detection with MS.106  Using RP columns in each dimension 
is a popular choice for several 2D-LC applications as result of easier method optimization 
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because of mobile phase compatibilities and the ease with which MS detectors can be 
coupled, resulting in robust methods, particularly for use with pharmaceuticals and 
derivatives.81,85,97,104,107-109 
 Earlier applications of comprehensive 2D-LC included the use of the first 
dimension column as an on-line extraction step before achieving chromatographic 
separation in the second dimension column.  Rao and Shinde used a restricted access 
material (RAM) column followed by a RP C18 column for the LC x LC determination of 
antiretroviral drugs in rat serum and urine.  Liquid-liquid extraction (LLE) and solid-
phase extractions (SPE) were first tried with the samples in an off-line technique, 
however, acceptable recoveries were not achieved for low concentrations of drugs.  These 
extraction procedures were also tedious to conduct.  Comprehensive 2D-LC was then 
successfully investigated for rat serum and urine samples by employing a RAM column 
in 1D as an on-line extraction step to remove proteins and large endogenous molecules, 
followed by chromatographic separation in 2D.  The method enabled fast extraction and 
separation of the samples within 20 min with only a filtering step required prior to direct 
injection into the 2D-LC system.  The method was also sensitive enough to detect low 
ng/mL concentrations of the antiretroviral drugs in rat plasma and serum.89 
 Mallet et al. used a comprehensive 2D-LC method, called sequential 2D 
extraction, in which the first dimension included a sample extraction technique with the 
purpose of providing decreased sample preparation time and increased separation within 
a single analysis.  A mixture of common illicit drugs and drugs of abuse, including 
amphetamine, MDMA, mescaline, lidocaine, cocaine, THC, and heroin, were spiked into 
urine and subjected to the 2D extraction and analysis.  The method was successful in 
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extracting and detecting the illicit drugs and drugs of abuse at concentrations as low as 10 
pg/mL.  Limits of quantitation were set to 1 ng/mL in a 1 mL urine sample and the 
average recovery was 88% achieved within a 15 min time frame.92 
 The LC x LC methods can also be implemented with analytical columns in each 
of the dimensions.  One such example was presented by Holčapek et al. for the analysis 
of lipidomic samples.  A RP column was placed in the first dimension followed by a 
hydrophilic interaction chromatography (HILIC) column in the second dimension.  The 
RP column enabled the separation of lipid species using the hydrophobic part of the 
molecule first, then any co-eluting species were separated in the second dimension on the 
basis of their differing polarities.  Although Holčapek’s work was a proof-of-concept 
study, it did demonstrate the potential of a comprehensive HILIC x RP method for the 
identification and lipids from human plasma and porcine brain samples.  In total, 143 
lipid species were identified in a run of  <2.5 h.110  
 Additional column combinations that have been reported in LC x LC methods, 
including size exclusion chromatography (SEC) x RP, ion-exchange chromatography 
(IEX) x SEC, IEX x RP, normal-phase (NP) or HILIC x RP, and HILIC x SEC.  
However, the most common combination is that of two reversed-phase columns (RP x 
RP).108  Combinations of two RP columns have received a lot of attention because of the 
potential for high peak capacities and suitability for use with pharmaceuticals and other 
small molecules.  Although combinations using RP columns in each dimension may not 
be highly orthogonal, variation of mobile phases and gradients can result in desirable 
peak capacities and resolving power for analytes of interest.111   
31 
   
 Methods using RP x RP have been used for the determination of antioxidants, 
separation of biological compounds, food analysis, and analysis of natural 
products.108,112,113  Natural products typically originate from plant materials which present 
a very complex sample matrix and contain biologically active substances, thus making 
them of interest for toxicological analyses.  Natural products present in Chinese herbal 
medicine (CHM) are of particular importance.105,114,115  The effectiveness of CHMs is 
believed to come from the combined properties of multiple biologically active 
components. Therefore CHMs often present a complex mixture of compounds for 
analysis that requires adequate separation before each can be identified.116  For example, 
Hu et al. developed a LC x LC system for the separation of Rhizoma chuanxiong and 
Angelica sinensis which represent two of the most commonly used drugs in the 
prescription of CHM.  The method used a cyano (CN) column in the first dimension to 
separate polar compounds and a silica monolithic ODS column in the second dimension 
for the separation of the less-polar compounds.  About 120 compounds from R. 
chuanxiong and 100 in A. sinensis were successfully separated.115  
Krieger used an RP x RP separation method in the analysis of Si-Wu-Tang; a 
CHM made from four different herbs, each with its own set of characteristic compounds 
that are used for identification purposes.  The high complexity and variability within Si-
Wu-Tang make it an ideal choice for separation using 2D-LC.  Detection was conducted 
with QTOF-MS and peaks were matched with library templates for each of the individual 
compounds.  Over 75% of the template peaks were matched to those detected in Si-Wu-
Tang, demonstrating the utility of this RP x RP method in the analysis of CHMs.105 
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 There have been many successful applications of LC x LC, however, the 
development and optimization of such methods present many challenges.  The two 
dimensions used must be compatible while also being orthogonal.  In order to achieve 
this goal, there are a multitude of parameters in each dimension, including column type 
and particle size, mobile phase selection, analysis time, gradient, and flow rate, that must 
first be optimized individually before they are optimized as part of the whole 
system.73,85,98,108   
The parameter that can be most influential and the most challenging to optimize is 
the solvent selection for the mobile phases in each dimension.  Solvent selection is 
particularly difficult when two different types of columns are used in the two dimensions 
(e.g., normal-phase and reversed-phased) that require different solvent types that may be 
incompatible.85,98,111  If solvents are not compatible, columns could be damaged by the 
use of improper solvents.  A major risk is that compounds separated in the first dimension 
can remix during transfer to the second dimension, or might not be eluted onto the second 
dimension at all, and thus 2D separation will not occur.85,106  
Another potential cause of effluent remixing can occur when the sampling time in 
the second dimension is longer than the peak width of the effluent transferring from the 
first dimension, thus causing separable peaks to elute in the same fraction.  The 
discrepancy between sampling time and peak width is referred to as “undersampling” and 
can lead to decreased peak capacity of the method.  Undersampling can be minimized 
through the appropriate selection of column dimensions for use in the second dimension, 
as well as optimization of the amount of time set for collection of the effluent from the 
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first dimension before transfer to the second, also referred to as the sampling 
time.78,85,98,117   
Dilution of an analyte or analytes is an inherent issue of chromatographic methods 
as the sample disperses along the column.  Negative effects of dilution are further 
compounded when two LC systems are combined, as in 2D-LC.  Solvent gradients can be 
used in each dimension as a way to minimize the effects of sample dilution.74,78  In RP x 
RP systems, gradients can also be used to improve separation when the columns chosen 
are not completely orthogonal.111  The length of time over which a gradient runs, referred 
to as the “gradient stop time,” is the maximum duration of the gradient in the second 
dimension.  The gradient stop time must always be less than the modulation or sampling 
time which is equal to the gradient stop time plus the time needed for the second 
dimension column to equilibrate.86    
Second dimension gradients in LC x LC are used to generate higher peak 
capacities, eliminate possible carryover effects, and to improve bandwidth suppression.  
The samples being analyzed by the 2D-LC system should be taken into consideration 
whenever a gradient type is chose and optimized.  Overall, gradients should be quick and 
have a steadily increasing slope to allow for better separations.  The use of gradients also 
ensures effective separation of complex mixtures, as the components are likely to have a 
variety of retention factors that must be accounted for.70,73  In 2D-LC, there are four 
common gradient types employed in the second dimension (Figure 1); full, segment, 
shift, and parallel.108   
Full gradients cover a very steep and wide gradient over the span of a very short 
amount of time.  These gradients provide high bandwidth suppression, which leads to 
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greater peak capacities.  However, there is a greater chance of carry-over, or wrap-
around, from compounds that are more strongly retained.  Another drawback of using a 
full gradient, particularly with RP x RP methods, is that compounds with lower (or 
higher) retention in the first dimension also have lower (or higher) retention in the second 
dimension.  These retention behaviors result in a diagonal appearance of eluted 
compounds in the final 2D contour plot.108 
Segment gradients are less steep than full gradients but still have significant 
bandwidth suppression effects, leading to increased peak capacity.  Instead of using a 
wide, continuous gradient over the entire separation period, a lower gradient coverage is 
used in the early section of the separation and a higher gradient coverage in the later 
section.  The alteration of gradients throughout the separation, though minimal, results in 
lower probabilities of wrap-around effects since the gradient range is not continuous as in 
a full gradient.108 
A “shifted gradient” is implemented when the second dimension uses a narrow 
gradient with a changing range or concentration throughout the analysis time.  Shifted 
gradients facilitate compression of peak bandwidths and increased peak capacity in the 
second dimension.  The continuous changing of the gradient minimizes wrap-around 
effects and demonstrates higher peak capacities than the other gradient types.  Through 
the use of a shifted gradient, more of the 2D separation space can be used, making it a 
valuable technique for improving separation and spreading peaks further apart.104  When 
a shifted gradient is used, though, there is the possibility that a peak from a single 
compound might elute in two adjacent separations, thus appearing to have two different 
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retention times.  Care should be taken to ensure that such peaks are correctly assigned as 
to one compound.86   
Parallel gradients are quasi-isocratic gradients which utilize a longer second 
dimension elution time and eliminate the need for post-gradient equilibration time, but 
result in larger bandwidth and lower peak capacities.  Parallel gradients are best used in 
accordance with the retention characteristics of the first dimension separation which 
requires more time and effort to optimize before the gradient can be used effectively.108 
Second dimension gradients in LC x LC are used to increase peak capacities, 
eliminate possible carryover effects, and to improve bandwidth suppression.  The 
samples being analyzed by the 2D-LC system should be taken into consideration 
whenever a gradient type is chosen and optimized.  The number of parameters that must 
be optimized during development of a 2D-LC method is several times greater than the 
number of parameters in a traditional 1D separation.  However, once a comprehensive 
LC x LC method has been optimized it can be easily automated for use in high 
throughput applications.   
The improved separation and resolving powers offered by 2D-LC can make such 
methods extremely attractive for the analysis of complex samples and mixtures.  Benefits 
of 2D-LC systems include increased peak capacities,70,103,118 separation of isomers,89 and 
increased separation of compounds and metabolites.72,88  Other important attributes of 
2D-LC include decreased sample preparation time and decreased potential for loss of 
analytes during preparation as the first dimension can be used to separate proteins and 
other unwanted substances from analytes, which is especially important in removing 
endogenous compounds from the biological matrices common in toxicological 
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analyses.18,78,88-90,94  There are currently no reports in the literature on the separation of 
coeluting or isomeric NPS using 2D-LC.  Examples of existing heart-cutting and 
comprehensive methods are given in Table 1 (see below).    Further investigations into 
the use of 2D-LC to resolve complex mixtures of NPS in biological specimens is 
therefore a major goal of the present project. 
 
Figure 1. Second-dimension gradient types over time for LC x LC separations: A) full gradient, B) 
segment gradient, C) parallel gradient, and D) shift gradient. 
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Table 1. Examples of 2D-LC method applications found throughout the literature. 
Matrix 2D-LC Mode Columns Detector(s) Reference 
ADCs LC x LC HIC x RP UV-MS [119,120] 
ADCs LC - LC SEC - RP DAD; MS [94] 
antibody digest products LC x LC 
SCX x RP; 
RP x RP; 
HILIC x RP 
UV; MS [121] 
antiretroviral drugs LC x LC RAM x RP ion-trap MS [89] 
benzenes LC x LC RP x RP UV [122] 
cannabinoids LC - LC RP - RP ESI-TOF-MS [99] 
CHMs LC x LC HSA x RP Ion-trap MS [123] 
drug impurities LC x LC RP x RP DAD; TOF-MS [124] 
drug metabolites LC x LC RP x RP ESI-MS/MS [72] 
E. coli and S. cerevisae metabolomic 
products LC x LC 
SCX x 
HILIC ESI-MS/MS [88] 
E. coli proteins LC x LC SEC x RP ESI-MS [84] 
EO-PO (co)oligomers LC x LC NP x RP ELSD [125] 
isomeric oligostyrenes LC x LC RP x RP UV [126] 
isomeric oligostyrenes LC x LC RP x RP UV [127] 
lipids LC x LC RP x HILIC ESI-MS/MS [110] 
low MW components of maize LC x LC RP x RP UV [128] 
oligostyrenes LC x LC RP x RP UV [129] 
paracetamol and ketorolac enantiomers LC - LC RP x chiral Ion-trap MS [93] 
peptides LC - LC RP - RP MALDI-TOF-MS [130] 
peptides LC - LC SCX - RP; RP - RP UV-MS [
131] 
peptides LC x LC SEC x RP ESI-MS [132] 
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peptides LC x LC RP x HILIC UV [133] 
pharmaceuticals mLC - LC RP - RP UV [97] 
pharmaceuticals and citrus oils LC x LC NP x RP DAD [134] 
phenolic antioxidants LC x LC RP x RP DAD [135] 
phenolics LC x LC HILIC x RP PDA; ESI-MS [136] 
proteins LC x LC IEX x RP UV; ESI-MS [83] 
sertraline enantiomers LC x LC RAM x chiral ESI-MS/MS [76] 
steroids, lemon oils LC x LC/LC NP x RP/RP DAD [137] 
TCMs LC x LC RP x RP DAD; APCI-MS [107] 
TCMs LC x LC RP x RP DAD [115] 
triacylglycerols in lipids LC x LC NP x RP APCI-MS [138] 
warfarin stereoisomers mLC - LC RP x chiral QTOF-MS [96] 
warfarins/hydroxywarfarins LC x LC RP x chiral ESI-MS/MS [139] 
*mLC – LC = multiple heart-cutting
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3. DEVELOPMENT OF DATABASE AND SPECTRAL LIBRARY  
3.1 Introduction 
The presence of novel psychoactive substances (NPS) on the illicit drug market 
and therefore present in toxicological specimens is not a new occurrence.  However, as 
NPS continue to be developed, analytical methods for detection and identification of such 
compounds must adapt to keep pace.140,141  Novel psychoactive substances are altered by 
illicit manufacturers to circumvent federal, state, and local legislation intended to control 
their usage in public.  Preventing a substance from falling under legal control can be 
achieved through an action as simple as altering a functional group through its removal, 
addition, or movement along the chemical structure.  As these changes are made, the 
structures of the resultant compounds no longer match those of substances that are illicit, 
thus placing them outside the purview of the controlled substance laws.2,5,18   
The constant emergence of new NPS also presents analytical challenges, since 
existing methods of detection are typically designed for specific functional groups or 
structures.6  Identification of analytes of interest in samples generally begins with the use 
of a screening technique to tentatively identify possible compounds or classes of 
compounds present in the sample.45,63,142  Methods using GC-MS and LC-MS have been 
developed for screening purposes but both typically require the use of libraries, which 
contain characteristic mass spectra generated using electron ionization (EI) or 
electrospray ionization (ESI) techniques, respectively, to make identifications.  
Using characteristic mass spectra to identify analytes in a sample is not a new 
concept.  Libraries exist containing spectra for as few as a couple dozen compounds to as 
many as several hundreds of thousands.7,38,49,53,143  The most common libraries contain 
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spectra generated through EI, because of their high degree of reproducibility and because 
EI-based libraries have been established for longer than those that are ESI-based.  
Libraries containing spectra from ESI sources have been increasing in popularity among 
forensic toxicology laboratories.47,53,56,144,145  There are several benefits to using ESI over 
EI, including the ability to maintain an intact molecular ion, which leads to increased 
confidence in identification because of the ionization in ESI being a “softer” or less 
intense technique than EI.  Techniques using ESI are also not limited to use with only 
volatile, thermally stable molecules as with EI sources in GC.42,52   Currently, there exist 
a number of GC libraries, but large LC libraries are lacking, and those that do exist do not 
contain many NPS or use theoretical accurate masses rather than masses measured from 
reference standards.7-9  
Development of ESI-based libraries for LC methods has historically involved the 
use of triple quadrupole mass spectrometry (QqQ-MS) but these instruments are 
considered to have low resolution, which makes differentiation of some NPS difficult, 
particularly those with extremely similar accurate masses.28,40  In contrast, high-
resolution mass spectrometry (HRMS) techniques, such as those using hybrid quadrupole 
time-of-flight mass spectrometers (QTOF-MS), are generally sensitive enough to 
distinguish between compounds with minute differences in accurate mass.40,66  Another 
benefit to using HRMS techniques is the ability to collect information for all ions while 
still maintaining high resolution and mass accuracy, which is ideal for comprehensive 
screening.  Collection of all ion data also allows for retrospective screening without the 
need for reanalysis of the sample; allowing for newly reported compounds to be searched 
for in previously analyzed samples.40,46,146  
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 The present study reports the development of a comprehensive compound 
database for 499 unique chemical entities considered to be possible NPS, metabolites, 
and related compounds.  A full HRMS spectral library was created for 410 of these 
compounds, with partial spectral information for another 25 compounds also included.  A 
comprehensive compound database was also created for 76 deuterated internal standard 
compounds.   
Materials and Methods 
3.1.1 Chemicals 
Optima LCMS grade methanol (MeOH), acetonitrile (ACN), HPLC water, and 
formic acid were purchased from Fisher Scientific (Fair Lawn, NJ, USA).  Ammonium 
formate (99%) was also purchased from Fisher Scientific. 
The ESI-L tuning mix (p/n: G1969-85000) and 0.1 mM HP-0321 (I8720263) 
were obtained from Agilent Technologies (Santa Clara, CA, USA) and used to prepare 
the tuning solution for the LC-QTOF-MS.   
 
3.1.2 Standards 
Reference standards for the NPS and internal standards were obtained from 
Cayman Chemical (Ann Arbor, MI, USA).  Standards that were received as neat solid 
material were put into solution with methanol (MeOH) for storage at -20°C.  Compounds 
that were not readily soluble in MeOH were put into solution with dimethyl sulfoxide 
(DMSO).  Each standard was assigned a unique identifying number for in-house usage 
(i.e., FIU-nnnn) in order to track usage of the compounds throughout sample preparation 
and analysis. 
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An arginine reference standard was also obtained from Cayman Chemical for use 
as a quality control standard.   
3.1.3 Sample Preparation  
Reference solutions were prepared from the reference standards of 499 NPS and 76 
internal standards at concentrations of 10 µg/mL in MeOH.  Working solutions were then 
prepared from the reference solutions at concentrations of 1 µg/mL in MeOH.  A 1.6 
ng/µL working solution of arginine was prepared in HPLC water for use as a quality 
control to ensure proper tuning and calibration of the instrument prior to FIA. 
3.1.4 Instrumentation and Software 
Instrumentation used for analysis included an Agilent 1290 Infinity UHPLC 
system coupled to an Agilent 6530 Accurate-Mass QTOF-MS (Agilent Technologies, 
Santa Clara, CA, USA).  A Zorbax Eclipse Plus C18 Rapid Resolution HD column (2.1 x 
50 mm, 1.8 µm; Agilent Technologies, Santa Clara, CA, USA) was used for separation 
during the database and library applicability test.  The QTOF-MS was operated in 
positive-ion electrospray mode with Jet Stream ESI technology.   
Agilent MassHunter LC/MS Acquisition software for the 6200 series TOF/6500 
series QTOF (Version B.06.00) was used to acquire spectral data.  MassHunter 
Qualitative Analysis software (Version B.06.00) was used to process the data.  
MassHunter Personal Compound Database Library (PCDL) Manager software (Version 
B.07.00, Build 7024.0) was used to create the compound database and high-resolution 
MS/MS spectral library.  ChemBioDraw Ultra (Version 14.0.0.117; PerkinElmer, 
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Waltham, MA, USA) was used to create the 2D chemical structure of each NPS for use in 
the PCDL. 
3.1.5 Methods 
Collection of spectral data for the MS/MS spectral library was done via flow 
injection analysis (FIA).  Diluted standards were individually injected directly into an 
Agilent 6530 series Accurate-Mass Quadrupole Time-of-Flight (QTOF) mass 
spectrometer with Jet Stream ESI ion source coupled to an Agilent 1290 Infinity Series 
Binary Pump system.  Most injection volumes were 1 µL, however, some compounds 
had to be injected at volumes up to 10 µL to produce spectra with base peak intensities 
over the 1000 count threshold.  A small percentage of compounds also had to be injected 
at concentrations of 2 µg/mL.  
 A 50:50 isocratic mobile phase system was used at a flow rate of 0.2 mL/min for 
2 min with aqueous (A) 5 mM ammonium formate in HPLC water with 0.1% formic 
acid, and organic (B) acetonitrile with 0.1% formic acid.  A positive mode electrospray 
ionization (ESI) targeted MS/MS method was used to collect the data.  The quadrupole 
used a narrow isolation mass window of 1.3 amu.  The ESI source parameters were: 
drying gas temperature 325°C; drying gas flow rate 5 L/min; nebulizer 30 psi; sheath gas 
temperature 375°C; sheath gas flow 12 L/min.  Scanning source parameters were: VCap 
voltage 4000 V; nozzle voltage 0 V; fragmentor voltage 140 V; skimmer voltage 65 V.   
Compounds were fragmented at three standard collision energies (10, 20, and 40 
eV) to produce characteristic fragmentation patterns.  The MS range was set to 50-1700 
m/z with an MS acquisition rate of 10 spectra per second.  The MS/MS range was set to 
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25-1700 m/z with an MS/MS acquisition rate of 3 spectra per second.  Spectral data were 
added to the MS/MS spectral library when the compound fragmentation produced a base 
peak of at least 1000 counts and had a mass accuracy within 5 ppm.  If these criteria were 
met, the compound information and fragment ion spectrum from each collision energy 
was imported into the PCDL using PCDL Manager software.  An arginine standard was 
run with each batch of standards to ensure that the instrument was properly tuned and 
calibrated. 
The “Find by Formula” (FBF) function of the Qualitative Analysis software was 
used to isolate a targeted compound from the FIA chromatogram.  The MS/MS spectra 
were then extracted and exported into the PCDL using the “Send Spectra to PCDL” 
function. 
3.2 Results and Discussion 
 Development of libraries for use with ESI-based methods are typically generated 
using QqQ-MS because of the greater availability of such instrumentation in laboratories.  
In these instruments, the first quadrupole (Q1) is typically used to scan for a specific 
precursor ion or range of ions of interest.  The selected ions then move to a collision cell 
(Q2) where they are fragmented using a neutral collision gas.  These ion fragments then 
pass to the third quadrupole (Q3) where selected fragment ions, or product ions, are 
allowed to pass to the detector while all other ions are filtered out.79  The fragmentation 
of ions, or transitions, from the precursor to the product ions is recorded using multiple 
reaction monitoring (MRM).  These MRM transitions are included in QqQ-MS libraries 
and serve as the characteristic fragmentation data for identification of compounds.  
However, the collision energy required to generate these characteristic MRM transitions 
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must be optimized for each compound prior to collection.  The need for optimization 
introduces another step and requires more time to add new compounds to the library.  
Libraries of MRM transitions also have low degrees of resolution as compared to HRMS 
techniques, which may result in significant challenges when trying to differentiate 
between compounds with similar accurate masses.66,146 
 Building a library using an HRMS technique such as QTOF-MS does not require 
collision energies and fragmentor voltages to be optimized prior to data collection.  
Instead, multiple collision energies can be employed and collection of all resultant 
spectra can be conducted simultaneously.  The capability to comprehensively collect 
spectra makes the rapid addition of spectra for new compounds possible and much easier 
to do than with MRM transition libraries.  The ability to collect high resolution full scan 
MS and MS/MS fragmentation data presents a large advantage for QTOF-MS 
instrumentation over QqQ-MS, since information about potential unknown compounds 
can be collected in addition to the high mass accuracy information of known compounds. 
 In the present research, the major goal was to create an HRMS spectral library for 
as many NPS standards from the synthetic cannabinoid, stimulant, hallucinogen, and 
other related classes using a QTOF-MS approach (Table 2 displays the number of 
compounds represented from each class of NPS; Table 3 displays the types of molecules 
included in the database).  These spectra were later combined with an existing HRMS 
library containing spectral data for an additional 260 compounds.147  The new compound 
database was first created using the PCDL software.  This database contained information 
for 499 entries including NPS, metabolites, and related compounds.  A second database 
was also created containing entries for 76 deuterated internal standards (see Appendices 1 
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and 2 for a complete listing of compounds contained in each respective database).  
Compounds selected for inclusion in the database were chosen from a variety of sources, 
including lists of commercially available standards, government documents and reports, 
scientific literature, and online drug-user forums.  Standard information input into the 
database included the compound common name, the IUPAC name, the molecular 
formula, calculated accurate mass, a 2D structure, as well as the CAS registry and 
ChemSpider numbers when available.  Reference standards for each entry were obtained 
from Cayman Chemical and the manufacturer’s product number was also included in the 
entry for traceability.  Figure 2 presents an example of the compound database generated 
using the MassHunter PCDL software with information for the compound acetyl fentanyl 
displayed.  Under the column labeled “Spectra”, the number of successfully acquired 
HRMS spectra for that compound is presented. 
  
Table 2. Distribution of compounds in database by class. 
Drug Class Number in Database 
Synthetic Cannabinoid 295 
Other* 89 
Cathinone 67 
Phenethylamine 29 
Tryptamine 14 
Piperazine 5 
*includes opioids, amphetamines, benzofurans, and other compounds. 
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Table 3. Distribution of compounds in database by molecule type. 
Molecule Type Number in Database 
Precursor Compound 293 
Metabolite 109 
Isomers 71 
Analogs* 21 
Glucuronides 5 
*derivatives of NPS that are not considered metabolites or isomers. 
High resolution mass spectra were generated by direct injection of 1 µL volumes 
of the 435 individual compound solutions into the ESI source of the QTOF-MS at 
concentrations of 1 µg/mL in MeOH.  After preparation in MeOH, the compounds were 
ionized in positive mode and targeted ions were subjected to three standard collision 
energies (10, 20, and 40 eV).  All resultant MS/MS spectral data were collected then 
processed to determine suitability for inclusion into the database.  Once MS/MS spectral 
data were included in the database, it was more properly referred to as the HRMS spectral 
library. 
 In order to be accepted into the library, there were several criteria that the 
collected data had to meet.  For each compound data file, the “Find by Formula” (FBF) 
function in MassHunter Qualitative Analysis was used to isolate the individual 
compound.  The FBF function was linked to the compound database which assigned 
identification using the accurate mass and generated chemical formula.  A secondary 
function within FBF was the “Extract MS/MS spectrum” function.  Using this, the 
MS/MS spectrum of the compound at each collision energy was extracted.  For inclusion 
in the HRMS spectral library, compounds identified using FBF needed to have a database 
search “score” >90 and a mass accuracy within ± 5 ppm.  The match “score” of a 
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compound is generated through the use of both a forward search (when data in the sample 
are matched against those in the library) and a reverse search (when library data are 
searched against data in the sample).  The MS/MS spectral data at each collision energy 
were then required to have base peak counts of at least 1000 to avoid inclusion of ion 
peaks from the background.  A small percentage of compound solutions needed to be 
injected at concentrations of 2 µg/mL or at volumes up to 10 µL in order to meet these 
criteria for inclusion in the HRMS spectral library. 
 
Figure 2. An image of the PCDL software used to create the compound database and MS/MS spectral 
library. 
 
 On the basis of the FBF scores >90, mass accuracy within ±5 ppm, and the 1000-
count MS threshold, full MS/MS spectral information at all three collision energies was 
included in the library for 410 of the 435 NPS, metabolites, and related compounds.  A 
representation of collected MS/MS spectra for the compound acetyl fentanyl is presented 
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in Figure 3.  Of the remaining 25 compounds, MS/MS spectra collected at two of the 
three collision energies were included for 19 compounds with another six compounds 
having only a single acceptable MS/MS spectrum.  The ions represented at relative 
abundances >10% for each MS/MS spectrum accepted into the library are presented in 
Appendix 3. 
3.3 Conclusion 
 The compound database and HRMS spectral library were successfully created 
containing approximately 550 compounds with MS/MS spectral data for over 470 
compounds at three distinct collision energies (10, 20, and 40 eV).  Retention time data 
were also included in the database for in-house use to help differentiate among 
compounds with similar fragmentation patterns.  The database and library were combined 
with another library that had been created as part of a previous project which included 
MS/MS spectra for an additional 260 compounds, bringing the number of compounds in 
the library with MS/MS data to over 700.  Entries for which complete MS/MS spectra 
could not be collected were still included in the database to be used for compound 
identification using accurate mass data.  Ultimately, over 800 compounds were 
represented in the database.   
 The high resolution and high mass accuracy of LC-QTOF-MS presents a 
significant advantage for screening and confirmation of NPS with a high degree of 
confidence in correct identification.  Through the use of a MS/MS spectral library, the 
confidence in identification is further increased.  Further work was conducted to evaluate 
the practicality of this technique for routine forensic toxicological screening of NPS 
following standard validation parameters.  
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Figure 3. Images of PCDL software showing the MS/MS 
spectral data of acetyl fentanyl.  MS/MS spectral data is shown 
at collision energies: A) 10 eV, B) 20 eV, and C) 40 eV. 
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4. COMPREHENSIVE LC-QTOF-MS METHOD VALIDATION 
4.1 Introduction 
Before the developed compound database and HRMS spectral library can be 
implemented for routine comprehensive screening, the method to be used in conjunction 
with the library must be fully validated.  Validation ensures that analysis using the 
method produces reliable data that are not false or susceptible to misinterpretation.  In 
clinical and forensic toxicology, unreliable data may be contested in court and could also 
result in mistreatment of patients or improper consequences of defendants in legal 
proceedings.148 
Standard validation practices have been set forth by the Toxicology 
Subcommittee of the Organization of Scientific Area Committees (OSACs).  These 
standard practices evolved from previously established standard practices from the 
Scientific Working Group for Forensic Toxicology (SWGTOX) which disbanded in 
2014.  The SWGTOX guidelines drew heavily from work published by Peters in 2007, 
who recommended a series of experiments to validate a method including the following 
criteria; selectivity, linearity, accuracy (bias), precision, and the limit of quantitation 
(LOQ).  Other parameters such as the limit of detection (LOD), recovery, reproducibility, 
ruggedness, stability, and matrix effects were also suggested by Peters for inclusion in 
method validation procedures.148,149 
A goal of the present work was to validate a method for screening and 
confirmation of over 800 NPS and related compounds.  In order to do so, validation 
experiments were initially designed following the SWGTOX guidelines and later updated 
following the release of the OSAC guidelines.150  Validation experiments for the present 
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work were conducted for the following parameters; linearity, accuracy, precision, LOD, 
LOQ, freeze/thaw stability, matrix effects, and carryover. 
Validation of a method for toxicological screening and confirmation is typically 
conducted for a single class of compounds or for a small set of compounds, as the process 
can require a significant amount of time and resources.  In the present work, method 
validation was conducted using a mixture approach in which each mixture of standards 
was validated as if it were a single compound.  Three validation mixtures were created, 
each containing between 27-33 compounds, and validated according to the guidelines set 
by the Toxicology Subcommittee of OSAC. 
The validated method was also used in the qualitative investigation of the 
applicability of the developed compound database and HRMS library for screening of 
blind-spiked urine specimens.  This investigation used 20 blank urine samples that were 
spiked with 0-1 NPS represented in the database and library.  The results of this 
qualitative investigation indicated that the database and library were suitable for 
screening purposes. 
4.2 Materials and Methods 
4.2.1 Chemicals 
Optima LCMS grade methanol (MeOH), HPLC water, and formic acid were 
purchased from Fisher Scientific (Fair Lawn, NJ, USA).  Ammonium formate (99%) was 
also purchased from Fisher Scientific. 
The ESI-L tuning mix (p/n: G1969-85000) and 0.1 mM HP-0321 (I8720263) 
were obtained from Agilent Technologies (Santa Clara, CA, USA) and used to prepare 
the tuning solution for the ESI-QTOF-MS.   
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A reference mass solution to ensure proper instrumental calibration throughout 
the analyses was created using the ESI TOF Mass Kit (p/n: G1959-85001) obtained from 
Agilent Technologies.  The kit contained 100 mM ammonium trifluoroacetate (TFANH4) 
in ACN:H2O (90:10), 5 mM purine in ACN:H2O (90:10), and 2.5 mM hexakis in 
ACN:H2O (90:10).   
4.2.2 Standards 
Reference standards used in the method validation are the same as those used in 
creation of the compound database and HRMS spectral library for both the compounds 
and for the deuterated internal standards.  All reference standards were obtained from 
Cayman Chemical (Ann Arbor, MI, USA). 
4.2.3 Preparation of Mixtures 
The same working solutions that were prepared for the creation of the compound 
database and HRMS library were used for method validation.  The working solutions 
contained individual reference standards at concentrations of 10 µg/mL in MeOH.  Three 
validation mixtures were created containing 29, 28 and 33 individual compounds, 
respectively, with each compound present at a concentration of 200 ng/mL in MeOH.  
The identity of the compounds contained in each mixture are displayed in Table 4, Table 
5, and Table 6.  The mixtures were designed so that compounds from a variety of NPS 
classes were represented in each and that no two compounds in a single mixture exhibited 
co-elution. 
An additional mixture was created to serve as the internal standard in each 
validation mixture for quantitation purposes.  The internal standard (IS) mixture 
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contained 22 deuterated internal standards representing a variety of NPS classes, each 
present in the mixture at a concentration of 200 ng/mL in MeOH.  The compounds 
contained in the IS mixture are presented in Table 7.  A compound from the IS mixture 
was matched with each NPS in the validation mixtures for quantitation purposes.  These 
“matches” were based on similarities between the NPS and IS compound structures since 
the IS should be chemically similar to the analyte of interest.  The IS compounds used in 
this research were chosen to represent a variety of drugs, with the majority from the SC 
class of compounds due to the relevance of SC in real-world samples as well as the large 
representation of SC in the database and library developed prior to the validation studies. 
  To validate the method in matrix, blank, pooled human urine was obtained from 
UTAK Laboratories (Valencia, CA, USA).  For all analyses in matrix, the urine was 
diluted with aqueous mobile phase at a 1:5 dilution.  
4.2.4 Instrumentation and Software 
Instrumentation used for analysis included an Agilent 1290 Infinity UHPLC 
system coupled to an Agilent 6530 Accurate-Mass QTOF-MS (Agilent Technologies, 
Santa Clara, CA, USA).  A Zorbax Eclipse Plus C18 Rapid Resolution HD column (3.0 x 
100 mm, 1.8 µm; Agilent Technologies, Santa Clara, CA, USA) was used for separation 
of compounds in the urine matrix.  The QTOF-MS was operated in positive-ion 
electrospray mode with Jet Stream ESI technology.   
Agilent MassHunter LC/MS Acquisition software for the 6200 series TOF/6500 
series QTOF (Version B.06.00) was used to acquire the data.  MassHunter Qualitative 
Analysis software (Version B.06.00) was used to process acquired retention time data and 
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to process the blind-spiked urine specimens.  MassHunter Quantitative Analysis software 
for QTOF (Version B.07.00, Build 7.0.457.0) was used for quantitation of the data.  The 
compound database and HRMS spectral library created and managed using MassHunter 
PCDL software (Version B.06.00) was used to identify compounds in the blind-spiked 
urine specimens. 
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Table 4. Compounds contained in validation Mix 1, their accurate masses, and retention times. 
Compound Name Accurate Mass (Da) Retention Time (min) 
25I-NBMD  441.0437 9.17 
3-Methylbuphedrone 191.1310 7.29 
4-APDB  177.1154 6.43 
4-fluoro-α-Pyrrolidinobutiophenone 235.1372 6.83 
4'-fluoro-α-Pyrrolidinopropiophenone 221.1216 6.17 
4-hydroxy MET 218.1419 5.21 
4-methoxy PV8  289.2042 8.97 
4-methoxy-α-Pyrrolidinopentiophenone  261.1729 7.70 
4-Methyl-α-ethylaminobutiophenone  205.1467 7.49 
5-fluoro SDB-006 338.1794 10.80 
5-Fluoropentylindole 205.1267 11.21 
5-MAPB  189.1154 6.99 
AB-005 352.2515 9.58 
AM-2233 azepane isomer 458.0855 8.66 
AM694 N-(5-hydroxypentyl) metabolite 433.0539 10.45 
AMT  130.0565 1.63 
Benocyclidine 299.1708 9.14 
Flubromazepam 331.9961 10.07 
JWH 031 2'-isomer 305.1780 13.32 
JWH 081 N-(5-hydroxypentyl) metabolite 387.1834 10.94 
JWH 200 5-hydroxyindole metabolite 400.1787 8.61 
JWH 203 339.1390 12.22 
N-Methyltryptamine 174.1157 5.73 
NPB-22 359.1634 11.53 
PB-22 6-hydroxyisoquinoline isomer 358.1681 11.98 
PCMPA  247.1936 8.25 
THCA-A 358.2144 19.14 
UR-144 N-heptyl analog 339.2562 15.45 
α-Pyrrolidinopentiophenone metabolite 1  233.1780 7.65 
 
 
 
 
 
 
 
 
57 
   
Table 5. Compounds contained in validation Mix 2, their accurate masses, and retention times. 
Compound Name Accurate Mass (Da) Retention Time (min) 
2,3-methylenedoxy pyrovalerone 275.1521 7.39 
25I-NBF 415.0445 9.11 
2C-T-2 241.1136 7.90 
2C-T-4 255.1293 8.51 
2-fluoromethcathinone 181.0903 5.22 
3,4-DHMA 181.1103 4.21 
3,4-dimethoxy- α-
pyrrolidinopentiophenone 291.1834 7.19 
3-methyl-α-
pyrrolidinopropiophenone 217.1467 6.93 
4’-methyl-N-
methylhexanophenone 219.1623 8.56 
4-ethyl-N,N-dimethylcathinone 205.1467 7.44 
4-fluoroisocathinone 167.0746 5.66 
4-hydroxy MiPT 232.1576 5.67 
4-MMC 177.1154 6.57 
A-796260 354.2307 10.90 
AB-005 azepine isomer 352.2515 9.78 
AB-FUBINACA 3-fluorobenzyl 
isomer 368.1649 10.49 
ADB-PINACA isomer 1 344.2212 11.20 
AKB48 N-(5-fluoropentyl) analog 383.2373 13.22 
Clencyclohexerol 318.0902 6.10 
EG-018 391.1936 16.98 
JWH 018 N-(5-hydroxypentyl) 
metabolite 357.1729 10.74 
JWH 018 N-propanoic acid 
metabolite 343.1208 10.31 
KM 233 362.2246 14.08 
Loperamide 476.2231 9.52 
MAM2201 N-pentanoic acid 
metabolite 385.1678 10.99 
N-Ethylbuphedrone 191.1310 6.53 
PB-22 346.1681 11.88 
PCPr 217.1830 8.35 
RCS-4 2-methoxy isomer 321.1729 11.60 
SER-601 434.2933 15.46 
UR-144 Degradant 311.2249 12.97 
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XLR11 N-(2-fluoropentyl) isomer 329.2155 12.46 
Δ8-THC 314.2246 14.79 
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Table 6. Compounds contained in validation Mix 3, their accurate masses, and retention times. 
Compound Name Accurate Mass (Da) Retention Time (min) 
(R)-(−)-MT-45 348.2565 9.48 
2,3-Dichlorophenylpiperazine 230.0378 8.31 
25H-NBOMe 301.1678 8.41 
2C-T 227.0980 7.50 
2-Methoxyamphetamine 165.1154 7.95 
3,4-Dimethylethcathinone 205.1467 7.64 
3C-P 253.1678 8.10 
4-Methoxyamphetamine 165.1154 7.42 
5-fluoro NNEI 374.1794 11.09 
9-octadecenamide/oleamide 281.2719 14.77 
AB-CHMINACA 356.2212 11.50 
AKB48 N-pentanoic acid metabolite 395.2209 11.81 
BB-22 4-hydroxyquinoline isomer 384.1838 13.46 
Cathine 151.0997 5.50 
Diclofensine 321.0687 9.87 
FUB-PB-22 396.1274 11.29 
HMA 181.1103 5.11 
JWH 018 2-hydroxyindole metabolite 357.1729 15.25 
JWH 251 3-methylphenyl isomer 319.1936 12.51 
MBZP 190.1470 5.47 
Mephedrone 177.1154 6.58 
Methylenedioxy Pyrovalerone metabolite 2 263.1521 5.92 
N-methyl-2-AI 147.1048 5.83 
NRG-3 241.1467 8.76 
PB-22 N-(5-hydroxypentyl) metabolite 374.1630 10.45 
RCS-4 N-(4-hydroxypentyl) metabolite 337.1678 10.33 
UR-144 N-(2-chloropentyl) analog 345.1859 13.07 
Δ9-THC 314.2246 14.44 
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Table 7. Compounds contained in the internal standard (IS) mixture and their accurate 
masses. 
Compound Accurate Mass (Da) 
Retention 
Time (min) 
(-)-11-nor-9-carboxy-Δ9-THC-d3 347.2176 12.57 
(±)-CP 47,497-C8-homolog-d7 339.3155 14.49 
25I-NBOMe-d3 430.0833 9.39 
3,4-Methylenedioxy pyrovalerone-d8 283.2024 7.51 
AB-FUBINACA-d4 372.1900 10.62 
AB-PINACA-d9 339.2621 11.18 
Acetyl norfentanyl-d5 223.1733 5.91 
ADB-PINACA-d9 353.2777 11.53 
AM 2201 N-(4-hydroxypentyl) metabolite-d5 380.1948 10.69 
Benocyclidine-d10 309.2335 9.27 
Butylone-d3 224.1240 6.51 
cis-Tramadol-d6 269.2262 7.17 
JWH 007-d9 328.2501 12.98 
JWH 018-d9 350.2345 12.65 
JWH 073 5-Hydroxyindole metabolite-d7 350.2012 11.21 
JWH 081 N-pentanoic acid metabolite-d5 406.1941 10.99 
MAM 2201 N-pentanoic acid metabolite-d5 390.1992 11.11 
Norsufentanil-d3 279.2026 8.05 
PB-22-d9 367.2246 11.99 
RCS-4 N-(5-hydroxypentyl) metabolite-d5 342.1992 10.46 
UR-144 N-(4-hydroxypentyl) metabolite-d5 332.2512 11.38 
XLR11-d5 334.2469 12.10 
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4.2.5 LC-QTOF-MS Method 
The LC separation was conducted with a gradient with 5 mM ammonium formate 
(AF) in HPLC water with 0.1% formic acid (FA) as the aqueous mobile phase (A) and 
MeOH with 0.1% FA as the organic mobile phase (B).  The mobile phase gradient was 
employed at a flow rate of 0.3 mL/min with composition beginning at 5% B from 0-1 
min, then increasing to 95% B from 1 – 9.5 min, and remaining at 9.5 min for the 
remainder of the analysis time.  An equilibration time of 3 min was also incorporated into 
the LC method.  Chromatographic column temperature was maintained at 40°C. 
Detection of the chromatographic data was completed using QTOF-MS in full 
scan mode.  The ESI source parameters were: drying gas temperature 325°C; drying gas 
flow rate 8 L/min; nebulizer 35 psi; sheath gas temperature 400°C; sheath gas flow 12 
L/min.  Scanning source parameters were: VCap voltage 3500 V; nozzle voltage 0 V; 
fragmentor voltage 125 V; skimmer voltage 65 V.   
Two reference ions, provided by the reference mass solution, were monitored 
with mass correction to ensure proper instrumental calibration throughout analysis; 
121.0509 m/z and 922.0098 m/z. 
4.2.6 Retention Time Collection 
Prior to validation of the method, retention data for all compounds were collected 
to prevent inclusion of any co-eluting compounds in the validation mixtures.  Individual 
compounds were injected at concentrations of 1 µg/mL in MeOH at volumes of 5 µL.  
Separation was conducted over 20 min using an Agilent Zorbax Eclipse Plus C18 Rapid 
Resolution HD column (3.0 x 100 mm; 1.8 µm) and the LC-QTOF-MS method described 
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above.  Retention data was collected using Full Scan mode with the MS range set to 50-
1700 m/z with an MS acquisition rate of 10 spectra per second.   
 The FBF function of Qualitative Analysis software was used to isolate the 
individual compound from each injected solution and the corresponding retention data 
were recorded.  These data were used to design the validation mixtures so that no two 
components of a mixture would co-elute, thus interfering with identification and 
quantitation of the compounds. 
4.2.7 Preparation of Samples in Urine 
Urine samples were prepared for all aspects of validation.  Calibrators were 
prepared in urine at seven different concentrations ranging between 2 – 120 ng/mL for 
each of the three validation mixes.  Samples included blank urine diluted at a ratio of 1:5 
using aqueous mobile phase.  The working validation mixtures containing compounds at 
concentrations of 200 ng/mL in MeOH were spiked into the diluted urine at appropriate 
volumes to make the calibrators.  Each sample was also spiked with the IS mixture at a 
concentration of 40 ng/mL. 
Quality control (QC) samples were created at three concentration levels within the 
calibration range; low, medium, and high (5, 20, and 80 ng/mL) in urine diluted (1:5) 
with aqueous mobile phase.  The QCs were also spiked with the IS mixture at a 
concentration of 40 ng/mL.  Blank urine samples (matrix blanks) were also prepared 
using pooled, blank urine diluted (1:5) with aqueous mobile phase.  The calibrators, QCs, 
and matrix blanks were used throughout the method validation process. 
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4.2.8 Preparation of Blind-Spiked Specimens 
Two sets of 20 specimens were prepared by a third party not involved in the 
analysis using blank, pooled urine from UTAK Laboratories.  The urine samples were 
spiked with 0-1 NPS and diluted with aqueous mobile phase at a 1:5 dilution.  No internal 
standard was included as this was a purely qualitative investigation. 
4.3 Results and Discussion 
4.3.1 Linearity 
Linearity experiments were conducted at seven calibration concentrations 
between 2 – 120 ng/mL.  These concentrations were set at 2, 5, 10, 20, 50, 100, and 120 
ng/mL and five replicates were run for each concentration level.  Measured 
concentrations were then modeled using linear regression and a weight of 1/x was 
applied.  An example weighted calibration curve for 25I-NBF from validation mix 2 is 
presented in Figure 5.  An example of an unweighted calibration curve for 25I-NBF is 
presented in Figure 4.  There were no major differences between the unweighted and 
weighted calibration curves, but per OSAC guidelines, a weighted model should be used 
when there are notable differences between variances at the lowest and highest 
concentrations.  This is the case when the concentration range is larger than one order of 
magnitude, as was the case with the calibration levels chosen in this study. 
Calibration curves were created for validation mixes 1, 2 and 3.  Mix 1 contained 
29 compounds, all of which had linear calibration curves.  Mix 2 contained 33 
compounds, of which 30 had linear calibration curves.  Mix 3 contained 28 compounds, 
of which 24 had acceptable linearity based on their calibration curves.  The data collected 
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during the linearity studies were also used in the calculation of the limit of detection 
(LOD) and the limit of quantitation (LOQ) for each compound. 
Figure 5. Weighted calibration curve for 25I-NBF from validation Mix 2. 
 
4.3.2 Accuracy and Precision 
Accuracy (bias) is the determination of how closely a compound’s calculated 
concentration corresponds to its actual concentration.  Precision is a measure of how 
closely the calculated concentrations of a compound compare with each other within a 
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Figure 4. Unweighted calibration curve for 25I-NBF from validation Mix 2. 
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single analysis and between separate analyses.  Accuracy and precision studies were 
preformed concurrently with the same samples known as the QC samples.   
Samples for the accuracy and precision studies were created at three different 
concentrations, representing the low, medium, and high range of the concentrations used 
in the calibration curves.  Three replicates of each concentration level were prepared on 
each of five consecutive days and analyzed on the day they were prepared.  
Accuracy was then calculated for each compound in each mixture using the 
following equation: 
𝐵𝑖𝑎𝑠 (%) 𝑎𝑡 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 =
 ቂீ௥௔௡  ெ௘௔௡ ௢௙ ஼௔௟௖௨௟௔௧௘ௗ ஼௢௡௖௘௡௧௥௔௧௜௢௡ିே௢௠௜௡௔  ஼௢௡௖௘௡௧௥௔௧௜௢௡
ே௢௠௜௡௔௟ ஼௢௡௖௘௡௧௥௔௧௜௢௡ 
ቃ  𝑥 100 (2) 
 
where the calculated concentration is the measured concentration of the compound during 
analysis and the nominal concentration is the concentration set for that calibration level.  
At each concentration, the maximum acceptable bias is ±20%.  The data used in bias 
studies were also used to calculate precision, as per the OSAC guidelines.150 
 Precision studies were conducted to determine variability between runs on the 
same day (intra-day variability) and between runs conducted on separate days (inter-day 
variability).  General precision values are expressed in terms of the coefficient of 
variation (% CV) as seen in Equation 3 following the calculation of the mean and 
standard deviation (s) of the response at each concentration. 
%𝐶𝑉 =  ௦
௠௘௔௡ ௥௘௦௣௢௡௦௘
    (3) 
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Acceptable precision values must have a % CV within a range of ±20% at each 
concentration.  Calculation of within-run precision was done using data from each of the 
three replicates at each concentration level (Equation 4).  The largest % CV value 
calculated at each concentration was used to assess the within-run precision. 
𝑊𝑖𝑡ℎ𝑖𝑛 − 𝑅𝑢𝑛 𝐶𝑉(%) =  ௦௧ௗ ௗ௘௩௜௔௧௜௢௡ ௢௙ ௔ ௦௜௡௚௟௘ ௥௨௡ ௢௙ ௦௔௠௣௟௘௦
௠௘௔௡ ௖௔௟௖௨௟௔௧௘ௗ ௩௔௟௨௘ ௢௙ ௔ ௦௜௡௚௟௘ ௥௨௡ ௢௙௦௔௠௣௟௘௦
 𝑥 100  (4) 
Calculation of between-run precision was conducted with data collected at each 
concentration over the course of five runs completed on separation days (Equation 5). 
𝐵𝑒𝑡𝑤𝑒𝑒𝑛 − 𝑅𝑢𝑛 𝐶𝑉(%) =  ௦௧ௗ ௗ௘௩ ௢௙ ௔௟௟ ௢௕௦௘௥௩௔௧௜௢௡௦ ௙௢௥ ௘௔௖௛ ௖௢௡௖௘௡௧௥௔௧௜௢௡
௚௥௔௡ௗ ௠௘௔௡ ௙௢௥ ௘௔௖௛ ௖௢௡௖௘௡௧௥௔௧௜௢௡
 𝑥 100   (5) 
Bias and precision data for Mix 1 are presented in Table 8 with all calculated bias 
values at each concentration within ±10.1%.  Overall precision values at each 
concentration were within ±10% CV, with all within-run and between-run precision 
values within ±20%.  Most of the within- and between-run precision values were within 
±10% with the exception of the low concentration within-run values. 
The bias and precision data were calculated for the 30 compounds in Mix 2 which 
demonstrated linearity.  The bias and precision data are presented in Table 9 with all 
values at each concentration within the limits of ±20%.  All bias values were within 
±10%.  Overall precision values were all within the limits of ±20% CV, with the majority 
within ±10%.  For the within-run and between-run precision values, all compounds had 
calculated values within ±20%. 
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The bias and precision data were calculated for the 24 compounds in Mix 3 with 
demonstrated linearity.  The bias and precision data are presented in Table 10 with all 
values at each concentration within the limits of ±20%.  All bias values were within 
±10%.  Overall precision values were all within ±10% CV.  The within-run and between-
run precision values were all within ±20%, with the majority within ±10%. 
4.3.3 Limits of Detection and Quantitation  
The limit of detection (LOD) and limit of quantitation (LOQ) represent the lowest 
concentrations at which an analyte may be detected by a method and quantitated, 
respectively.  Both values were calculated using the slope (m) and y-intercept values 
generated during the linearity studies.  The LOD was calculated using the following 
equation: 
𝐿𝑂𝐷 =  ଷ.ଷ௦೤
஺௩௚೘
     (6) 
where sy is the standard deviation of the y-intercept and Avgm is the average slope.  The 
LODs for compounds in Mix 1 were all in the low ng/mL (ppb) range with values 
ranging from 0.2 to 2.9 ng/mL (Table 11).  The LODs for compounds in Mix 2 were all 
in the low ng/mL (ppb) range with values ranging from 0.1 to 2.2 ng/mL (Table 12).  The 
LODs calculated for compounds in Mix 3 were also in the lower ng/mL range with 
values between 0.2 and 1.6 ng/mL.  Most values were below 1.1 ng/mL (Table 13). 
The LOQ values were calculated in a similar manner to the LOD values using the 
following equation: 
𝐿𝑂𝑄 = ଵ଴ ೤
஺௩௚೘
     (7) 
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All of the calculated LOQs for Mix 1 are shown in Table 11 with a range of values from 
0.6 to 8.8 ng/mL, with most values ≤ 5.0 ng/mL.  The LOQ values for Mix 2 are shown 
in Table 12 with a range of values from 0.3 to 6.8 ng/mL, with most values at less than 
5.0 ng/mL.  The LOQ values for Mix 3 are shown in Table 13 with values between 0.6 
and 4.7 ng/mL. 
The calculated LOD and LOQ values demonstrate that the method is sensitive 
enough to detect low concentrations of analytes in human urine and can be applied to 
specimens with compounds present at pharmacologically relevant levels.  A wide range 
of NPS concentrations in human specimens have been reported in the literature.  For 
some SC, such as JWH 018, concentrations have been reported in postmortem cases 
between 0.1 and 199 ng/mL with an average concentration of 17.5 ng/mL,151 which is 
within the range of detection of the method presented in this research for related JWH 
018 compounds whose LOD and LOQ values were as low as 0.4 and 1.1 ng/mL, 
respectively.  Another case reported in the literature involved acute fatal poisoning by 
NNEI, an analog of JWH-018.  The concentrations in whole blood collected postmortem 
ranged from 0.64-0.99 ng/mL depending on from where in the body the samples were 
collected.152  The method validated in the present work achieved LOD and LOQ values 
for 5-fluoro NNEI of 0.2 and 0.6 ng/mL, respectively, indicating that the method would 
be suitable for use in detecting NNEI and related analogs in real-world samples.  A third 
case of NPS in postmortem samples was from a fatal case of multiple drug intoxication 
caused by the SCs AB-CHMINACA and 5-fluoro-AMB, combined with diphenidine.  
Postmortem tissue concentrations for AB-CHMINACA ranged from 7.55-38.9 ng/g.153  
The validated method obtained LOD and LOQ values of 0.8 and 2.3 ng/mL, respectively, 
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for AB-CHMINACA.  The values reported in the literature demonstrate that the LOD and 
LOQ values obtained by the method from the present research are relevant for use in 
detection of NPS in both antemortem and postmortem human specimens. 
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Table 8. Bias and precision data for compounds in Mix 1.  Concentrations for low, med, and high are 5, 20, and 80 ng/mL, respectively. 
 Bias (%) Precision (% CV) Within-Run (%) Between-Run (%) 
Compound Name low med high low med high low med high low med high 
α-Pyrrolidinopentiophenone 
metabolite 1 1.6 2.0 0.4 6.4 3.2 0.7 12.9 4.0 1.3 6.4 3.2 0.7 
25I-NBMD 1.6 2.0 0.4 5.6 3.1 0.7 10.0 4.6 1.3 5.6 3.1 0.7 
3-Methylbuphedrone 1.7 2.1 0.4 3.5 2.6 0.7 6.5 4.8 0.7 3.5 2.6 0.7 
4-APDB 0.8 1.0 0.2 3.6 2.5 0.9 7.8 3.6 2.0 3.6 2.5 0.9 
4-fluoro-α-
Pyrrolidinobutiophenone 1.4 1.8 0.4 4.4 3.7 1.0 5.1 3.6 1.7 4.4 3.7 1.0 
4'-fluoro-α-
Pyrrolidinopropiophenone 1.6 2.0 0.4 5.1 4.0 0.9 9.3 2.0 1.4 5.1 4.0 0.9 
4-hydroxy MET 2.8 3.2 0.6 5.0 3.1 0.7 10.2 3.0 1.1 5.0 3.1 0.7 
4-methoxy PV8 1.2 1.5 0.3 4.5 2.3 0.8 9.0 4.3 1.7 4.5 2.3 0.8 
4-methoxy-α-
Pyrrolidinopentiophenone 1.9 2.4 0.5 5.5 3.0 0.8 12.0 3.5 1.7 5.5 3.0 0.8 
4-Methyl-α-
ethylaminobutiophenone 3.3 4.2 0.8 3.5 2.7 1.0 5.6 3.9 1.4 3.5 2.7 1.0 
5-fluoro SDB-006 2.2 2.7 0.5 8.4 4.6 1.1 15.5 3.8 1.4 8.4 4.6 1.1 
5-Fluoropentylindole 3.4 4.2 0.8 5.3 2.5 0.9 11.1 3.6 2.1 5.3 2.5 0.9 
5-MAPB 1.2 1.5 0.3 6.5 3.0 1.1 12.0 6.1 2.5 6.5 3.0 1.1 
AB-005 0.5 0.6 0.1 6.7 3.2 1.4 10.9 6.0 3.5 6.7 3.2 1.4 
AM-2233 azepane isomer 2.3 2.8 0.6 7.6 5.2 1.0 11.8 9.4 1.6 7.6 5.2 1.0 
AM694 N-(5-hydroxypentyl) 
metabolite 8.1 10.1 2.0 5.0 5.5 1.5 6.4 7.7 3.1 5.0 5.5 1.5 
AMT 0.3 1.0 0.2 4.3 2.8 0.6 6.0 2.7 0.8 4.3 2.8 0.6 
Benocyclidine 3.9 4.8 1.0 5.3 4.4 0.8 7.0 4.0 0.7 5.3 4.4 0.8 
Flubromazepam 1.7 2.1 0.4 5.1 4.2 1.1 9.2 5.9 2.1 5.1 4.2 1.1 
JWH 031 2'-isomer 1.0 1.2 0.2 7.3 4.9 1.2 11.4 7.6 2.5 7.3 4.9 1.2 
71 
   
JWH 081 N-(5-
hydroxypentyl) metabolite 1.2 1.5 0.3 7.0 4.7 0.6 11.4 10.7 1.1 7.0 4.7 0.6 
JWH 200 5-hydroxyindole 
metabolite 1.5 1.9 0.4 8.8 3.4 1.5 18.1 4.8 3.2 8.8 3.4 1.5 
JWH 203 1.0 1.3 0.3 7.6 4.3 0.7 13.2 8.2 1.3 7.6 4.3 0.7 
N-Methyltryptamine 0.01 0.01 0.003 4.8 2.4 0.7 6.9 4.1 1.5 4.8 2.4 0.7 
NPB-22 1.0 1.3 0.3 6.5 4.1 1.7 10.5 5.5 3.9 6.5 4.1 1.7 
PB-22 6-hydroxyisoquinoline 
isomer 0.04 0.05 0.009 7.6 3.9 1.0 11.1 5.2 2.1 7.6 3.9 1.0 
PCMPA 3.7 4.7 0.9 7.4 3.3 0.5 16.4 4.2 0.6 7.4 3.3 0.5 
THCA-A 2.7 3.1 0.6 7.2 4.8 0.8 15.3 7.6 1.1 7.2 4.8 0.8 
UR-144 N-heptyl analog 1.8 2.2 0.4 6.1 5.5 1.0 7.9 5.8 0.7 6.1 5.5 1.0 
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Table 9. Bias and precision data for compounds in Mix 2.  Concentrations for low, med, and high are 5, 20, and 80 ng/mL, respectively. 
 Bias (%) Precision (% CV) Within-Run (%) Between-Run (%) 
Compound Name low med high low med high low med high low med high 
2,3-methylenedoxy 
pyrovalerone 2.7 0.6 0.3 7.7 2.6 1.5 17.0 2.9 2.5 7.7 2.6 1.5 
25I-NBF 1.8 1.8 0.7 3.5 3.0 2.5 6.6 5.1 2.6 3.5 3.0 2.5 
2C-T-2 1.3 1.0 3.2 6.2 4.4 6.9 11.0 4.3 1.9 6.2 4.4 6.9 
2C-T-4 3.0 4.4 2.7 9.7 6.6 7.4 6.7 6.1 2.8 9.7 6.6 7.4 
2-fluoromethcathinone 1.8 3.0 1.7 9.2 6.4 4.3 10.1 9.1 4.4 9.2 6.4 4.3 
3,4-dimethoxy- α-
pyrrolidinopentiophenone 0.5 1.5 1.3 5.6 5.6 4.5 8.7 8.4 3.8 5.6 5.6 4.5 
3-methyl-α-
pyrrolidinopropiophenone 4.1 0.9 3.1 5.6 8.7 5.7 6.9 7.0 3.0 5.6 8.7 5.7 
4’-methyl-N-
methylhexanophenone 2.5 0.1 0.5 5.3 5.4 2.0 9.3 7.5 2.6 5.3 5.4 2.0 
4-ethyl-N,N-
dimethylcathinone 3.6 0.8 0.6 5.8 5.2 3.0 7.6 6.9 3.2 5.8 5.2 3.0 
4-hydroxy MiPT 5.1 0.5 3.7 5.5 6.8 6.8 5.8 2.6 1.5 5.5 6.8 6.8 
4-MMC 1.5 1.7 2.7 6.3 8.6 5.2 8.7 6.8 3.2 6.3 5.6 5.2 
A-796260 4.5 5.8 2.3 9.9 5.7 6.4 13.6 3.0 1.4 9.9 5.7 6.4 
AB-005 azepine isomer 4.1 0.8 2.8 5.0 6.0 4.8 8.3 3.3 3.9 5.0 6.0 4.8 
AB-FUBINACA 3-
fluorobenzyl isomer 4.0 1.3 3.3 5.6 5.1 6.0 8.4 4.7 4.0 5.6 5.1 6.0 
ADB-PINACA isomer 1 4.0 3.7 0.6 6.3 1.8 3.2 11.0 2.9 4.6 6.3 1.8 3.2 
AKB48 N-(5-fluoropentyl) 
analog 3.5 2.0 0.7 6.5 5.5 2.0 6.4 2.9 2.5 6.5 5.5 2.0 
Clencyclohexerol 6.1 3.4 0.4 15.7 1.6 1.1 9.6 2.3 1.7 15.7 1.6 1.1 
EG-018 5.2 7.0 0.8 6.9 6.0 3.2 3.7 2.5 3.6 6.9 6.0 3.2 
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JWH 018 N-(5-hydroxypentyl) 
metabolite 4.1 0.9 2.5 5.6 8.0 4.0 6.0 2.9 1.4 5.6 8.0 4.0 
JWH 018 N-propanoic acid 
metabolite 0.6 0.2 3.3 5.4 4.8 6.4 11.5 4.7 3.4 5.4 4.8 6.4 
KM 233 2.6 9.8 2.4 11.4 7.2 7.5 4.3 2.8 4.1 11.4 7.2 7.5 
Loperamide 0.9 2.9 0.01 3.9 3.0 1.50 5.5 4.2 2.2 3.9 3.0 1.5 
MAM2201 N-pentanoic acid 
metabolite 1.5 3.7 1.5 6.0 2.6 2.2 12.1 3.6 2.3 6.0 2.6 2.2 
N-Ethylbuphedrone 2.5 2.3 0.8 8.1 8.1 4.2 4.3 6.5 7.2 8.1 8.1 4.2 
PCPr 5.6 0.001 3.7 6.9 7.0 6.5 8.5 10.4 8 6.9 7.0 6.5 
RCS-4 2-methoxy isomer 7.5 3.6 1.5 6.2 4.9 1.2 7.4 3.0 1.6 6.2 4.9 1.2 
SER-601 3.5 3.3 2.3 4.6 2.5 5.0 6.6 2.2 1.5 4.6 2.5 5.0 
UR-144 Degradant 6.9 4.1 1.4 5.4 1.8 4.0 8.7 2.7 1.5 5.4 1.8 4.0 
XLR11 N-(2-fluoropentyl) 
isomer 7.3 2.4 0.3 7.5 4.0 2.2 8.5 2.7 0.7 7.5 4.0 2.2 
Δ8-THC 6.1 6.2 0.5 10.3 6.3 3.5 10.6 5.2 4.4 10.3 6.3 3.5 
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Table 10. Bias and precision data for compounds in Mix 3.  Concentrations for low, med, and high are 5, 20, and 80 ng/mL, respectively.  
Bias (%) Precision (% CV) Within-Run (%) Between-Run (%) 
Compound Name low med high low med high low med high low med high 
(R)-(−)-MT-45 0.6 0.7 0.2 1.3 1.4 0.5 1.9 1.4 0.7 1.3 1.4 0.5 
2,3-
Dichlorophenylpiperazine 3.3 4.1 0.8 3.5 4.5 0.9 2.6 2.5 0.4 3.5 4.5 0.9 
25H-NBOMe 1.0 1.2 0.3 1.2 1.0 0.6 2.1 1.0 1.1 1.2 1.0 0.6 
2C-T 0.4 0.5 0.1 1.4 1.3 0.5 2.6 0.9 0.8 1.4 1.3 0.5 
2-Methoxyamphetamine 0.5 0.7 0.2 1.1 1.3 0.6 0.8 0.7 0.9 1.1 1.2 0.6 
3,4-Dimethylethcathinone 0.5 0.7 0.1 0.9 1.1 0.5 0.9 1.9 0.7 0.9 1.1 0.5 
3C-P 0.3 0.3 0.1 1.5 1.4 0.5 2.7 1.2 0.9 1.5 1.4 0.5 
4-Methoxyamphetamine 0.6 0.8 0.2 1.6 1.0 0.5 3.7 0.7 0.8 1.6 1.0 0.5 
5-fluoro NNEI 2.1 2.6 0.5 2.6 3.1 0.7 1.4 1.3 0.7 2.6 3.1 0.7 
9-
octadecenamide/oleamide 0.2 0.2 0.04 1.7 2.4 0.8 2.2 4.3 1.1 1.7 2.4 0.8 
AB-CHMINACA 0.4 0.5 0.1 0.7 0.7 0.5 1.1 0.7 0.8 0.7 0.7 0.5 
AKB48 N-pentanoic acid 
metabolite 1.0 1.3 0.3 1.0 0.9 0.4 1.3 0.9 0.6 1.0 0.9 0.4 
Cathine 0.4 2.2 0.5 7.3 4.4 1.3 11.6 5.8 2.0 7.3 4.4 1.3 
Diclofensine 0.2 0.2 0.04 0.5 0.6 0.5 0.7 0.8 0.8 0.5 0.6 0.5 
FUB-PB-22 1.3 1.6 0.3 1.2 1.5 0.6 1.5 1.6 1.0 1.2 1.5 0.6 
HMA 1.1 0.3 0.01 4.4 1.7 0.7 10.2 3.8 1.1 4.4 1.7 0.7 
MBZP 5.3 1.6 0.1 5.1 2.1 0.3 2.6 2.6 0.4 5.1 2.1 0.3 
Mephedrone 0.4 0.4 0.1 1.0 1.2 0.5 1.1 1.9 0.7 1.0 1.2 0.5 
Methylenedioxy 
Pyrovalerone metabolite 2 0.5 0.6 0.1 1.3 0.9 0.5 2.4 1.2 1.0 1.3 0.9 0.5 
N-methyl-2-AI 0.7 0.9 0.2 1.3 1.3 0.5 1.9 1.5 0.8 1.3 1.3 0.5 
NRG-3 0.03 0.04 0.01 0.7 0.9 0.7 0.8 1.3 1.1 0.7 0.9 0.7 
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PB-22 N-(5-
hydroxypentyl) metabolite 1.0 1.3 0.3 1.8 1.6 0.5 3.2 0.9 0.7 1.8 1.6 0.5 
RCS-4 N-(4-
hydroxypentyl) metabolite 0.5 0.7 0.1 1.7 1.1 0.6 3.6 1.0 1.1 1.7 1.1 0.6 
UR-144 N-(2-chloropentyl) 
analog 0.03 0.03 0.01 0.8 0.4 0.3 1.7 0.5 0.4 0.8 0.4 0.3 
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4.3.4 Freeze-Thaw Stability 
Storage conditions can affect analyte stability in samples and in forensic 
toxicology it is common for laboratories to freeze urine specimens upon receipt to 
preserve them until a time when they may be analyzed.  Thus, analyte stability must be 
determined using a series of freeze and thaw cycles.  In accordance with OSAC method 
validation guidelines, urine samples fortified with the analytes underwent freeze-thaw 
cycles in which they were frozen for 24 hours then removed from the freezer and allowed 
to thaw unassisted at room temperature.  This cycle was then repeated two more times.  
An analyte was considered stable when the average signal was within the method’s 
acceptable bias, which in these studies was ±20% of the time zero average signal. 
Samples in this series of studies were prepared in four sets of blank urine diluted 
with water (1:5) with Mixes 2 and 3 at high and low calibration concentrations (e.g., 5 
and 120 ng/mL).  These sets were labeled as T0, T1, T2, and T3, representing each time 
point of the three freeze-thaw cycles, with T0 as the time zero signal where the sample 
has not been subjected to any freeze-thaw cycles.  The analyte signal was determined 
using the analyte response determined using the Quantitative Analysis software. The 
averages of these values at each concentration from each time point were then compared 
to the corresponding time zero value average using Equation 2.  Results for Mix 2 after 
three freeze-thaw cycles are displayed in Table 14 and the results for Mix 3 are displayed 
in Table 15.   
The majority of the analytes in Mix 2 fell within ±20% bias with only a few 
compounds at the low concentration having a bias value greater than 20%.  The seven 
compounds in Mix 2 at with significant stability problems at the low concentration after 
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three freeze-thaw cycles were all synthetic cannabinoids.  Stability of synthetic 
cannabinoids has not been extensively studied, although there have been reports of 
instability for several compounds.26,154 
All compounds in Mix 3 at the high concentration had bias values within ±20% 
after three freeze-thaw cycles.  At the low concentration, only two compounds had bias 
values >20%: oleamide and AKB48 N-pentanoic acid metabolite.  Oleamide is an agonist 
of cannabinoid 1 (CB1) receptors and AKB48 N-pentanoic acid metabolite is a potential 
urinary metabolite of the synthetic cannabinoid AKB48.   
4.3.5 Matrix Effects 
Matrix effects occur when compounds that naturally occur in the sample matrix 
co-elute with analytes of interest and cause either suppression or enhancement of the 
ionization of the target molecule.  Suppression or enhancement of analyte ions can affect 
the values for LOD, LOQ, and bias in quantitative methods and therefore, values should 
not exceed ±25%.  The equation used to calculate matrix effects is shown in Equation 8.  
However, if the calculated value for matrix effects is outside of the ±25% range, the 
laboratory conducting the validation must demonstrate that the matrix effects do not 
cause significant adverse effects to the critical validation parameters. 
𝑀. 𝐸. (%) = ቀ௑
ത௔௥௘௔ ௢௙ ௌ௘௧ ଶ
௑ത௔௥௘௔ ௢௙ ௌ௘௧ ଵ
− 1ቁ 𝑥 100   (8) 
where 𝑋ത is the average area of each set, with Set 1 representing standards prepared in 
water and Set 2 representing standards prepared in urine. 
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 Samples for each set were prepared at low and high concentrations of 5 and 100 
ng/mL, respectively.  Six replicates of each sample at each concentration were analyzed 
with the peak areas of each analyte measured and recorded using the Qualitative Analysis 
software.  Calculated ion suppression and enhancement values for Mixes 1-3 are shown 
in Table 16, Table 17, and Table 18, respectively. 
 Nearly half of the compounds in Mix 1 did not have significant ion suppression or 
enhancement due to matrix effects.  However, there were several compounds that did 
exhibit significant matrix effects.  More than half of the compounds in Mix 2 displayed 
significant ion suppression, as indicated by ionization differences between the neat 
samples prepared in water and the samples prepared in urine, particularly at the high 
concentration of 100 ng/mL.  Several compounds in Mix 3 also displayed significant ion 
suppression at both the low and high concentrations.  However, the critical validation 
parameters (e.g., LOD, LOQ, and bias) of the compounds of both mixes prepared in urine 
are still well within acceptable ranges.   
The matrix effects exhibited were recorded but do not prevent validation of the 
method for these compounds.   The results of the matrix effect studies indicate that more 
thorough sample preparation for urine specimens containing NPS may be necessary prior 
to analysis.  Possible cleanup steps may include further dilution (1:10) or SPE, either on-
line or off-line.  There was no clear trend as to which compounds exhibited the most 
significant matrix effects, however, it was noted that several of the tryptamine and 
metabolites of the synthetic cannabinoid classes were among those that exhibited the 
most ion suppression or enhancement. 
 
79 
   
4.3.6 Carryover  
Analytical methods that include a chromatographic separation step may be subject 
to issues of carryover, which occurs when analytes from a previous sample appear in the 
next sample of a batch, usually as a result of incomplete elution from the separation 
column.  Carryover may lead to inaccurate qualitative or quantitative results thus 
negatively affecting the reliability of the method.  In order to assess carryover, blank 
urine samples were analyzed immediately after the highest concentration calibrator, 
which was 120 ng/mL.  The analysis of the blank urine samples was conducted in 
triplicate for Mixes 1-3.  Using both the Qualitative and Quantitative Analysis software, 
it was determined that there was no significant carryover of any compounds in any of the 
mixes.  An example of the lack of carryover from the method is shown in Figure 7 
through the overlay of the chromatograms generated for oleamide at 5 ng/mL and in the 
blank urine that was analyzed immediately following a 120 ng/mL sample.  Oleamide 
was one of the few analytes that exhibited carryover effects and had the largest peak area 
of those generated.  However, when compared with the peak area of oleamide 
demonstrated at a low concentration of 5 ng/mL, it is clearly shown that the degree of 
carryover is minimal.  
 
 
 
 
Oleamide 
5 ng/mL 
blank urine  
Figure 7. Carryover study for oleamide in Mix 3 comparing analyte concentration present in a 5 ng/mL 
sample with that in a blank urine sample that was analyzed immediately following a 120 ng/mL sample. 
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4.3.7 Analysis of Blind-Spiked Specimens 
Analysis of the blind-spiked urine specimens was conducted using the validated 
LC-QTOF-MS screening method.  Chromatographic separation of the urine specimens 
was conducted using the Zorbax Eclipse Plus C18 RRHD column and an injection volume 
of 10 µL.  The ESI source was operated in positive mode.  
Two acquisition methods were used with the QTOF-MS; Full Scan MS and Auto 
MS/MS.  The same LC, ESI source, and scan parameters were used for each acquisition 
method.  Full Scan MS collected all ion data and did not subject the ions to any collision 
energy.  MS range was 100-1000 m/z and the acquisition rate was 1.5 spectra/s.  The 
Auto MS/MS used an MS range of 100-1000 m/z with an acquisition rate of 3 spectra/s, 
while the MS/MS mass range was 50-1000 m/z with an acquisition rate of 3 spectra/s.   
MS/MS fragmentation was performed at three collision energies of 10, 20, and 40 eV.  
The quadrupole used a narrow isolation width of 1.3 m/z.  Reference mass correction was 
also enabled to ensure proper instrumental calibration throughout the analysis, using 
masses 121.0509 m/z and 922.0098 m/z. 
Agilent MassHunter Qualitative Analysis software was used to perform library 
and database searches for data collected using both Full Scan MS and Auto MS/MS 
modes.  The compound database and library previously created was used for searching.  
For Full Scan MS data analysis, searching was conducted using the “Find Compounds by 
Formula” (FBF) followed by the “Search Library” and “Search Database” commands.  
Analysis of the data collected using Auto MS/MS mode was very similar except that the 
“Find Compounds by Auto MS/MS” command was used instead of the FBF.  The 
potential compound list generated after this command usually included over 250 
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compounds per sample.  This list was then subjected to a search using the accurate mass 
library which employed both forward (matching peaks in the sample against those in the 
library) and reverse (matching peaks in the library against those in the sample) searching.  
Search parameters were set to include precursor ion expansion of ±10 ppm + 2 mDa and 
product ion expansion of ±20 ppm + 2 mDa.  The library search parameters were set to a 
minimum of 70 for both forward and reverse scores. 
Compounds identified by the library search were then subjected to a database 
search which compared the mass of a compound in the sample with the corresponding 
molecular formula in the database.  The database search had a mass tolerance set to ±10 
ppm.  Positive identifications required a library score >80 and a database score >70.  
Mass error was also required to be <10 ppm. 
The scores generated through database and library searching are calculated using 
an algorithm that is proprietary information of the MassHunter Qualitative Analysis 
software.  However, some factors that contribute to this score may include isotope 
abundance, and the presence and intensity of specific ion fragments. 
Two sets of 20 blind-spiked specimens were prepared in diluted urine (1:5) by a 
laboratory member that was not conducting the analysis, hence the term “blind.”  The 
specimens contained 0-1 NPS and were identical for both sets.  The concentration of 
compounds in Set 1 was either 2 or 20 ng/mL with all specimens in Set 2 prepared at a 
concentration of 200 ng/mL.  
Screening of Set 1 resulted in positive identification of the NPS or blank 
specimen for 13/20 specimens (Table 19).  Screening of the higher level Set 2 samples 
resulted in more positive identifications, with 15/20 correctly identified (Table 20).  
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Three of the specimens in Set 2 (specimens 4, 8, and 9) were not originally identified 
correctly, however, the true identity of the NPS in the specimen was included on a “hit 
list” or list of possible identifications.  Closer analysis of the ion fragmentation patterns 
for the analyzed specimens, as well as consideration of the retention times included as 
part of the in-house database, ultimately resulted in the correct identification.    
Specimen 1 from both sets contained mephedrone but was identified as 3-
methylmethcathinone (3-MMC) using the compound database.  Both NPS have the 
chemical formula C11H15NO with an identical accurate mass of 177.1154 Da.  This result 
demonstrates the importance of MS/MS spectral data in the identification of NPS and the 
determination between two very different compounds that share the same chemical 
formula.  The MS/MS spectral data for mephedrone were not included in the HRMS 
library; inclusion of MS/MS data for mephedrone would have resulted in the correct 
identification of the compound in specimen 1.   
Although not all of the compounds in the blind-spiked specimens were correctly 
identified, the preliminary qualitative screening results indicate the utility of the 
compound database and HRMS spectral library for identification of NPS in human urine 
specimens.  It is important to note that the HRMS library used in the above study was 
created in-house and had not been curated to remove background ions as curation of the 
library was not included in the scope of the present research.  The method used for 
screening did not include any extraction or preconcentration procedures prior to analysis, 
and instead utilized a “dilute-and-shoot” approach in which samples in urine were simply 
diluted using water at a ratio of 1:5.  Dilute-and-shoot is a simple method for screening of 
urine specimens, but it does not remove endogenous and possibly interfering compounds, 
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which could contribute to the misidentification or nonidentification of some samples.  
Use of a more thorough sample preparation may have resulted in improved results for the 
screening of the blind-spiked samples. 
4.4 Conclusion 
Validation of a method for screening and confirmation of NPS and related 
compounds was completed following guidelines established by the Toxicology 
Subcommittee of OSAC.  Studies were conducted on NPS in urine to assess linearity, 
accuracy (bias), precision, LOD, LOQ, freeze-thaw stability, ion suppression or 
enhancement due to matrix effects, and carryover.  While not all compounds were able to 
be fully validated using the method, a significant majority of the compounds in each 
mixture were successfully validated.  It was expected that the positive-mode method 
would not be applicable to all NPS of interest given their wide variety of physiochemical 
properties, however, the results demonstrate that a mixture approach is a viable technique 
for validation of a screening and confirmation method for a significantly large number of 
NPS and related compounds. 
The validated method was also used in conjunction with the compound database 
and HRMS spectral library that was developed (see Chapter 3) to qualitatively screen two 
series of 20 blind-spiked specimens in human urine.  The qualitative screening was 
conducted as a preliminary test of applicability to real-world specimens.  Positive 
identification was achieved for the majority of the compounds present in the specimens, 
indicating potential for real-world applicability.  It is believed that identification could be 
further improved through curation of the MS/MS spectral data in the HRMS library to 
remove ions from compounds present in the background.  However, as a preliminary test, 
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applicability of the database and HRMS spectral library used with the validated method 
for screening and confirmation was confirmed. 
 
Table 11. LOD and LOQ values for compounds in Mix 1. 
Compound Name LOD (ng/mL) LOQ (ng/mL) 
α-Pyrrolidinopentiophenone metabolite 1 0.6 1.8 
25I-NBMD 0.2 0.6 
3-Methylbuphedrone 0.5 1.6 
4-APDB 2.5 7.5 
4-fluoro-α-Pyrrolidinobutiophenone 0.4 1.2 
4'-fluoro-α-Pyrrolidinopropiophenone 0.5 1.4 
4-hydroxy MET 0.8 2.4 
4-methoxy PV8 0.7 2.2 
4-methoxy-α-Pyrrolidinopentiophenone 0.7 2.1 
4-Methyl-α-ethylaminobutiophenone 0.2 0.6 
5-fluoro SDB-006 0.7 2.2 
5-Fluoropentylindole 0.6 1.9 
5-MAPB 0.7 2.0 
AB-005 0.3 0.9 
AM-2233 azepane isomer 0.5 1.5 
AM694 N-(5-hydroxypentyl) metabolite 0.6 1.8 
AMT 2.9 8.8 
Benocyclidine 1.4 4.2 
Flubromazepam 0.3 0.8 
JWH 031 2'-isomer 0.7 2.1 
JWH 081 N-(5-hydroxypentyl) metabolite 1.0 3.0 
JWH 200 5-hydroxyindole metabolite 0.7 2.2 
JWH 203 1.0 3.1 
N-Methyltryptamine 2.0 6.1 
NPB-22 0.5 1.5 
PB-22 6-hydroxyisoquinoline isomer 0.5 1.5 
PCMPA 0.5 1.5 
THCA-A 1.4 4.1 
UR-144 N-heptyl analog 0.8 2.3 
 
 
85 
   
Table 12. LOD and LOQ values for compounds in Mix 2. 
Compound Name LOD (ng/mL) LOQ (ng/mL) 
2,3-methylenedoxy pyrovalerone 0.7 2.1 
25I-NBF 0.3 0.9 
2C-T-2 0.5 1.4 
2C-T-4 0.5 1.5 
2-fluoromethcathinone 2.2 6.8 
3,4-dimethoxy- α-
pyrrolidinopentiophenone 1.7 4.4 
3-methyl-α-pyrrolidinopropiophenone 0.8 2.4 
4’-methyl-N-methylhexanophenone 0.7 2.1 
4-ethyl-N,N-dimethylcathinone 1.2 3.6 
4-hydroxy MiPT 0.2 0.7 
4-MMC 1.0 3.1 
A-796260 0.4 1.3 
AB-005 azepine isomer 0.4 1.1 
AB-FUBINACA 3-fluorobenzyl 
isomer 0.8 2.9 
ADB-PINACA isomer 1 0.4 1.3 
AKB48 N-(5-fluoropentyl) analog 0.4 1.1 
Clencyclohexerol 0.2 0.7 
EG-018 0.3 1.0 
JWH 018 N-(5-hydroxypentyl) 
metabolite 0.5 1.6 
JWH 018 N-propanoic acid metabolite 0.4 1.1 
KM 233 0.3 1.0 
Loperamide 0.5 1.5 
MAM2201 N-pentanoic acid 
metabolite 0.3 0.9 
N-Ethylbuphedrone 0.8 2.4 
PCPr 0.4 1.1 
RCS-4 2-methoxy isomer 0.9 2.8 
SER-601 0.1 0.3 
UR-144 Degradant 0.4 1.2 
XLR11 N-(2-fluoropentyl) isomer 0.4 1.3 
Δ8-THC 0.8 2.5 
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Table 13. LOD and LOQ values for compounds in Mix 3. 
Compound Name LOD (ng/mL) LOQ (ng/mL) 
(R)-(−)-MT-45 0.5 1.4 
2,3-Dichlorophenylpiperazine 0.6 1.7 
25H-NBOMe 0.3 0.8 
2C-T 1.3 3.9 
2-Methoxyamphetamine 1.0 2.9 
3,4-Dimethylethcathinone 0.3 0.8 
3C-P 0.8 2.5 
4-Methoxyamphetamine 0.8 2.3 
5-fluoro NNEI 0.2 0.6 
9-octadecenamide/oleamide 1.6 4.7 
AB-CHMINACA 0.8 2.3 
AKB48 N-pentanoic acid metabolite 0.3 0.8 
Cathine 1.2 3.8 
Diclofensine 0.2 0.7 
FUB-PB-22 0.3 0.9 
HMA 1.3 3.9 
MBZP 0.6 1.9 
Mephedrone 0.4 1.2 
Methylenedioxy Pyrovalerone metabolite 2 0.7 2.0 
N-methyl-2-AI 0.4 1.1 
NRG-3 1.0 2.9 
PB-22 N-(5-hydroxypentyl) metabolite 0.3 1.0 
RCS-4 N-(4-hydroxypentyl) metabolite 1.0 3.0 
UR-144 N-(2-chloropentyl) analog 0.5 1.6 
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Table 14. Stability data for Mix 2 compounds after three freeze-thaw cycles. 
 Bias (%) 
Compound Name Low (5 ng/mL) High (120 ng/mL) 
2,3-methylenedoxy pyrovalerone 9.3 4.6 
25I-NBF 9.6 7.9 
2C-T-2 14.3 6.9 
2C-T-4 9.8 5.0 
2-fluoromethcathinone 25.9 5.1 
3,4-dimethoxy- α-
pyrrolidinopentiophenone 4.8 5.6 
3-methyl-α-
pyrrolidinopropiophenone 11.5 6.5 
4’-methyl-N-
methylhexanophenone 13.8 7.2 
4-ethyl-N,N-dimethylcathinone 14.3 9.6 
4-hydroxy MiPT 16.8 16.3 
4-MMC 4.9 4.0 
A-796260 7.0 19.5 
AB-005 azepine isomer 20.7 7.6 
AB-FUBINACA 3-fluorobenzyl 
isomer 4.7 14.0 
ADB-PINACA isomer 1 9.9 5.7 
AKB48 N-(5-fluoropentyl) 
analog 38.5 9.4 
Clencyclohexerol 19.4 17.7 
EG-018 84.1 0.2 
JWH 018 N-(5-hydroxypentyl) 
metabolite 18.3 9.1 
JWH 018 N-propanoic acid 
metabolite 16.7 19.9 
KM 233 73.6 12.8 
Loperamide 3.9 4.9 
MAM2201 N-pentanoic acid 
metabolite 12.1 4.8 
N-Ethylbuphedrone 17.9 11.2 
PCPr 8.5 10.9 
RCS-4 2-methoxy isomer 18.4 5.1 
SER-601 82.7 3.2 
UR-144 Degradant 52.3 7.5 
XLR11 N-(2-fluoropentyl) 
isomer 47.5 3.6 
Δ8-THC 67.0 19.1 
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Table 15. Stability data for Mix 3 compounds after three freeze-thaw cycles. 
 Bias (%) 
Compound Name Low (5 ng/mL) High (120 ng/mL) 
(R)-(−)-MT-45 4.1 5.5 
2,3-Dichlorophenylpiperazine 7.1 8.0 
25H-NBOMe 2.5 8.0 
2C-T 3.1 4.6 
2-Methoxyamphetamine 8.5 3.9 
3,4-Dimethylethcathinone 10.6 10.9 
3C-P 1.6 5.4 
4-Methoxyamphetamine 5.3 18.8 
5-fluoro NNEI 5.9 12.9 
9-octadecenamide/oleamide 32.8 11.8 
AB-CHMINACA 17.7 10.0 
AKB48 N-pentanoic acid metabolite 29.2 14.6 
Cathine 16.1 14.5 
Diclofensine 5.6 3.3 
FUB-PB-22 9.7 12.5 
HMA 8.3 6.3 
MBZP 1.9 9.1 
Mephedrone 7.9 11.7 
Methylenedioxy Pyrovalerone 
metabolite 2 6.1 15.7 
N-methyl-2-AI 12.5 13.8 
NRG-3 5.5 15.1 
PB-22 N-(5-hydroxypentyl) metabolite 10.5 9.5 
RCS-4 N-(4-hydroxypentyl) metabolite 10.6 13.3 
UR-144 N-(2-chloropentyl) analog 18.3 5.5 
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Table 16. Ion suppression and enhancement (matrix effects) values for compounds in Mix 1.  
M.E. (%) 
Compound Name Low (5 ng/mL) High (100 ng/mL) 
25I-NBMD  8.04 -27.14 
3-Methylbuphedrone  -18.57 -21.87 
4-APDB  -52.74 -47.14 
4-fluoro-α-Pyrrolidinobutiophenone  -29.12 -32.58 
4'-fluoro-α-Pyrrolidinopropiophenone  -22.64 -28.71 
4-hydroxy MET -38.35 -45.23 
4-methoxy PV8 4.16 -30.44 
4-methoxy-α-Pyrrolidinopentiophenone  -7.17 -22.65 
4-Methyl-α-ethylaminobutiophenone  -22.95 -39.56 
5-fluoro SDB-006 -20.65 -13.49 
5-Fluoropentylindole -7.85 -6.14 
5-MAPB  -11.10 -26.86 
AB-005 113.44 -22.24 
AM-2233 azepane isomer -10.89 -40.69 
AM694 N-(5-hydroxypentyl) metabolite -5.16 -2.61 
AMT  -30.27 -34.55 
Benocyclidine 21.52 -25.53 
Flubromazepam -55.79 -27.25 
JWH 031 2'-isomer -19.97 13.60 
JWH 081 N-(5-hydroxypentyl) metabolite 1.70 11.84 
JWH 200 5-hydroxyindole metabolite -24.72 -12.64 
JWH 203 1.14 -3.39 
N-Methyltryptamine -92.05 -54.53 
NPB-22 49.11 -3.00 
PB-22 6-hydroxyisoquinoline isomer 53.07 -2.49 
PCMPA -3.68 -22.44 
THCA-A -28.26 -3.48 
UR-144 N-heptyl analog -46.81 -2.99 
α-Pyrrolidinopentiophenone metabolite 1 -20.50 -28.36 
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Table 17. Ion suppression and enhancement (matrix effects) values for compounds in Mix 2. 
 M.E. (%) 
Compound Name Low (5 ng/mL) High (100 ng/mL) 
2,3-methylenedoxy pyrovalerone -15.0 -40.3 
25I-NBF -52.5 -60.7 
2C-T-2 -62.7 -63.0 
2C-T-4 -76.0 -73.1 
2-fluoromethcathinone -16.9 -41.4 
3,4-dimethoxy- α-pyrrolidinopentiophenone 19.2 -43.2 
3-methyl-α-pyrrolidinopropiophenone 3.1 -48.0 
4’-methyl-N-methylhexanophenone -75.1 -79.3 
4-ethyl-N,N-dimethylcathinone -41.2 -66.0 
4-hydroxy MiPT -8.2 -15.8 
4-MMC -68.4 -74.1 
A-796260 -7.4 -41.3 
AB-005 azepine isomer -54.7 -59.9 
AB-FUBINACA 3-fluorobenzyl isomer -19.2 -38.3 
ADB-PINACA isomer 1 9.1 -16.7 
AKB48 N-(5-fluoropentyl) analog -8.3 -5.1 
Clencyclohexerol -71.3 -52.1 
EG-018 -16.9 -8.0 
JWH 018 N-(5-hydroxypentyl) metabolite -1.5 -37.2 
JWH 018 N-propanoic acid metabolite -19.0 -32.2 
KM 233 -18.8 -18.6 
Loperamide -2.1 -34.6 
MAM2201 N-pentanoic acid metabolite -3.4 -18.2 
N-Ethylbuphedrone -43.6 -30.2 
PCPr -32.9 -65.6 
RCS-4 2-methoxy isomer 16.3 -8.4 
SER-601 -3.1 -5.2 
UR-144 Degradant 19.4 -5.0 
XLR11 N-(2-fluoropentyl) isomer 18.0 -5.5 
Δ8-THC -16.6 -23.4 
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Table 18. Ion suppression and enhancement (matrix effects) values for compounds in Mix 3.  
M.E. (%) 
Compound Name Low (5 ng/mL) High (100 ng/mL) 
(R)-(−)-MT-45 32.5 -30.5 
2,3-Dichlorophenylpiperazine -74.3 -76.4 
25H-NBOMe 21.6 -29.7 
2C-T -3.7 -45.6 
2-Methoxyamphetamine -45.9 -52.8 
3,4-Dimethylethcathinone -38.5 -48.5 
3C-P 64.3 -26.8 
4-Methoxyamphetamine -67.6 -58.8 
5-fluoro NNEI -30.6 -18.0 
9-octadecenamide/oleamide -3.1 -6.4 
AB-CHMINACA -3.0 -4.9 
AKB48 N-pentanoic acid 
metabolite -4.2 -5.5 
Cathine -70.5 -19.9 
Diclofensine -24.4 -52.6 
FUB-PB-22 -20.6 -11.2 
HMA -36.6 8.7 
MBZP -6.8 -32.2 
Mephedrone -73.3 -80.1 
Methylenedioxy Pyrovalerone 
metabolite 2 9.9 -49.4 
N-methyl-2-AI -64.4 -67.0 
NRG-3 -44.2 -57.0 
PB-22 N-(5-hydroxypentyl) 
metabolite 2.3 -32.7 
RCS-4 N-(4-hydroxypentyl) 
metabolite -20.1 -16.1 
UR-144 N-(2-chloropentyl) 
analog -40.7 -3.6 
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Table 19. Results of blind-spiked urine specimen screening for Set 1. Specimens were prepared at 
concentrations of 2 or 20 ng/mL. 
Sample True ID Correct 
1 Mephedrone No 
2 PB-22 N-(5-hydroxypentyl) metabolite Yes 
3 MDPV metabolite 2 Yes 
4 BB-22 Yes 
5 AKB48 N-pentanoic acid No 
6 Blank Yes 
7 PB-22 4-hydroxyisoquinoline isomer Yes 
8 PB-22 5-hydroxyisoquinoline isomer Yes 
9 AB-FUBINACA Yes 
10 MDPV Yes 
11 25H-NBOMe No 
12 MDPV No 
13 MDPV metabolite 1 Yes 
14 2C-T No 
15 PCEEA Yes 
16 Blank Yes 
17 5-fluoro PB-22 3-carboxyindole metabolite No 
18 25H-NBOMe Yes 
19 PB-22 N-(5-hydroxypentyl) metabolite Yes 
20 2C-T No 
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Table 20. Results of blind-spiked urine specimen screening for Set 2. Specimens were prepared at 
concentrations of 200 ng/mL. 
Sample True ID Correct 
1 Mephedrone No 
2 PB-22 N-(5-hydroxypentyl) metabolite Yes 
3 MDPV metabolite 2 Yes 
4 BB-22 Yes 
5 AKB48 N-pentanoic acid No 
6 Blank Yes 
7 PB-22 4-hydroxyisoquinoline isomer Yes 
8 PB-22 5-hydroxyisoquinoline isomer Yes 
9 AB-FUBINACA Yes 
10 MDPV Yes 
11 25H-NBOMe No 
12 MDPV Yes 
13 MDPV metabolite 1 Yes 
14 2C-T No 
15 PCEEA Yes 
16 Blank Yes 
17 5-fluoro PB-22 3-carboxyindole metabolite Yes 
18 25H-NBOMe No 
19 PB-22 N-(5-hydroxypentyl) metabolite Yes 
20 2C-T Yes 
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5. DEVELOPMENT OF 2D-LC METHOD 
5.1 Introduction 
Novel psychoactive substances (NPS), also known as “designer drugs” and “legal 
highs,” refer to emerging drugs of abuse that are variations of existing compounds 
intended to cause a CNS psychotropic effect.  Major categories of NPS include synthetic 
cannabinoids, cathinones, piperazines, tryptamines, and phenethylamines.40,69  As more 
and more NPS are synthesized and appear on the market, analytical complications arise, 
due to the need to separate and identify compounds with minor or novel structural 
differences.  These changes may include the alteration of a single functional group or the 
shifting of a functional group on the molecule to create isomers.  Such alterations may 
render some NPS so comparable in structure and physicochemical properties that they 
cannot be separated using traditional techniques such as gas chromatography (GC) or 
liquid chromatography (LC) and therefore will not be detected as individual 
compounds.70-72  NPS of interest that are in complex matrices may also provide an 
analytical challenge, as a multitude of components can interfere with the detection of the 
analyte of interest.98 
Synthetic cannabinoids (SC) were originally developed for research purposes to 
study the pharmacology of compounds that interacted with CB1 and/or CB2 receptors.25  
SC in particular pose a significant challenge to chromatographic separations due to the 
large number of compounds and metabolites that exist, and even more so due to the 
presence of numerous isomers for many SC.155-157  For example, the naphthoylindole 
derivatives have increased in street popularity and include compounds such as JWH 018, 
JWH 019, JWH 080, and JWH 250, all of which share a structure with variation only on 
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the indole alkyl side chain.77,158  Isomers of SC may also have similar chromatographic 
retention times, making baseline separation difficult.  Such co-elution can be a major 
analytical challenge during traditional one-dimensional (1D) chromatographic analyses of 
large numbers of NPS, including SC.  This can be problematic for identification purposes 
if the coeluting compounds are unknown or previously unreported, particularly if they are 
indistinguishable using accurate mass data (e.g., in the case of isomeric derivatives).25,143  
Currently, analytical methods for detecting large numbers of SC in a single 
analysis are not as common as methods intended for a small group of select 
SC.26,156,157,159,160  One such approach was applied to a mixture containing 54 SC and 21 
NPS from other classes.26  However, this screening method relied on the use of known 
retention times and accurate masses of precursor and qualifier ions.  Such is generally the 
case for other methods requiring the use of libraries and databases which depend on 
known accurate masses and retention times.26,143,157,161  This reliance on library data 
becomes problematic when screening for unknown or previously unreported SC, since 
there exist many isomers and related compounds with similar accurate masses, 
fragmentation patterns, and/or chromatographic retention times.  In these instances, it is 
important to have an improved initial separation, so that compounds may be analyzed 
individually once they reach the detector.45,77 
Two-dimensional liquid chromatography (2D-LC) has been proposed as a method 
to improve separation and resolution of complex mixtures prior to further mass spectral 
analysis.73,74  This method has been shown to be effective in the separation of 
pharmaceuticals and small molecules such as methamphetamine, anti-retroviral drugs, 
traditional Chinese medicinal preparations, and antiretroviral drugs from complex 
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samples.71,72,75,88-90,92,105  In the case of NPS such as SC, the improved resolving power 
that 2D-LC can provide may be useful for chromatographically resolving these 
compounds prior to characterization by mass spectrometry.   
To date, there are no reports on the use of 2D-LC specifically for separation of co-
eluting or isomeric NPS, although the demonstrated utility of 2D-LC for other classes of 
xenobiotics indicates that such a method could be effective.81,89,94,162  In the present 
study, the separation of both isomeric and non-isobaric mixtures of SC was examined 
using a 2D-LC separation system coupled with high resolution mass spectrometry 
(HRMS).  To perform the separation, two orthogonal LC column systems, or dimensions, 
were joined to improve the resolving power of the overall separation by combining the 
power of each dimension.79,80,86  This work does not present a validated method, but 
rather serves as a proof-of-concept investigation.  Results of this study confirm the 
potential utility of comprehensive 2D-LC combined with HRMS for the separation and 
identification of co-eluting, non-isobaric and isomeric SC. 
5.2 Materials and Methods 
5.2.1 Chemicals 
Methanol, acetonitrile, and HPLC water (all Optima LC/MS grade) were 
purchased from Fisher Scientific (Fair Lawn, NJ, USA).  Trifluoroacetic acid (TFA) was 
purchased from Sigma-Aldrich (St. Louis, MO, USA).   
5.2.2 Standards 
The synthetic cannabinoids JWH 073 2’-naphthyl-N-(1,1-dimethylethyl) isomer, JWH 
080, JWH 203, FUB-144, PB-22, MAM 2201 N-(2-fluoropentyl) isomer, and XLR-12, in 
addition to five isomers of the synthetic cannabinoid JWH 019 (i.e., N-(2-fluorohexyl), 
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N-(3-fluorohexyl), N-(4-fluorohexyl), N-(5-fluorohexyl), and N-(6-fluorohexyl) isomers) 
were obtained as neat solids from Cayman Chemical (Ann Arbor, MI, USA).  Individual 
stock solutions of the standards were prepared at concentrations of 1 µg/mL in methanol.   
Stock solutions of the SC were used to create individual component working 
solutions as well as three test mixes, each containing five individual components.  In 
previous 1D-LC work, very close retention times were observed for the individual 
components of each mix using a Zorbax Eclipse Plus RRHD C18 column (3.0 x 100 mm; 
1.8 µm; Agilent Technologies, Santa Clara, CA).  Retention times were collected over 20 
min using a gradient that reached 90% B at 9.5 min, then held for the final 6.5 min.  
These retention times are given in Table 21.  In other words, the separation of all the 
constituents in the mixtures described here was not achievable by conventional means.  
Co-elution (CE) Mix 1 contained five JWH 019 isomers, while CE Mixes 2 and 3 each 
contained five non-isobaric (but co-eluting) synthetic cannabinoids.  The composition of 
each mix is shown in Table 21 and the structures of all compounds examined are shown 
in Figure 8.  The individual working solutions and mixes were prepared in MeOH:H2O 
(50:50 v/v) with each component present at a concentration of 1 µg/mL. 
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Table 21. Synthetic cannabinoids present in each co-elution (CE) mix. 
 Compound Name aPeak # Molecular Formula 
Exact Mass 
(Da) 
bRT (min) 
CE 
Mix 
1 
JWH 019 N-(2-
fluorohexyl) isomer 1 C25H24FNO 373.1842 12.16 
JWH 019 N-(3-
fluorohexyl) isomer 2 C25H24FNO 373.1842 12.25 
JWH 019 N-(4-
fluorohexyl) isomer 3 C25H24FNO 373.1842 11.90 
JWH 019 N-(5-
fluorohexyl) isomer 4 C25H24FNO 373.1842 11.75 
JWH 019 N-(6-
fluorohexyl) isomer 5 C25H24FNO 373.1842 11.76 
CE 
Mix 
2 
JWH 080 6 C24H23NO2 357.1729 12.16 
JWH 203 7 C21H22ClNO 339.1390 12.22 
PB-22 8 C23H22N2O2 346.1681 11.88 
MAM 2201 N-(2-
fluoropentyl) isomer 9 C25H24FNO 373.1842 12.20 
XLR12 10 C20H24F3NO 351.1810 12.01 
CE 
Mix 
3 
JWH 073 2’-naphthyl-N-
(1,1-dimethylethyl) isomer 11 C23H21NO 327.1623 12.20 
JWH 019 N-(2-
fluorohexyl) isomer 1 C25H24FNO 373.1842 12.16 
JWH 080 6 C24H23NO2 357.1729 12.16 
JWH 203 7 C21H22ClNO 339.1390 12.22 
FUB-144 12 C23H24FNO 349.1842 12.26 
aPeak number as indicated in Figures 13, 14, and 15. 
bRetention time observed in 1D-LC separation performed in Chapter 4. 
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Figure 8. Structures of NPS in CE mixes (see Table 21 for mixture compositions): (1) JWH 019 N-(2-
fluorohexyl) isomer, (2) JWH 019 N-(3-fluorohexyl) isomer, (3) JWH 019 N-(4-fluorohexyl) isomer, (4) 
JWH 019 N-(5-fluorohexyl) isomer, (5) JWH 019 N-(6-fluorohexyl) isomer, (6) JWH 080, (7) JWH 203, 
(8) PB-22, (9) MAM2201 N-(2-fluoropentyl) isomer, (10) XLR12, (11) JWH 073 2’-naphthyl-N-(1,1-
dimethylethylisomer), and (12) FUB-144. 
. 
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5.2.3 Instrumentation 
Comprehensive, on-line 2D-LC analysis was performed with an Agilent Infinity 
1290 2D-LC solution system (Agilent Technologies, Santa Clara, CA, USA) composed 
of two G4220A binary pumps, a G4226A temperature controlled autosampler, a G1316C 
thermostatted column compartment, and a G1170A Infinity Valve Drive with a two-
position eight-port switching valve (pressure limit 1200 bar; p/n 5067-4214) and two 20-
µL sampling loops.  The configuration of the 2D-LC instruments is shown in Figure 9. 
Schematic of the two-position, four-port duo valve (right) used in conjunction with ta two-
position, six-port valve (left) to connect the two dimensions..   
 
Figure 9. Schematic of the two-position, four-port duo valve (right) used in conjunction with ta two-
position, six-port valve (left) to connect the two dimensions.   
 
For initial investigation of the columns chosen for each dimension, two Agilent 
1290 diode array detectors were used, one after the 1D separation and another following 
the 2D separation.  Once the initial investigations were completed, the 2D-LC system 
utilized the same Agilent 1290 diode array detector placed directly after the first 
dimension.  In addition, an Agilent 6530 Accurate-Mass Quadrupole Time-of-Flight 
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(QTOF) mass spectrometer with Jetstream ESI source was placed directly after the 
second dimension and used as the 2D detector (Figure 10).  Positive mode ESI source 
settings were as follows: gas temperature, 300 ºC; drying gas flow rate, 8 L/min; 
nebulizer pressure, 35 psi; sheath gas temperature, 350 ºC; sheath gas flow rate, 11 
L/min; capillary voltage, 3500 V; and nozzle voltage, 1000 V.  The QTOF fragmentor 
and skimmer voltages were 175 and 65 V, respectively.  Mass spectral data were 
collected in Full Scan mode with a mass range of 100 – 1700 m/z, and an acquisition rate 
of 1 spectrum/s.  No collision energy was employed during the MS data collection. 
 
Figure 10. Schematic for the 2D-LC setup used in final system. 
 
The software used to acquire, view, and analyze the analytical data included 
MassHunter Data Acquisition (version B.06.01), MassHunter Qualitative Analysis 
(version B.07.00), Open Lab Control Panel, and ChemStation (version C.01.07), all from 
Agilent Technologies (Santa Clara, CA, USA).  Compounds were identified based on 
accurate mass with a mass tolerance of ±5 ppm using the Qualitative Analysis software.   
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5.2.4 Analytical Columns and Separation 
Separation of the components of each mix was initially examined in 1D-LC mode 
on each of the three columns listed below.  These separations involved a 20-min gradient 
with (A) water + 0.1% formic acid and (B) MeOH + 0.1% formic acid at a flow rate of 
0.3 mL/min.  The gradient ran 5% to 95% B from 0.5 to 9.5 min, where it was then held 
at 95% for the remainder of the analysis. 
Both the 1D and 2D separations employed reversed-phase LC conditions.  Three 
columns were tested; a Zorbax Eclipse Plus RRHD column (3.0 x 100 mm; 1.8 µm; 
Agilent Technologies, Santa Clara, CA), a Poroshell 120 Bonus-RP column (2.1 x 
150mm, 2.7 µm; Agilent Technologies, Santa Clara, CA), and an Ascentis Express 
biphenyl column (2.1 mm x 100 mm, 2.7 µm; Supelco, Bellefonte, PA).  In the final 2D 
method, the Poroshell 120 Bonus-RP column was chosen for 1D and the Ascentis Express 
biphenyl column was chosen for 2D.  Parameters for each dimension were optimized 
separately in 1D-LC separations before optimizing the complete 2D-LC separation 
system.  Both dimensions used HPLC water with 0.1% TFA for the aqueous (A) solvent.  
For the 1D separation, the (B) solvent was a mixture of acetonitrile (ACN) and water 
(95:5 v/v), and in the second dimension it was a mixture of methanol (MeOH) and water 
(95:5 v/v).  Columns were maintained at 40 °C in both dimensions.  The temperature 
controlled autosampler was maintained at a temperature of 20 °C.  In the first dimension, 
the flow rate was 0.1 mL/min, and the following solvent gradient was used for elution 
from the column: 5-5-80-80-95-95-100-10-5-5% B from 0-0.5-19-20-30-37-42-42.01-45 
min, respectively.  The semi-shifted gradient used in the second dimension is shown in 
Figure 11 and the 2D flow rate was 0.55 mL/min.  The 2D gradient stop time was 0.95 
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min and the modulation time was 1.15 min. 
For each injection, UV spectra were collected with the diode array detector after 
the 1D column at 210, 220, 230, 240, and 250 nm.  This was done to monitor any 
potential component separation that occurred solely in the first dimension.  Working 
solutions of each compound were first run individually through the 2D-LC system to 
collect UV spectra and chromatograms for each compound.  CE mixes were run under 
the same conditions and their data compared to those collected for the individual 
compounds.  The volume of sample injected into the 1D column was 2 µL. 
 
Figure 11. Solvent gradients used in the first and second dimensions of the 2D-LC separation. 
 
5.3 Results and Discussion 
Tentative determination of unknown compounds in samples can be conducted 
using a method known as suspect screening through the use of predicted or characteristic 
properties of compounds (i.e., accurate mass, isotope pattern, product ion spectrum).63  
This method, though, is most effective when sample data are compared with previously 
collected data in a library or database.  In the case of truly unknown and unreported 
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compounds, it could be difficult to determine if the sample data represents a single 
analyte or a possible mixture of analytes or endogenous compounds, thus highlighting the 
need for adequate separation.46 
The use of 2D-LC has several benefits for analytical separation of both small and 
large molecules.  These include increased peak capacities, greater resolving power, 
separation of isomers and isobars, and better separation of compounds and metabolites, 
particularly in complex mixtures.70,72,76,86,88,118  The increased separation power of 2D-LC 
derives from the combined resolution and peak capacities of the two orthogonal 
dimensions.  There are two general approaches to 2D-LC; comprehensive and heart-
cutting separation.  The present research focused on the use of comprehensive 2D-LC, 
which involves the complete transfer of all effluent from 1D to 2D.  This approach enables 
full automation of the chromatographic analysis, is preferred for use in non-targeted 
analyses, and minimizes analyte loss.  Low analyte loss makes comprehensive analysis 
the preferred 2D method for analytes present at low concentrations in complex 
matrices.70,71,85,86,163  Despite these advantages, development of a working on-line, 
comprehensive 2D-LC method is time-consuming, due to the need to optimize all aspects 
of each individual dimension, including column type, mobile phase selection and 
compatibility, analysis time, gradient, and flow rate, prior to development of the complete 
2D system.73,98,108 
The improved separation power of 2D-LC itself does not directly lead to 
identification, but can provide additional, orthogonal information to assist in proper 
identification of compounds.  This is particularly evident when identification based on 
MS-data might be challenging based on interfering compounds or in instances of 
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previously unreported substances.  Less lengthy methods with orthogonal properties 
exist, but they may have their own limitations.  Techniques combining ion mobility 
spectrometry (IMS) with HRMS to collect orthogonal identification information 
represent are examples of such methods.  In IMS, substances are characterized based on 
the speed at which analyte ions move through an applied electric field and gas 
atmosphere before reaching the detector.  Minute differences in this speed, or drift time, 
combined with the orthogonal resolving power of HRMS might be able to provide 
identification of isomeric and chemically related compounds.164  However, increased 
performance with IMS methods, particularly for applications with drugs of abuse, is often 
a result of improved sample preparation steps such as solid-phase extraction (SPE) or 
paper spray.165,166  These steps require more time and effort for sample preparation prior 
to analysis and could cause potential sample loss, contamination, or even decrease of ion 
intensities, which can be avoided through the use of a comprehensive 2D-LC method of 
separation.  Overlapping drift time peaks may also still occur in some instances.  These 
overlaps could be corrected by using a different drift gas, however, when working with 
unknown compounds, it is not always apparent that such overlap has occurred and that 
differing IMS conditions are needed during the analysis prior to MS-detection.165   
In the present study, an RP x RP separation was developed involving an Agilent 
Poroshell 120 Bonus-RP column in the first dimension and an Ascentis Express biphenyl 
column in the second dimension.  The latter column was chosen due to its ability to 
separate aromatic compounds, including synthetic cannabinoids, as a result of the π-π 
interactions and the influence of analyte shape on interactions between the compound 
ring structures and the biphenyl moieties of the column stationary phase.167,168  
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Resolution of the components of each mix was initially examined on each column 
separately.  The initial 1D-LC separation of CE Mixes 1 and 2 on the Zorbax Eclipse Plus 
C18 column demonstrated that there was co-elution of multiple compounds in each mix 
(Figure 12a and 12b).  The Bonus-RP column was then investigated for its selectivity 
toward the compounds in CE Mixes 1 and 2.  Figure 13a and 13b show the 
chromatograms for these two mixes, respectively.  This column demonstrated improved 
separation of the mixture components, indicating that it would be a good selection for the 
final 2D-LC method. 
 
 
Figure 12. UV chromatograms (λ=220 nm) for 1D separations of (a) CE Mix 1, 
and (b) CE Mix 2 with the Zorbax Eclipse Plus C18 column. 
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Use of the biphenyl column in 1D-LC separation mode also demonstrated some 
initial separation of the isomeric compounds in CE Mix 1 (Figure 14a) and the non-
isobaric components of CE Mix 2 (Figure 14b).  These data suggested that the biphenyl 
column could be a good choice for use in the final 2D-system in order to achieve full 
separation and resolution of all mixture components.  The Bonus-RP and biphenyl 
columns were then combined in a 2D-system and tested for separation of CE mixes using 
diode array and QTOF-MS for detection in the first and second dimensions, respectively.  
Optimization of the final 2D-LC method based on the results of the 1D-LC experiments 
was performed to increase its applicability to the wider range of compounds included in 
the CE mixes, as well as to facilitate coupling of the two dimensions.  While the 
mechanics of a 2D-LC system are only briefly discussed here, further information can be 
found in recently published works discussing general function of 2D-LC systems.74,102 
The resulting 2D-LC method was then tested on CE Mixes 1 and 2 (i.e., isomeric 
and non-isobaric component mixtures, respectively) with diode array detection following 
the first dimension and QTOF-MS identification following the second.  In addition, as a 
further test, a new non-isobaric component mixture (i.e., CE Mix 3) was formulated.  
This contained two components from CE Mix 2 (JWH 080 and JWH 203) in addition to 
three other SC for which very close retention times were also observed in 1D-LC 
analyses (JWH 073 2’-naphthyl-N-(1,1-dimethylethyl) isomer, JWH 019 N-(2-
fluorohexyl) isomer, and FUB-144).  CE Mixes 1 and 2 were used for initial testing of the 
2D-LC method.  CE Mix 3 was later created containing components from CE Mixes 1 
and 2, in addition to other non-isobaric compounds, as a final test of the method.  2D-LC 
of CE Mix 1 resulted in excellent separation of the JWH-019 2-, 5-, and 6-fluorohexyl 
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isomers with slight co-elution of the 3- and 4-fluorohexyl isomers (Figure 15a).  2D-LC 
of CE Mix 2 resulted in complete separation of PB-22, JWH 203, and XLR-12, with 
slight co-elution of MAM-2201 N-(2-fluoropentyl) isomer and JWH 080 (Figure 15b).   
Finally, 2D-LC separation of CE Mix 3 yielded complete resolution of all five 
cannabinoid components (Figure 15c). 
 
Figure 13. UV chromatograms (λ=240 nm) for 1D separations of (a) CE Mix 1, and (b) CE Mix 2 using the 
Bonus-RP column over 3 min at a flow rate of 0.5 mL/min with a gradient of 50-95% B; A: water + 0.1% 
TFA, and B: acetonitrile.  Peak numbers correspond to compounds listed in Table 21. 
The present research focused on the initial development of an on-line, 
comprehensive 2D-LC method for the separation of synthetic cannabinoids using a 
reversed-phase (RP) column in each dimension.  2D-LC involving RP columns has been 
employed with pharmaceuticals and other small molecules, suggesting their potential 
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utility for separation of NPS including SC,85,94,97,108,124  Two detectors were used for 
method development; a diode array detector after the first dimension and a quadrupole 
time-of-flight (QTOF) mass spectrometer after the second dimension.  In a final method, 
the first detector would be unnecessary, as the 2D MS detector provides accurate mass 
data of the separated compounds for identification within ±5 ppm.   
 
Figure 14. UV chromatograms (λ=240 nm) for 1D separation of (a) CE Mix 1 over 5 min, and (b) CE Mix 
2 over 3 min using the biphenyl column at a flow rate of 0.5 mL/min with a gradient of 70-95% B; A: water 
+ 0.1% TFA, and B: MeOH.  Peak numbers correspond to compounds listed in Table 21. 
 
The Bonus-RP column was ultimately selected for use in 1D in part due to its 
column packing which has a polar amide group in the long alkyl chain, making it a good 
choice for use with basic analytes, generally resulting in good peak shape, as well as the 
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different separation selectivities it demonstrated as compared to standard C18 columns, 
including the one initially tested in the present study.169,170  The stationary phase in the 
biphenyl column used in the second dimension is quite different, with a biphenyl moiety 
bonded to the silica particle.  This chemistry provides selectivity that is complementary to 
typical C18 RP columns, which is useful in the context of a 2D-LC method.  
Consequently, a biphenyl column can be an ideal choice for use with SC, due to the 
greater affinity for the aromatic groups and alkyl chains present in many of these 
compounds.167,168,171 
5.4 Conclusion 
The present report is the first to describe a comprehensive, on-line two-
dimensional liquid chromatography (RP x RP) method that would be a suitable technique 
for the separation of NPS.  Results of the study serve as a proof-of-concept for the 
application of 2D-LC to the separation of isomeric and structurally related SC.  We 
believe that with further investigation, optimization, and validation, 2D-LC will be a 
viable tool for more reliable separation of complex mixtures of SC compared to what can 
currently be achieved using conventional 1D-LC. 
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Figure 15. Contour plots demonstrating the 2D separation of CE mixes 1, 2, and 3.  Peak number 
correspond to those listed in Table 21. 
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6. SUMMARY AND PROSPECT 
The constant emergence of novel psychoactive substances will continue to present 
new analytical challenges to both forensic and clinical toxicology laboratories.  Current 
screening methods typically rely on screening methods designed for specific compounds 
or compound classes which have demonstrated inconsistent, and often lacking, 
applicability to specimens containing NPS.  Other methods of screening, such as the use 
of accurate mass databases and MS/MS libraries, present another option for more 
comprehensive, general screening and confirmation of compounds in human specimens.  
However, these tools are lacking in the presence of many NPS and remedying such 
deficiencies requires resources to which some laboratories do not have access (i.e., poor 
availability of reference standards).  The ability to identify these substances in forensic 
and clinical human specimens is important for conducting comprehensive toxicological 
screening and confirmation.  It was this project’s aim to create a large high resolution 
MS/MS spectral library and compound database for several hundreds of novel 
psychoactive substances and related compounds in order to aid the forensic and clinical 
toxicological communities in detecting and identifying such substances in human 
specimens.  A method for comprehensive screening and confirmation was also validated 
for use with the HRMS spectral library and compound database using a mixture 
approach.   
 Mass spectral techniques have gained favor in toxicological laboratories for 
screening purposes due to their capability of collecting data with high degrees of 
selectivity and sensitivity which greatly aid in identification substances in toxicological 
samples.  These techniques also have an advantage over other methods of screening, such 
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as immunoassays, in that they are not designed to detect a specific compound or 
compound class, but rather can be applied to a much broader range of potential analytes. 
 Spectral libraries and compound databases are used in conjunction with mass 
spectrometry techniques and can be extremely useful for screening purposes.  In cases 
where a reference standard is not available to a laboratory, these resources can be 
searched and can present a tentative identification based on information contained within 
the database.  When data are collected using high resolution mass spectrometry 
techniques, such as the LC-QTOF-MS used in this research, the selectivity is greatly 
increased thus improving confidence in correct identification.  This high resolution and 
high mass accuracy enables differentiation between compounds with very similar 
accurate masses.  The characteristic MS/MS spectral data collected using HRMS 
techniques also increases confidence in identification based on fragmentation patterns of 
each analyte.  HRMS data collection can include information for all ions present in the 
sample which can then be retrospectively searched when new NPS are reported without 
the need for sample reanalysis.  The use of the compound database and MS/MS spectral 
library created by this work can greatly assist forensic and clinical toxicological 
laboratories in saving valuable time and resources when attempting to identify novel 
psychoactive substances in toxicological specimens.   
 Following completion of the compound database and MS/MS library, a 
comprehensive method for screening and confirmation was validated following standard 
guidelines from the Toxicology Subcommittee of the Organization of Scientific Area 
Committees.  Proof of concept was achieved for the use of a mixture approach for 
validation as opposed to validating the method for a single compound or class of 
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compounds one at a time.  This technique saved valuable time and resources, and also 
demonstrated that the method could be applied comprehensively to a broad range of NPS 
from a variety of compound classes.  The mixture approach has shown that it can be used 
in the future by other laboratories when validating toxicological screening and 
confirmation methods for a large group of NPS.  The method was successfully validated 
for detection and identification of NPS at low ng/mL concentrations.  Applicability of the 
method with the database and HRMS spectral library was also demonstrated through the 
qualitative screening of blind-spiked human urine specimens. 
 Finally, throughout the creation of the compound database and MS/MS spectral 
library, and during the subsequent method validation, it became apparent that some 
compounds could not be differentiated based on MS/MS data or chromatographically.  
This was especially apparent with isomeric compounds and those with related chemical 
structures.  Typically, HRMS methods may be used to determine compounds with highly 
similar accurate masses, however, in instances of unreported and truly unknown NPS, it 
would be difficult to determine if a collected mass spectrum was representative of a 
single analyte or of multiple ones.  In the case of isomers which have the same or similar 
MS/MS spectra, chromatographic information can be used.  However, if adequate 
separation of the compounds cannot be achieved through traditional chromatographic 
methods, a different approach must be used.  Two-dimensional liquid-chromatography 
(2D-LC) was investigated as part of this project to determine if it could be a viable option 
for separation of co-eluting compounds; mainly isomers and structurally similar 
compounds.   
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 Mixtures of synthetic cannabinoids—both isomeric and non-isobaric—were 
created for the 2D-LC investigations.  An on-line, comprehensive method using a Bonus-
RP column in the first dimension and a biphenyl column in the second dimension was 
developed as a proof-of-concept for the application of 2D-LC to separation of such 
mixtures.  Separation was successfully achieved for all compounds present in each 
mixture, but further development will be required in order to broaden applicability of the 
technique to NPS from other compound classes, as separation parameters can be 
compound specific.  
 A large compound database and MS/MS spectral library was successfully created 
and a corresponding method for screening and confirmation was fully validated using a 
mixture approach.  These resources present valuable tools for forensic and clinical 
toxicology laboratories to use when screening for a wide variety of NPS.  A two-
dimensional liquid chromatographic method for separation of synthetic cannabinoids was 
also developed and demonstrated successful separation of isomeric and non-isobaric 
compounds from that class.   
 Future work will be required, however, to update and expand the compound 
database and MS/MS spectral library as more NPS are reported and as appropriate 
reference standards become commercially available.  HRMS techniques should continue 
to gain favor for toxicological applications as they demonstrate improved selectivity and 
sensitivity over other screening approaches.  Further investigation of two-dimensional 
liquid chromatography for improved separation of isomeric and structurally related NPS 
should also be conducted, as complete separation using traditional methods is likely to be 
challenged as more compounds emerge on the market. 
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Appendix 1. Compounds included in the NPS database with their unique in-house identifying number. 
Compound Name Formula Accurate Mass FIU Number 
(±)-Ethylphenidate C15H21NO2 247.1572 FIU 0279 
2,4,6-Trimethoxyamphetamine C12H19NO3 225.1365 FIU 0280 
2-Bromoamphetamine C9H12BrN 213.0153 FIU 0281 
2-Chloroamphetamine C9H12ClN 169.0658 FIU 0282 
2-methoxy Ketamine C14H19NO2 233.1416 FIU 0283 
2-Methoxyamphetamine C10H15NO 165.1154 FIU 0284 
3,4-EDMC C12H15NO3 221.1052 FIU 0285 
3-Bromoamphetamine C9H12BrN 213.0153 FIU 0286 
3-Chloroamphetamine C9H12ClN 169.0658 FIU 0287 
3-Iodoamphetamine C9H12IN 261.0014 FIU 0288 
3-Methoxyamphetamine C10H15NO 165.1154 FIU 0289 
4-Bromoamphetamine C9H12BrN 213.0153 FIU 0290 
4-Chloroamphetamine C9H12ClN 169.0658 FIU 0291 
4-Hydroxyamphetamine C9H13NO 151.0997 FIU 0292 
4-Methoxyamphetamine C10H15NO 165.1154 FIU 0293 
4-MTA C10H15NS 181.0925 FIU 0294 
4-MTA (hydrochloride 
preparation) C10H15NS 181.0925 FIU 0295 
D-Amphetamine C9H13N 135.1048 FIU 0296 
deschloro-N-ethyl-Ketamine C14H19NO 217.1467 FIU 0297 
Diclofensine C17H17Cl2NO 321.0687 FIU 0298 
DOI C11H16INO2 321.0226 FIU 0299 
HMA C10H15NO2 181.1103 FIU 0300 
Lisdexamfetamine C15H25N3O 263.1998 FIU 0301 
Propylhexedrine C10H21N 155.1674 FIU 0302 
CMP C10H17N 151.1361 FIU 0303 
2,5-DMMA C12H19NO2 209.1416 FIU 0304 
3,4-DHMA C10H15NO2 181.1103 FIU 0305 
4-bromo-2,5-DMMA C12H18BrNO2 287.0521 FIU 0306 
para-
Methoxymethamphetamine C11H17NO 179.1310 FIU 0307 
Methiopropamine C8H13NS 155.0769 FIU 0308 
N,N-DMA C11H17N 163.1361 FIU 0309 
2C-G C12H19NO2 209.1416 FIU 0310 
2C-T C11H17NO2S 227.0980 FIU 0311 
2C-T-7 C13H21NO2S 255.1293 FIU 0312 
2C-TFM C11H14F3NO2 249.0977 FIU 0313 
bk-2C-B C10H12BrNO3 273.0001 FIU 0314 
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3C-B-fly C13H16BrNO2 297.0364 FIU 0315 
3C-P C14H23NO3 253.1678 FIU 0316 
N-methyl-2-AI C10H13N 147.1048 FIU 0317 
Escaline C12H19NO3 225.1365 FIU 0318 
Mescaline C11H17NO3 211.1208 FIU 0319 
2-Amino-1-phenylbutane C10H15N 149.1204 FIU 0320 
2-Ethylamino-1-phenylbutane C12H19N 177.1517 FIU 0321 
4-CAB C10H14ClN 183.0815 FIU 0322 
Cathine C9H13NO 151.0997 FIU 0323 
(R)-(−)-MT-45 C24H32N2 348.2565 FIU 0324 
(S)-(+)-MT-45 C24H32N2 348.2565 FIU 0325 
2,3-Dichlorophenylpiperazine C10H12Cl2N2 230.0378 FIU 0326 
MBZP C12H18N2 190.1470 FIU 0327 
MT-45 C24H32N2 348.2565 FIU 0328 
Mepirapim C19H27N3O 313.2154 FIU 0329 
2-Fluoroisocathinone C9H10FNO 167.0746 FIU 0330 
3,4-Dimethylethcathinone C13H19NO 205.1467 FIU 0331 
4-methoxy-N,N-
Dimethylcathinone C12H17NO2 207.1259 FIU 0332 
4-Methylethcathinone 
metabolite ((±)-Ephedrine 
stereochemistry) 
C12H19NO 193.1467 FIU 0333 
4-Methylethcathinone 
metabolite ((±)-
Pseudoephedrine 
stereochemistry) 
C12H19NO 193.1467 FIU 0334 
N-ethyl-N-Methylcathinone C12H17NO 191.1310 FIU 0335 
Isopentedrone C12H17NO 191.1310 FIU 0336 
Mephedrone C11H15NO 177.1154 FIU 0337 
Mephedrone metabolite ((±)-
Ephedrine stereochemistry) C11H17NO 179.1310 FIU 0338 
Mephedrone metabolite ((±)-
Pseudoephedrine 
stereochemistry) 
C11H17NO 179.1310 FIU 0339 
NRG-3 C16H19NO 241.1467 FIU 0340 
Pentedrone metabolite ((±)-
Ephedrine stereochemistry) C12H19NO 193.1467 FIU 0341 
Pentedrone metabolite ((±)-
Pseudoephedrine 
stereochemistry) 
C12H19NO 193.1467 FIU 0342 
Benzedrone C17H19NO 253.1467 FIU 0343 
(−)-(S)-Cathinone C9H11NO 149.0841 FIU 0344 
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2,3-Dimethylethcathinone C13H19NO 205.1467 FIU 0345 
2,4-Dimethylethcathinone C13H19NO 205.1467 FIU 0346 
Diethylcathinone C13H19NO 205.1467 FIU 0347 
2,3-Dimethylmethcathinone C12H17NO 191.1310 FIU 0348 
2,4-Dimethylmethcathinone C12H17NO 191.1310 FIU 0349 
3,4-Dimethylmethcathinone 
metabolite ((±)-Ephedrine 
stereochemistry) 
C12H19NO 193.1467 FIU 0350 
3,4-Dimethylmethcathinone 
metabolite ((±)-
Pseudoephedrine 
stereochemistry) 
C12H19NO 193.1467 FIU 0351 
3-Bromomethcathinone C10H12BrNO 241.0102 FIU 0352 
4-Bromomethcathinone C10H12BrNO 241.0102 FIU 0353 
4-Fluoromethcathinone 
metabolite ((±)-Ephedrine 
stereochemistry) 
C10H14FNO 183.1059 FIU 0354 
4-Fluoromethcathinone 
metabolite ((±)-
Pseudoephedrine 
stereochemistry) 
C10H14FNO 183.1059 FIU 0355 
(−)-3,4-Methylenedioxy 
Pyrovalerone C16H21NO3 275.1521 FIU 0356 
(+)-3,4-Methylenedioxy 
Pyrovalerone C16H21NO3 275.1521 FIU 0357 
2,3-MDA C10H13NO2 179.0946 FIU 0358 
2,3-MDMA C11H15NO2 193.1103 FIU 0359 
3,4-MDMA C11H15NO2 193.1103 FIU 0360 
3,4-Methylenedioxy-5-
methylethcathinone C13H17NO3 235.1208 FIU 0361 
3,4-Methylenedioxy-N-
benzylcathinone C17H17NO3 283.1208 FIU 0362 
Methylenedioxy Pyrovalerone C16H21NO3 275.1521 FIU 0363 
Methylenedioxy Pyrovalerone 
Metabolite 1 C16H23NO3 277.1678 FIU 0364 
Methylenedioxy Pyrovalerone 
metabolite 2 C15H21NO3 263.1521 FIU 0365 
N-acetyl-3,4-
Methylenedioxymethcathinone C13H15NO4 249.1001 FIU 0366 
N-hydroxy MDA C10H13NO3 195.0895 FIU 0367 
Myristicin C11H12O3 192.0786 FIU 0368 
Piperonyl methyl ketone C10H10O3 178.0630 FIU 0369 
Safrole C10H10O2 162.0681 FIU 0370 
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25B-NBOMe C18H22BrNO3 379.0783 FIU 0371 
25C-NBOMe C18H22ClNO3 335.1288 FIU 0372 
25D-NBOMe C19H25NO3 315.1834 FIU 0373 
25E-NBOMe C20H27NO3 329.1991 FIU 0374 
25G-NBOMe C20H27NO3 329.1991 FIU 0375 
25H-NBOMe C18H23NO3 301.1678 FIU 0376 
25H-NBOMe imine analog C18H21NO3 299.1521 FIU 0377 
25I-NBF C17H19FINO2 415.0445 FIU 0378 
25I-NBMD C18H20INO4 441.0437 FIU 0379 
25I-NBOMe 3-methoxy isomer C18H22INO3 427.0644 FIU 0380 
25I-NBOMe 4-methoxy isomer C18H22INO3 427.0644 FIU 0381 
25I-NBOMe imine analog C18H20INO3 425.0488 FIU 0382 
25N-NBOMe C18H22N2O5 346.1529 FIU 0383 
25T2-NBOMe C19H25NO3S 347.1555 FIU 0384 
30C-NBOMe C20H26ClNO5 395.1500 FIU 0385 
3-methoxy PCP C18H27NO 273.2093 FIU 0386 
4-methoxy PCP C18H27NO 273.2093 FIU 0387 
PCEEA C16H25NO 247.1936 FIU 0388 
PCMPA C16H25NO 247.1936 FIU 0389 
PCPr C15H23N 217.1830 FIU 0390 
Benocyclidine C19H25NS 299.1708 FIU 0391 
2-methyl-α-
Pyrrolidinopropiophenone C14H19NO 217.1467 FIU 0392 
3,4-dimethoxy-α-
Pyrrolidinopentiophenone C17H25NO3 291.1834 FIU 0393 
3'-fluoro-α-
Pyrrolidinopropiophenone C13H16FNO 221.1216 FIU 0394 
3-methyl-α-
Pyrrolidinopropiophenone C14H19NO 217.1467 FIU 0395 
4’-Methyl-N-
methylhexanophenone C14H21NO 219.1623 FIU 0396 
4-fluoro-α-
Pyrrolidinobutiophenone C14H18FNO 235.1372 FIU 0397 
4-fluoro-α-
Pyrrolidinopentiophenone C15H20FNO 249.1529 FIU 0398 
4'-fluoro-α-
Pyrrolidinopropiophenone C13H16FNO 221.1216 FIU 0399 
4-methoxy-α-
Pyrrolidinobutiophenone C15H21NO2 247.1572 FIU 0400 
4-methoxy-α-
Pyrrolidinopentiophenone C16H23NO2 261.1729 FIU 0401 
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4-Methyl-α-
ethylaminobutiophenone C13H19NO 205.1467 FIU 0402 
4-Methyl-α-
ethylaminopentiophenone C14H21NO 219.1623 FIU 0403 
α-Ethylaminopentiophenone C13H19NO 205.1467 FIU 0404 
α-Pyrrolidinobutiophenone C14H19NO 217.1467 FIU 0405 
α-Pyrrolidinobutiothiophenone C12H17NOS 223.1031 FIU 0406 
α-Pyrrolidinopentiophenone 
metabolite 1 C15H23NO 233.1780 FIU 0407 
α-
Pyrrolidinopentiothiophenone C13H19NOS 237.1187 FIU 0408 
4-fluoro PV8 C17H24FNO 277.1842 FIU 0409 
4-fluoro PV9 C18H26FNO 291.1998 FIU 0410 
4-methoxy PV8 C18H27NO2 289.2042 FIU 0411 
4-methoxy PV9 C19H29NO2 303.2198 FIU 0412 
PV8 C17H25NO 259.1936 FIU 0413 
PV9 C18H27NO 273.2093 FIU 0414 
Pyrovalerone C16H23NO 245.1780 FIU 0415 
4-APB C11H13NO 175.0997 FIU 0416 
4-APDB C11H15NO 177.1154 FIU 0417 
5-APDB C11H15NO 177.1154 FIU 0418 
5-EAPB C13H17NO 203.1310 FIU 0419 
5-MAPB C12H15NO 189.1154 FIU 0420 
5-MAPDB C12H17NO 191.1310 FIU 0421 
6-APB C11H13NO 175.0997 FIU 0422 
6-APDB C11H15NO 177.1154 FIU 0423 
7-APB C11H13NO 175.0997 FIU 0424 
3-Methylbuphedrone C12H17NO 191.1310 FIU 0425 
4-Fluorobuphedrone C11H14FNO 195.1059 FIU 0426 
4-Methylbuphedrone C12H17NO 191.1310 FIU 0427 
4-methyl-N-Methylbuphedrone C13H19NO 205.1467 FIU 0428 
Buphedrone metabolite ((±)-
Ephedrine stereochemistry) C11H17NO 179.1310 FIU 0429 
Buphedrone metabolite ((±)-
Pseudoephedrine 
stereochemistry) 
C11H17NO 179.1310 FIU 0430 
N-Ethylbuphedrone C12H17NO 191.1310 FIU 0431 
Dimethocaine C16H26N2O2 278.1994 FIU 0432 
Nitracaine C16H24N2O4 308.1736 FIU 0433 
(−)-11-nor-9-carboxy-Δ9-THC C21H28O4 344.1988 FIU 0434 
(±)-Cannabichromene C21H30O2 314.2246 FIU 0435 
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(±)-ORG 28611 C23H33N3O2 383.2573 FIU 0436 
5-fluoro NNEI C24H23FN2O 374.1794 FIU 0437 
5-fluoro NNEI 2'-naphthyl 
isomer C24H23FN2O 374.1794 FIU 0438 
5-fluoro SDB-005 C23H21FN2O2 376.1587 FIU 0439 
5-fluoro SDB-006 C21H23FN2O 338.1794 FIU 0440 
A-796260 C22H30N2O2 354.2307 FIU 0441 
A-836339 C16H26N2O2S 310.1715 FIU 0442 
JW 618 C17H14F6N2O2 392.0959 FIU 0443 
JW 642 C21H20F6N2O3 462.1378 FIU 0444 
MN-25 C26H37N3O3 439.2835 FIU 0445 
MN-25-2-methyl derivative C27H39N3O3 453.2991 FIU 0446 
NNEI C24H24N2O 356.1889 FIU 0447 
NNEI 2'-naphthyl isomer C24H24N2O 356.1889 FIU 0448 
Salvinorin A C23H28O8 432.1784 FIU 0449 
Salvinorin B C21H26O7 390.1679 FIU 0450 
SDB-005 C23H22N2O2 358.1681 FIU 0451 
SDB-006 C21H24N2O 320.1889 FIU 0452 
THCA-A C22H30O4 358.2144 FIU 0453 
Δ8-THC C21H30O2 314.2246 FIU 0454 
Δ9-THC C21H30O2 314.2246 FIU 0455 
AM1248 azepane isomer C26H34N2O 390.2671 FIU 0456 
AM2201 benzimidazole analog C23H21FN2O 360.1638 FIU 0457 
JZL 184 C27H24N2O9 520.1482 FIU 0458 
KM 233 C25H30O2 362.2246 FIU 0459 
KML29 C24H21F6NO7 549.1222 FIU 0460 
LY2183240 C17H17N5O 307.1433 FIU 0461 
LY2183240 2’-isomer C17H17N5O 307.1433 FIU 0462 
SER-601 C28H38N2O2 434.2933 FIU 0463 
Tetrahydrocannabivarin C19H26O2 286.1933 FIU 0464 
Yangonin C15H14O4 258.0892 FIU 0465 
Cannabidiolic Acid C22H30O4 358.2144 FIU 0466 
Cannabigerol C21H32O2 316.2402 FIU 0467 
EG-018 C28H25NO 391.1936 FIU 0468 
(±)-JWH 018 N-(2-
hydroxypentyl) metabolite C24H23NO2 357.1729 FIU 0469 
(±)-JWH 018 N-(3-
hydroxypentyl) metabolite C24H23NO2 357.1729 FIU 0470 
(±)-JWH 018 N-(4-
hydroxypentyl) metabolite C24H23NO2 357.1729 FIU 0471 
138 
   
(R)-(−)-JWH 018 N-(4-
hydroxypentyl) metabolite C24H23NO2 357.1729 FIU 0472 
(S)-(+)-JWH 018 N-(4-
hydroxypentyl) metabolite C24H23NO2 357.1729 FIU 0473 
5-fluoro JWH 018 adamantyl 
analog C24H30FNO 367.2311 FIU 0474 
JWH 018 2-hydroxyindole 
metabolite C24H23NO2 357.1729 FIU 0475 
JWH 018 4-hydroxyindole 
metabolite C24H23NO2 357.1729 FIU 0476 
JWH 018 5-hydroxyindole 
metabolite C24H23NO2 357.1729 FIU 0477 
JWH 018 6-hydroxyindole 
metabolite C24H23NO2 357.1729 FIU 0478 
JWH 018 7-hydroxyindole 
metabolite C24H23NO2 357.1729 FIU 0479 
JWH 018 8-quinolinyl 
carboxamide C23H23N3O 357.1841 FIU 0480 
JWH 018 benzimidazole 
analog C23H22N2O 342.1732 FIU 0481 
JWH 018 N-(1-ethylpropyl) 
isomer C24H23NO 341.1780 FIU 0482 
JWH 018 N-(4-oxo-pentyl) 
metabolite C24H21NO2 355.1572 FIU 0483 
JWH 018 N-(5-hydroxypentyl) 
metabolite C24H23NO2 357.1729 FIU 0484 
JWH 018 N-(5-hydroxypentyl) 
β-D-Glucuronide C30H31NO8 533.2050 FIU 0485 
JWH 018 N-pentanoic acid β-
D-Glucuronide C30H29NO9 547.1842 FIU 0486 
JWH 018 N-propanoic acid 
metabolite C22H17NO3 343.1208 FIU 0487 
JWH 019 5-hydroxyindole 
metabolite C25H25NO2 371.1885 FIU 0488 
JWH 019 N-(2-fluorohexyl) 
isomer C25H24FNO 373.1842 FIU 0489 
JWH 019 N-(3-fluorohexyl) 
isomer C25H24FNO 373.1842 FIU 0490 
JWH 019 N-(4-fluorohexyl) 
isomer C25H24FNO 373.1842 FIU 0491 
JWH 019 N-(5-fluorohexyl) 
isomer C25H24FNO 373.1842 FIU 0492 
JWH 019 N-(5-hydroxyhexyl) 
metabolite C25H25NO2 371.1885 FIU 0493 
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JWH 019 N-(6-fluorohexyl) 
isomer C25H24FNO 373.1842 FIU 0494 
JWH 019 N-(6-hydroxyhexyl) 
metabolite C25H25NO2 371.1885 FIU 0495 
JWH 019 N-(6-hydroxyhexyl) 
β-D-Glucuronide C31H33NO8 547.2206 FIU 0496 
JWH 030 2-naphthoyl isomer C20H21NO 291.1623 FIU 0497 
JWH 031 2'-isomer C21H23NO 305.1780 FIU 0498 
JWH 071 C21H17NO 299.1310 FIU 0499 
JWH 073 2-hydroxyindole 
metabolite C23H21NO2 343.1572 FIU 0500 
JWH 073 4-hydroxyindole 
metabolite C23H21NO2 343.1572 FIU 0501 
JWH 073 5-hydroxyindole 
metabolite C23H21NO2 343.1572 FIU 0502 
JWH 073 6-hydroxyindole 
metabolite C23H21NO2 343.1572 FIU 0503 
JWH 073 6-methoxyindole 
analog C24H23NO2 357.1729 FIU 0504 
JWH 073 7-hydroxyindole 
metabolite C23H21NO2 343.1572 FIU 0505 
JWH 073 N-(2-hydroxybutyl) 
metabolite C23H21NO2 343.1572 FIU 0506 
JWH 073 N-(4-hydroxybutyl) 
metabolite C23H21NO2 343.1572 FIU 0507 
JWH 073 N-(4-hydroxybutyl) 
β-D-Glucuronide C29H29NO8 519.1893 FIU 0508 
JWH 073 N-butanoic acid 
metabolite C23H19NO3 357.1365 FIU 0509 
(±)-JWH 073 N-(3-
hydroxybutyl) metabolite C23H21NO2 343.1572 FIU 0510 
(R)-(−)-JWH 073 N-(3-
hydroxybutyl) metabolite C23H21NO2 343.1572 FIU 0511 
(S)-(+)-JWH 073 N-(3-
hydroxybutyl) metabolite C23H21NO2 343.1572 FIU 0512 
JWH 080 C24H23NO2 357.1729 FIU 0513 
JWH 081 4-hydroxynaphthyl 
metabolite C24H23NO2 357.1729 FIU 0514 
JWH 081 N-(4-hydroxypentyl) 
metabolite C25H25NO3 387.1834 FIU 0515 
JWH 081 N-(5-hydroxypentyl) 
metabolite C25H25NO3 387.1834 FIU 0516 
JWH 081 N-pentanoic acid 
metabolite C25H23NO4 401.1627 FIU 0517 
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JWH 081-N-
(cyclohexylmethyl) analog C27H27NO2 397.2042 FIU 0518 
JWH 116 C26H27NO 369.2093 FIU 0519 
JWH 122 N-(4-hydroxypentyl) 
metabolite C25H25NO2 371.1885 FIU 0520 
JWH 122 N-(5-hydroxypentyl) 
metabolite C25H25NO2 371.1885 FIU 0521 
JWH 133 C22H32O 312.2453 FIU 0522 
JWH 145 2-phenyl isomer C26H25NO 367.1936 FIU 0523 
JWH 146 C28H29NO 395.2249 FIU 0524 
JWH 149 C26H27NO 369.2093 FIU 0525 
JWH 167 C21H23NO 305.1780 FIU 0526 
JWH 176 C25H24 324.1878 FIU 0527 
JWH 193 C26H26N2O2 398.1994 FIU 0528 
JWH 198 C26H26N2O3 414.1943 FIU 0529 
JWH 200 4-hydroxyindole 
metabolite C25H24N2O3 400.1787 FIU 0530 
JWH 200 5-hydroxyindole 
metabolite C25H24N2O3 400.1787 FIU 0531 
JWH 200 6-hydroxyindole 
metabolite C25H24N2O3 400.1787 FIU 0532 
JWH 200 7-hydroxyindole 
metabolite C25H24N2O3 400.1787 FIU 0533 
JWH 203 C21H22ClNO 339.1390 FIU 0534 
JWH 203 N-(4-hydroxypentyl) 
metabolite C21H22ClNO2 355.1339 FIU 0535 
JWH 203 N-(5-hydroxypentyl) 
metabolite C21H22ClNO2 355.1339 FIU 0536 
JWH 203 N-pentanoic acid 
metabolite C21H20ClNO3 369.1132 FIU 0537 
JWH 210 2-ethylnaphthyl 
isomer C26H27NO 369.2093 FIU 0538 
JWH 210 5-hydroxyindole 
metabolite C26H27NO2 385.2042 FIU 0539 
JWH 210 N-(4-hydroxypentyl) 
metabolite C26H27NO2 385.2042 FIU 0540 
JWH 210 N-(5-hydroxypentyl) 
metabolite C26H27NO2 385.2042 FIU 0541 
JWH 210 N-pentanoic acid 
metabolite C26H25NO3 399.1834 FIU 0542 
JWH 213 C27H29NO 383.2249 FIU 0543 
JWH 250 5-hydroxyindole 
metabolite C22H25NO3 351.1834 FIU 0544 
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JWH 250 N-(4-hydroxypentyl) 
metabolite C22H25NO3 351.1834 FIU 0545 
JWH 250 N-(5-hydroxypentyl) 
metabolite C22H25NO3 351.1834 FIU 0546 
JWH 250 N-pentanoic acid 
metabolite C22H23NO4 365.1627 FIU 0547 
JWH 307 5'-isomer C25H24FNO 373.1842 FIU 0548 
JWH 309 5'-isomer C30H27NO 417.2093 FIU 0549 
JWH 387 C24H22BrNO 419.0885 FIU 0550 
JWH 398 N-(4-hydroxypentyl) 
metabolite C24H22ClNO2 391.1339 FIU 0551 
JWH 398 N-(5-hydroxypentyl) 
metabolite C24H22ClNO2 391.1339 FIU 0552 
JWH 398 N-pentanoic acid 
metabolite C24H20ClNO3 405.1132 FIU 0553 
JWH 412 C24H22FNO 359.1685 FIU 0554 
(−)-CP 47,497 C21H34O2 318.2559 FIU 0555 
(−)-CP 55,940 C24H40O3 376.2977 FIU 0556 
(+)-CP 47,497 C21H34O2 318.2559 FIU 0557 
(+)-CP 55,940 C24H40O3 376.2977 FIU 0558 
(±)3-epi CP 47,497-C8-
homolog C22H36O2 332.2715 FIU 0559 
(±)5-epi CP 55,940 C24H40O3 376.2977 FIU 0560 
(±)-CP 47,497 C21H34O2 318.2559 FIU 0561 
(±)-CP 47,497-C7-hydroxy 
metabolite C21H34O3 334.2508 FIU 0562 
(±)-CP 47,497-C8-homolog C22H36O2 332.2715 FIU 0563 
(±)-CP 55,940 C24H40O3 376.2977 FIU 0564 
(±)-epi CP 47,497 C21H34O2 318.2559 FIU 0565 
CP 47,497-C6-homolog C20H32O2 304.2402 FIU 0566 
CP 47,497-C8-homolog C-8-
hydroxy metabolite C22H36O3 348.2664 FIU 0567 
CP 47,497-C9-homolog C23H38O2 346.2872 FIU 0568 
CP 47,497-para-quinone analog C21H32O3 332.2351 FIU 0569 
RCS-4 4-hydroxyphenyl 
metabolite C20H21NO2 307.1572 FIU 0570 
RCS-4 M10 metabolite C20H21NO3 323.1521 FIU 0571 
RCS-4 M11 metabolite C20H19NO3 321.1365 FIU 0572 
RCS-4 M9 metabolite C20H21NO3 323.1521 FIU 0573 
RCS-4 N-(4-hydroxypentyl) 
metabolite C21H23NO3 337.1678 FIU 0574 
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RCS-4 N-(5-carboxypentyl) 
metabolite C21H21NO4 351.1471 FIU 0575 
RCS-4 N-(5-hydroxypentyl) 
metabolite C21H23NO3 337.1678 FIU 0576 
5-fluoro NPB-22 C22H20FN3O2 377.1540 FIU 0577 
5-fluoro PB-22 C23H21FN2O2 376.1587 FIU 0578 
5-fluoro PB-22 3-
carboxyindole metabolite C14H16FNO2 249.1165 FIU 0579 
5-fluoro PB-22 3-
hydroxyquinoline isomer C21H21FN2O2 352.1587 FIU 0580 
5-fluoro PB-22 4-
hydroxyisoquinoline isomer C23H21FN2O2 376.1587 FIU 0581 
5-fluoro PB-22 4-
hydroxyquinoline isomer C23H21FN2O2 376.1587 FIU 0582 
5-fluoro PB-22 5-
hydroxyisoquinoline isomer C23H21FN2O2 376.1587 FIU 0583 
5-fluoro PB-22 5-
hydroxyquinoline isomer C23H21FN2O2 376.1587 FIU 0584 
5-fluoro PB-22 6-
hydroxyisoquinoline isomer C23H21FN2O2 376.1587 FIU 0585 
5-fluoro PB-22 6-
hydroxyquinoline isomer C23H21FN2O2 376.1587 FIU 0586 
5-fluoro PB-22 7-
hydroxyisoquinoline isomer C23H21FN2O2 376.1587 FIU 0587 
5-fluoro PB-22 7-
hydroxyquinoline isomer C23H21FN2O2 376.1587 FIU 0588 
5-fluoro PB-22 8-
hydroxyisoquinoline isomer C23H21FN2O2 376.1587 FIU 0589 
5-fluoro PB-22 N-(2-
fluoropentyl) isomer C23H21FN2O2 376.1587 FIU 0590 
5-fluoro PB-22 N-(3-
fluoropentyl) isomer C23H21FN2O2 376.1587 FIU 0591 
5-fluoro PB-22 N-(4-
fluoropentyl) isomer C23H21FN2O2 376.1587 FIU 0592 
FDU-PB-22 C26H18FNO2 395.1322 FIU 0593 
FUB-PB-22 C25H17FN2O2 396.1274 FIU 0594 
NPB-22 C22H21N3O2 359.1634 FIU 0595 
PB-22 C23H22N2O2 358.1681 FIU 0596 
PB-22 3-carboxyindole 
metabolite C14H17NO2 231.1259 FIU 0597 
PB-22 3-hydroxyquinoline 
isomer C23H22N2O2 358.1681 FIU 0598 
PB-22 4-hydroxyisoquinoline 
isomer C23H22N2O2 358.1681 FIU 0599 
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PB-22 4-hydroxyquinoline 
isomer C23H22N2O2 358.1681 FIU 0600 
PB-22 5-hydroxyisoquinoline 
isomer C23H22N2O2 358.1681 FIU 0601 
PB-22 5-hydroxyquinoline 
isomer C23H22N2O2 358.1681 FIU 0602 
PB-22 6-hydroxyisoquinoline 
isomer C23H22N2O2 358.1681 FIU 0603 
PB-22 6-hydroxyquinoline 
isomer C23H22N2O2 358.1681 FIU 0604 
PB-22 7-hydroxyisoquinoline 
isomer C23H22N2O2 358.1681 FIU 0605 
PB-22 7-hydroxyquinoline 
isomer C23H22N2O2 358.1681 FIU 0606 
PB-22 8-hydroxyisoquinoline 
isomer C23H22N2O2 358.1681 FIU 0607 
PB-22 N-(4-hydroxypentyl) 
metabolite C23H22N2O3 374.1630 FIU 0608 
PB-22 N-(4-hydroxypentyl)-3-
carboxyindole metabolite C14H17NO3 347.1208 FIU 0609 
PB-22 N-(5-hydroxypentyl) 
metabolite C23H22N2O3 374.1630 FIU 0610 
PB-22 N-(5-hydroxypentyl)-3-
carboxyindole metabolite C14H17NO3 247.1208 FIU 0611 
PB-22 N-pentanoic acid 
metabolite C23H20N2O4 388.1423 FIU 0612 
PB-22 N-pentanoic acid-3-
carboxyindole metabolite C14H15NO4 261.1001 FIU 0613 
AM2201 8-quinolinyl 
carboxamide C23H22FN3O 375.1747 FIU 0614 
BB-22 C25H24N2O2 384.1838 FIU 0615 
BB-22 3-carboxyindole 
metabolite C16H19NO2 257.1416 FIU 0616 
BB-22 3-hydroxyquinoline 
isomer C25H24N2O2 384.1838 FIU 0617 
BB-22 4-hydroxyisoquinoline 
isomer C25H24N2O2 384.1838 FIU 0618 
BB-22 4-hydroxyquinoline 
isomer C25H24N2O2 384.1838 FIU 0619 
BB-22 5-hydroxyisoquinoline 
isomer C25H24N2O2 384.1838 FIU 0620 
BB-22 5-hydroxyquinoline 
isomer C25H24N2O2 384.1838 FIU 0621 
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BB-22 6-hydroxyisoquinoline 
isomer C25H24N2O2 384.1838 FIU 0622 
BB-22 6-hydroxyquinoline 
isomer C25H24N2O2 384.1838 FIU 0623 
BB-22 7-hydroxyisoquinoline 
isomer C25H24N2O2 384.1838 FIU 0624 
BB-22 7-hydroxyquinoline 
isomer C25H24N2O2 384.1838 FIU 0625 
BB-22 8-hydroxyisoquinoline 
isomer C25H24N2O2 384.1838 FIU 0626 
AM1220 azepane isomer C26H26N2O 382.2045 FIU 0627 
AM2201 2-hydroxyindole 
metabolite C24H22FNO2 375.1635 FIU 0628 
AM2201 5-hydroxyindole 
metabolite C24H22FNO2 375.1635 FIU 0629 
AM2201 6-hydroxyindole 
metabolite C24H22FNO2 375.1635 FIU 0630 
AM2201 7-hydroxyindole 
metabolite C24H22FNO2 375.1635 FIU 0631 
AM2201 N-(4-hydroxypentyl) 
metabolite C24H22FNO2 375.1635 FIU 0632 
AM2233 azepane isomer C22H23IN2O 458.0855 FIU 0633 
EAM2201 C26H26FNO 387.1998 FIU 0634 
NM2201 C24H22FNO2 375.1635 FIU 0635 
AM2201 N-(3-chloropentyl) 
isomer C24H22ClNO 375.1390 FIU 0636 
MAM2201 N-(2-fluoropentyl) 
isomer C25H24FNO 373.1842 FIU 0637 
MAM2201 N-(3-fluoropentyl) 
isomer C25H24FNO 373.1842 FIU 0638 
MAM2201 N-(4-fluoropentyl) 
isomer C25H24FNO 373.1842 FIU 0639 
MAM2201 N-(4-
hydroxypentyl) metabolite C25H24FNO2 389.1791 FIU 0640 
MAM2201 N-(5-chloropentyl) 
analog C25H24ClNO 389.1546 FIU 0641 
MAM2201 N-(5-chloropentyl) 
analog-d5 C25H19D5ClNO 394.1860 FIU 0642 
MAM2201 N-pentanoic acid 
metabolite C25H23NO3 385.1678 FIU 0643 
(±)-UR-144 N-(4-
hydroxypentyl) metabolite C21H29NO2 327.2198 FIU 0644 
UR-144 Degradant C21H29NO 311.2249 FIU 0645 
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UR-144 Degradant N-
pentanoic acid metabolite C21H27NO3 341.1991 FIU 0646 
UR-144 N-(2-chloropentyl) 
analog C21H28ClNO 345.1859 FIU 0647 
UR-144 N-(2-hydroxypentyl) 
metabolite C21H29NO2 327.2198 FIU 0648 
UR-144 N-(3-chloropentyl) 
analog C21H28ClNO 345.1859 FIU 0649 
UR-144 N-(4-chloropentyl) 
analog C21H28ClNO 345.1859 FIU 0650 
UR-144 N-(5-bromopentyl) 
analog C21H28BrNO 389.1354 FIU 0651 
UR-144 N-(5-chloropentyl) 
analog C21H28ClNO 345.1859 FIU 0652 
UR-144 N-(5-hydroxypentyl) 
metabolite C21H29NO2 327.2198 FIU 0653 
UR-144 N-(5-hydroxypentyl) 
β-D-Glucuronide C27H37NO8 503.2519 FIU 0654 
UR-144 N-pentanoic acid 
metabolite C21H27NO3 341.1991 FIU 0655 
UR-144 N-(5-methylhexyl) 
analog C23H33NO 339.2562 FIU 0656 
UR-144 N-heptyl analog C23H33NO 339.2562 FIU 0657 
FUB-144 C23H24FNO 349.1842 FIU 0658 
XLR11 6-hydroxyindole 
metabolite C21H28FNO2 345.2104 FIU 0659 
XLR11 Degradant C21H28FNO 329.2155 FIU 0660 
XLR11 N-(2-fluoropentyl) 
isomer C21H28FNO 329.2155 FIU 0661 
XLR11 N-(3-fluoropentyl) 
isomer C21H28FNO 329.2155 FIU 0662 
XLR11 N-(4-fluoropentyl) 
isomer C21H28FNO 329.2155 FIU 0663 
XLR11 N-(4-hydroxypentyl) 
metabolite C21H28FNO2 345.2104 FIU 0664 
XLR11 N-(4-pentenyl) analog C21H27NO 309.2093 FIU 0665 
XLR12 C20H24F3NO 351.1810 FIU 0666 
Acetyl fentanyl C21H26N2O 322.2045 FIU 0667 
Acetyl norfentanyl C13H18N2O 218.1419 FIU 0668 
Butyryl fentanyl C23H30N2O 350.2358 FIU 0669 
para-Fluorofentanyl C22H27FN2O 354.2107 FIU 0670 
AH 7921 C16H22Cl2N2O 328.1109 FIU 0671 
ATM4 4-acetoxy analog C23H25NO5 395.1733 FIU 0672 
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3-hydroxy Phenazepam C15H10BrClN2O2 363.9614 FIU 0673 
Bromazepam C14H10BrN3O 315.0007 FIU 0674 
Delorazepam C15H10Cl2N2O 304.0170 FIU 0675 
Diclazepam C16H12Cl2N2O 318.0327 FIU 0676 
Etizolam C17H15ClN4S 342.0706 FIU 0677 
Flubromazepam C15H10BrFN2O 331.9961 FIU 0678 
MCOPPB C26H40N4 408.3253 FIU 0679 
Pyrazolam C16H12BrN5 353.0276 FIU 0680 
1'-naphthoyl-2-methylindole C20H15NO 285.1154 FIU 0681 
2-Fluoropentylindole C13H16FN 205.1267 FIU 0682 
3-Fluoropentylindole C13H16FN 205.1267 FIU 0683 
4-Fluoropentylindole C13H16FN 205.1267 FIU 0684 
5-fluoropentyl-3-
pyridinoylindole C19H19FN2O 310.1481 FIU 0685 
5-Fluoropentylindole C13H16FN 205.1267 FIU 0686 
5-IT C11H14N2 174.1157 FIU 0687 
6-IT C11H14N2 174.1157 FIU 0688 
A-834735 C22H29NO2 339.2198 FIU 0689 
A-834735 degredant C22H29NO2 339.2198 FIU 0690 
methyl-1-(5-fluoropentyl)-1H-
indole-3-Carboxylate C15H18FNO2 263.1322 FIU 0691 
methyl-1-(cyclohexylmethyl)-
1H-indole-3-carboxylate C17H21NO2 271.1572 FIU 0692 
methyl-1-pentyl-1H-indole-3-
Carboxylate C15H19NO2 245.1416 FIU 0693 
ADBICA C20H29N3O2 343.2260 FIU 0694 
ADBICA N-(4-hydroxypentyl) 
metabolite C20H29N3O3 359.2209 FIU 0695 
ADBICA N-(5-hydroxypentyl) 
metabolite C20H29N3O3 359.2209 FIU 0696 
ADBICA N-pentanoic acid 
metabolite C20H27N3O4 373.2002 FIU 0697 
AM694 N-(5-hydroxypentyl) 
metabolite C20H20INO2 433.0539 FIU 0698 
AM694 N-pentanoic acid 
metabolite C20H18INO3 447.0331 FIU 0699 
Harmine C13H12N2O 212.0950 FIU 0700 
tetrahydro-Harmine C13H16N2O 216.1263 FIU 0701 
5-chloro AB-PINACA C18H25ClN4O2 364.1666 FIU 0702 
5-fluoro ABICA C19H26FN3O2 347.2009 FIU 0703 
5-fluoro AB-PINACA C18H25FN4O2 348.1962 FIU 0704 
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5-fluoro AB-PINACA N-(4-
hydroxypentyl) metabolite C18H25FN4O3 364.1911 FIU 0705 
5-fluoro ADBICA C20H28FN3O2 361.2166 FIU 0706 
5-fluoro ADB-PINACA C19H27FN4O2 362.2118 FIU 0707 
5-fluoro AMB C19H26FN3O3 363.1958 FIU 0708 
5-fluoro MN-18 C23H22FN3O 375.1747 FIU 0709 
5-fluoro-AKB48 N-(4-
hydroxypentyl) metabolite C23H30FN3O2 399.2322 FIU 0710 
5-fluoro-THJ C22H21FN4O 376.1699 FIU 0711 
AB-005 C23H32N2O 352.2515 FIU 0712 
AB-005 azepane isomer C23H32N2O 352.2515 FIU 0713 
AB-CHMINACA C20H28N4O2 356.2212 FIU 0714 
AB-FUBINACA C20H21FN4O2 368.1649 FIU 0715 
AB-FUBINACA 2-
fluorobenzyl isomer C20H21FN4O2 368.1649 FIU 0716 
AB-FUBINACA 3-
fluorobenzyl isomer C20H21FN4O2 368.1649 FIU 0717 
AB-FUBINACA isomer 1 C20H21FN4O2 368.1649 FIU 0718 
AB-FUBINACA isomer 2 C20H21FN4O2 368.1649 FIU 0719 
AB-FUBINACA isomer 5 C20H21FN4O2 368.1649 FIU 0720 
AB-PINACA C18H26N4O2 330.2056 FIU 0721 
AB-PINACA N-(2-
fluoropentyl) isomer C18H25FN4O2 348.1963 FIU 0722 
AB-PINACA N-(4-
fluoropentyl) isomer C18H25FN4O2 348.1963 FIU 0723 
AB-PINACA N-(4-
hydroxypentyl) metabolite C18H26N4O3 346.2005 FIU 0724 
AB-PINACA N-(5-
hydroxypentyl) metabolite C18H26N4O3 346.2005 FIU 0725 
AB-PINACA pentanoic acid 
metabolite C18H24N4O4 360.1798 FIU 0726 
AKB48 N-(5-fluoropentyl) 
analog C23H30FN3O 383.2373 FIU 0727 
MN-18 C23H23N3O 357.1841 FIU 0728 
THJ C22H22N4O 358.1794 FIU 0729 
THJ 018 C23H22N2O 342.1732 FIU 0730 
THJ 2201 C23H21FN2O 360.1638 FIU 0731 
ADB-FUBINACA C21H23FN4O2 382.1805 FIU 0732 
ADB-PINACA C19H28N4O2 344.2212 FIU 0733 
ADB-PINACA isomer 1 C19H28N4O2 344.2212 FIU 0734 
ADB-PINACA isomer 2 C19H28N4O2 344.2212 FIU 0735 
ADB-PINACA isomer 3 C19H28N4O2 344.2212 FIU 0736 
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ADB-PINACA N-(4-
hydroxypentyl) metabolite C19H28N4O3 360.2161 FIU 0737 
ADB-PINACA N-(5-
hydroxypentyl) metabolite C19H28N4O3 360.2161 FIU 0738 
ADB-PINACA pentanoic acid 
metabolite C19H26N4O4 374.1954 FIU 0739 
AKB48 N-(4-fluorobenzyl) 
analog C25H26FN3O 403.2060 FIU 0740 
AKB48 N-(4-hydroxypentyl) 
metabolite C23H31N3O2 381.2416 FIU 0741 
AKB48 N-(5-hydroxypentyl) 
metabolite C23H31N3O2 381.2416 FIU 0742 
AKB48 N-pentanoic acid 
metabolite C23H29N3O3 395.2209 FIU 0743 
AMB C19H27N3O3 345.2052 FIU 0744 
4-acetoxy DiPT C18H26N2O2 302.1994 FIU 0745 
4-acetoxy DMT C14H18N2O2 246.1368 FIU 0746 
4-hydroxy DET C14H20N2O 232.1576 FIU 0747 
4-hydroxy DiPT C16H24N2O 260.1889 FIU 0748 
4-hydroxy MET C13H18N2O 218.1419 FIU 0749 
4-hydroxy MiPT C14H20N2O 232.1576 FIU 0750 
4-methyl-α-Ethyltryptamine C13H18N2 202.1470 FIU 0751 
5-methoxy-α-Ethyltryptamine C13H18N2O 218.1419 FIU 0752 
DiPT C16H24N2 244.1939 FIU 0753 
DOET C13H21NO2 223.1572 FIU 0754 
DPT C16H24N2 244.1939 FIU 0755 
N-Methyltryptamine C11H14N2 174.1157 FIU 0756 
AMT C5H10N2S 130.0565 FIU 0757 
Methylphenidate C14H19NO2 233.1416 FIU 0758 
MMAI C11H15NO 177.1154 FIU 0759 
Etaqualone C17H16N2O 264.1263 FIU 0760 
Hydroxy Bupropion C13H18ClNO2 255.1026 FIU 0761 
Lagochiline C20H36O5 356.2563 FIU 0762 
Levamisole C11H12N2S 204.0721 FIU 0763 
Loperamide C29H33ClN2O2 476.2231 FIU 0764 
N-Phenylacetyl-L-
prolylglycine ethyl ester C17H22N2O4 318.1580 FIU 0765 
Phenylpiracetam C12H14N2O2 218.1055 FIU 0766 
PRE-084 C19H27NO3 317.1991 FIU 0767 
Sildenafil C22H30N6O4S 474.2049 FIU 0768 
Sildenafil Citrate C22H30N6O4S 474.2049 FIU 0769 
Thiosildenafil C22H30N6O3S2 490.1821 FIU 0770 
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Acetildenafil C25H34N6O3 466.2692 FIU 0771 
Benzydamine C19H23N3O 309.1841 FIU 0772 
Boldenone Cypionate C27H38O3 410.2821 FIU 0773 
Caffeine C8H10N4O2 194.0804 FIU 0774 
Carisoprodol C12H24N2O4 260.1736 FIU 0775 
Cl-2201 C24H21ClFNO 393.1296 FIU 0776 
Clencyclohexerol C14H20Cl2N2O2 318.0902 FIU 0777 
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Appendix 2. Compounds included in the internal standard database with their unique in-house identifying 
number. 
Compound Name Formula Accurate Mass FIU Number 
JWH 007-d9 C22H16D9NO 328.2501 FIU 0778 
JWH 015-d7 C23H14D7NO 334.2063 FIU 0779 
JWH 018-d9 C24H14D9NO 350.2345 FIU 0780 
JWH 018 2-hydroxyindole 
metabolite-d9 C24H14D9NO2 366.2294 FIU 0781 
JWH 018 4-hydroxyindole 
metabolite-d9 C24H14D9NO2 366.2294 FIU 0782 
JWH 018 5-hydroxyindole 
metabolite-d9 C24H14D9NO2 366.2294 FIU 0783 
JWH 018 6-hydroxyindole 
metabolite-d9 C24H14D9NO2 366.2294 FIU 0784 
JWH 018 7-hydroxyindole 
metabolite-d9 C24H14D9NO2 366.2294 FIU 0785 
(±)-JWH 018 N-(4-
hydroxypentyl) 
metabolite-d5 
C24H18D5NO2 362.2043 FIU 0786 
JWH 018 N-(5-
hydroxypentyl) 
metabolite-d5 
C24H18D5NO2 362.2043 FIU 0787 
JWH 018 N-(5-
hydroxypentyl) β-D-
Glucuronide-d5 
C30H26D5NO8 538.2364 FIU 0788 
JWH 018 N-pentanoic 
acid metabolite-d5 C24H16D5NO3 376.1865 FIU 0789 
JWH 018 N-pentanoic 
acid metabolite-d4 C24H17D4NO3 375.1773 FIU 0790 
JWH 019 N-(5-
hydroxyhexyl) metabolite-
d5 
C25H20D5NO2 376.2199 FIU 0791 
JWH 073-d7 C23H14D7NO 334.2063 FIU 0792 
(±)-JWH 073 N-(3-
hydroxybutyl)metabolite-
d5 
C23H16D5NO2 348.1886 FIU 0793 
JWH 073 N-(4-
hydroxybutyl) metabolite-
d5 
C23H16D5NO2 348.1886 FIU 0794 
JWH 073 2-hydroxyindole 
metabolite-d7 C23H14D7NO2 350.2012 FIU 0795 
JWH 073 4-hydroxyindole 
metabolite-d7 C23H14D7NO2 350.2012 FIU 0796 
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JWH 073 5-hydroxyindole 
metabolite-d7 C23H14D7NO2 350.2012 FIU 0797 
JWH 073 6-hydroxyindole 
metabolite-d7 C23H14D7NO2 350.2012 FIU 0798 
JWH 073 7-hydroxyindole 
metabolite-d7 C23H14D7NO2 350.2012 FIU 0799 
JWH 073 N-butanoic acid 
metabolite-d5 C23H14D5NO3 362.1679 FIU 0800 
JWH 081-d9 C25H16D9NO2 380.2450 FIU 0801 
JWH 081 N-(4-
hydroxypentyl) 
metabolite-d5 
C25H20D5NO3 392.2148 FIU 0802 
JWH 081 N-(5-
hydroxypentyl) 
metabolite-d5 
C25H20D5NO3 392.2148 FIU 0803 
JWH 081 N-pentanoic 
acid metabolite-d5 C25H18D5NO4 406.1941 FIU 0804 
JWH 122-d9 C25H16D9NO  364.2501 FIU 0805 
JWH 122 N-(5-
hydroxypentyl) 
metabolite-d5 
C25H20D5NO2 376.2199 FIU 0806 
JWH 200-d5 C25H19D5N2O2 389.2152 FIU 0807 
JWH 203 N-(4-
hydroxypentyl) 
metabolite-d5 
C21H17D5ClNO2 360.1653 FIU 0808 
JWH 203 N-(5-
hydroxypentyl) 
metabolite-d5 
C21H17D5ClNO2 360.1653 FIU 0809 
JWH 203 N-pentanoic 
acid metabolite-d5 C21H15D5ClNO3 360.1653 FIU 0810 
JWH 210-d9 C26H10D9NO 370.2032 FIU 0811 
JWH 250-d5 C22H20D5NO2 340.2199 FIU 0812 
JWH 250 N-(4-
hydroxypentyl) 
metabolite-d5 
C22H20D5NO3 356.2148 FIU 0813 
JWH 250 N-(5-
hydroxypentyl) 
metabolite-d5 
C22H20D5NO3 356.2148 FIU 0814 
JWH 398-d9 C24H13D9ClNO 384.1955 FIU 0815 
(±)-JWH 398 N-(4-
hydroxypentyl) 
metabolite-d5 
C24H17ClD5NO2 396.1653 FIU 0816 
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JWH 398 N-(5-
hydroxypentyl) metabolite 
d5 
C24H17ClD5NO2 396.1653 FIU 0817 
JWH 398 N-pentanoic 
acid metabolite-d5 C24H15ClD5NO3 410.1446 FIU 0818 
(-)-11-nor-9-carboxy-Δ9-
THC-d3 C21H25D3O4 347.2176 FIU 0819 
(±)-CP 47,497-d11 C21H23D11O2 329.3249 FIU 0820 
(±)-CP 47,497-C8-
homolog-d7 C22H29D7O2 339.3155 FIU 0821 
(±)-CP 55,940-d11 C24H29D11O3 387.3668 FIU 0822 
AM694 N-pentanoic acid 
metabolite-d5 C20H13D5INO3 452.0645 FIU 0823 
AM2201-d5 C24H17D5FNO 364.1999 FIU 0824 
AM2201 N-(4-
hydroxypentyl) 
metabolite-d5 
C24H17D5FNO2 380.1948 FIU 0825 
MAM2201-d5 C25H19D5FNO 378.2156 FIU 0826 
MAM2201 N-pentanoic 
acid metabolite-d5 C25H18D5NO3 390.1992 FIU 0827 
PB-22-d9 C23H13D9N2O2 367.2246 FIU 0828 
UR-144-d5 C21H24D5NO 316.2563 FIU 0829 
UR-144 N-(4-
hydroxypentyl) 
metabolite-d5 
C21H24D5NO2 332.2512 FIU 0830 
UR-144 N-(5-
hydroxypentyl) 
metabolite-d5 
C21H24D5NO2 332.2512 FIU 0831 
UR-144 N-pentanoic acid 
metabolite-d5 C21H22D5NO3 346.2305 FIU 0832 
XLR11-d5 C21H23D5FNO 334.2469 FIU 0833 
XLR11 N-(4-
hydroxypentyl) 
metabolite-d5 
C21H23D5FNO2 350.2418 FIU 0834 
RCS-4-d9 C21H14D9NO2 330.2294 FIU 0835 
RCS-4 N-(4-
hydroxypentyl) 
metabolite-d5 
C21H18D5NO3 342.1992 FIU 0836 
RCS-4 N-(5-
hydroxypentyl) 
metabolite-d5 
C21H18D5NO3 342.1992 FIU 0837 
RCS-4 N-pentanoic acid 
metabolite-d5 C21H16D5NO4 356.1784 FIU 0838 
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25I-NBOMe-d3 C18H19D3INO3 430.0833 FIU 0839 
Benocyclidine-d10 C19H15D10NS 309.2335 FIU 0840 
3,4-Methylenedioxy 
Pyrovalerone-d8 C16H13D8NO3 283.2024 FIU 0841 
AB-PINACA-d9 C18H17D9N4O2 339.2621 FIU 0842 
ADB-PINACA-d9 C19H19D9N4O2 353.2777 FIU 0843 
ADBICA-d9 C20H20D9N3O2 352.2825 FIU 0844 
AB-FUBINACA-d4 C20H17D4FN4O2 372.1900 FIU 0845 
AKB48-d9 C23H22D9N3O 374.3032 FIU 0846 
Acetyl fentanyl-d5 C21H22D5ClN2O 363.2126 FIU 0847 
Acetyl norfentanyl-d5 C13H13D5N2O 223.1733 FIU 0848 
Norsufentanil-d3 C16H21D3N2O2 279.2026 FIU 0849 
Butylone-d3 C12H12D3NO3 224.1240 FIU 0850 
cis-Tramadol-d6 C16H19D6NO2 269.2262 FIU 0851 
Meconin-d3 C10H7D3O4 197.0767 FIU 0852 
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Appendix 3. The novel psychoactive substances added to the HRMS library along with ions collected at 
different collision energies that had relative abundances greater than 10% in the MS/MS spectra. 
Compound Name CE (eV) Ion (Relative Abundance %) 
(±)-Ethylphenidate  
10 248.16451 (100); 84.08077 (56) 
20 84.08077 (100) 
40 84.08077 (100); 56.04948 (17) 
2-Bromoamphetamine  
10 
168.96474 (100); 196.99603 (57); 
214.02258 (21) 
20 168.96474 (100) 
40 
90.04640 (100); 168.96474 (87); 
89.03857 (43); 117.06988 (24); 
91.05423 (11) 
2-Chloroamphetamine  
10 
125.01525 (100); 153.04655 (33); 
170.07310 (11) 
20 125.01525 (100) 
40 
170.01525 (100); 89.03857 (75); 
98.99960 (40); 90.04640 (30); 63.02293 
(10) 
2-Methoxy ketamine  
10 203.10666 (100); 175.11174 (79); 234.14885 (33) 
20 121.06479 (100); 175.11174 (93); 203.10666 (54); 67.05423 (14) 
40 91.05423 (100); 121.06479 (43); 67.05423 (12) 
3,4-
Ethylenedioxymethcathinone  
10 204.10190 (100); 222.11247 (46) 
20 
204.10190 (100); 189.07843 (83); 
148.07568 (34); 163.07536 (16); 
58.06512 (16); 133.05222 (12) 
40 
133.05222 (100); 91.05423 (47); 
148.07568 (40); 120.08077 (20); 
105.05730 (20); 58.06512 (18); 
189.07843 (14); 77.03857 (13); 
65.03857 (10) 
3-Bromoamphetamine  
10 196.99603 (100); 168.96474 (96); 214.02258 (13); 118.07771 (12) 
20 168.96474 (100); 118.07771 (23); 117.06988 (13) 
40 
117.06988 (100); 90.04640 (81); 
168.96474 (75); 89.03857 (28); 
91.05423 (21); 115.05423 (14) 
3-Chloroamphetamine  10 125.01525 (100); 153.04655 (54) 20 125.01525 (100) 
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40 125.01525 (100); 89.03857 (65); 98.99960 (34); 90.04640 (24) 
3-Iodoamphetamine  
10 244.98216 (100); 216.95087 (97); 262.00873 (43) 
20 216.95087 (100); 118.07771 (13) 
40 90.04640 (100); 117.06988 (74); 216.95087 (51); 89.03857 (23) 
3-Methoxyamphetamine  
10 121.06398 (100); 149.09555 (51) 
20 121.06398 (100); 91.05381 (20) 
40 
91.05383 (100); 78.04608 (73); 
65.03838 (57); 77.03832 (47); 
121.06432 (26) 
4-Bromoamphetamine  
10 196.99603 (100); 168.96474 (95); 214.02258 (13); 118.07771 (12) 
20 168.96474 (100); 118.07771 (23); 117.06988 (13) 
40 
117.06988 (100); 90.04640 (81); 
168.96474 (75); 89.03857 (28); 
91.05423 (21); 115.05423 (14) 
4-Chloroamphetamine  
10 125.01525 (100); 153.04655 (54) 
20 125.01525 (100) 
40 125.01525 (100); 89.03857 (65); 98.99960 (34); 90.04640 (24) 
4-Hydroxyamphetamine  
10 107.04914 (100); 135.08044 (96) 
20 107.04914 (100) 
40 
77.03857 (100); 107.04914 (42); 
79.05423 (14); 51.02293 (12); 91.05423 
(11) 
4-Methylthioamphetamine   
10 165.07324 (100); 117.06988 (32); 137.04195 (25) 
20 
137.04195 (100); 117.06988 (99); 
118.07771 (27); 115.05423 (24); 
165.07324 (20); 150.04977 (20); 
135.02629 (10) 
40 
117.06988 (100); 91.05423 (73); 
115.05423 (70); 122.01847 (48); 
121.01065 (25); 135.02629 (16); 
137.04195 (16); 78.04640 (16) 
4-Methylthioamphetamine 
(hydrochloride) 
10 165.07324 (100); 117.06988 (32); 137.04195 (24) 
20 117.06988 (100); 137.04195 (97); 118.07771 (26); 115.05423 (23); 
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165.07324 (18); 150.04977 (17); 
135.02629 (10) 
40 
117.06988 (100); 91.05423 (74); 
115.05423 (67); 122.01847 (48); 
121.01065 (26); 135.02629 (18); 
78.04640 (17); 137.04195 (16) 
d-Amphetamine  
10 91.05423 (100); 119.08553 (25) 
20 91.05423 (100) 
40 91.05423 (100); 65.03857 (87); 39.02293 (10) 
Deschloro-N-ethyl-Ketamine  
10 
173.09608 (100); 218.15395 (62); 
145.10118 (37); 46.06512 (27); 
91.05423 (11) 
20 
91.05423 (100); 145.10118 (91); 
173.09608 (31); 46.06512 (19); 
67.05423 (18); 129.06987 (14) 
40 91.05423 (100) 
Diclofensine  
10 322.07599 (100) 
20 
322.07599 (100); 121.06479 (24); 
279.03378 (21); 44.04948 (11); 
291.03378 (10) 
40 
44.04948 (100); 121.06479 (86); 
91.05423 (33); 158.97629 (24); 
209.09608 (23); 241.04147 (23); 
221.09608 (19); 244.06494 (16); 
165.03398 (15); 256.06494 (15); 
213.04655 (13); 208.08827 (12); 
77.03857 (11); 182.97629 (10) 
DOI  
10 305.00330 (100); 322.02985 (17); 276.97198 (10) 
20 
276.97198 (100); 305.00330 (80); 
178.09883 (72); 289.97983 (45); 
163.07536 (20); 150.06754 (10) 
40 
135.08044 (100); 274.95636 (55); 
105.06988 (55); 163.07536 (40); 
105.03349 (38); 246.96144 (37); 
120.05697 (35); 91.05423 (31); 
77.03857 (24); 90.04640 (21); 
103.05423 (19); 148.05188 (18); 
79.05423 (17); 289.97983 (14); 
122.07262 (13); 276.97198 (12); 
178.09883 (11) 
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HMA  
10 165.09100 (100); 137.05971 (27); 133.06479 (22); 105.06988 (13) 
20 
100.06988 (100); 137.05971 (95); 
133.06479 (62); 165.09100 (18); 
79.05423 (17) 
40 
77.03857 (100); 79.05423 (52); 
94.04131 (43); 103.05423 (32); 
105.06988 (17); 65.03857 (17); 
66.04640 (16); 122.03623 (16); 
51.02293 (10) 
Lisdexamfetamine  
10 264.20703 (100); 247.18050 (38); 84.08077 (29); 129.10223 (22) 
20 84.08077 (100); 247.18050 (14); 119.08553 (13); 136.11208 (10) 
40 84.08077 (100); 91.05423 (37); 56.04948 (16) 
Propylhexedrine  
10 156.17468 (100); 69.06988 (43); 83.08553 (17) 
20 
69.06988 (100); 55.05423 (46); 
83.08553 (35); 41.03858 (21); 57.06988 
(11) 
40 55.05423 (100); 41.03858 (90); 69.06988 (14); 39.02293 (14) 
CMP  
10 58.06512 (100); 79.05423 (44); 93.06988 (23); 121.10117 (12) 
20 79.05423 (100); 58.06512 (63); 77.03857 (30); 93.06988 (21);  
40 77.03857 (100); 79.05423 (19); 51.02293 (18); 58.06512 (16) 
2,5-DMMA 
10 179.10666 (100); 151.07536 (42); 210.14885 (37); 164.08318 (13) 
20 
151.07536 (100); 164.08318 (61); 
121.06479 (32); 179.10666 (22); 
149.05971 (10); 123.08044 (10) 
40 
91.05423 (100); 121.06479 (73); 
149.05971 (59); 77.03857 (55); 
78.04640 (23); 65.03857 (16); 
107.04914 (15); 93.06988 (13); 
103.05423 (10);  
3,4-DHMA  
10 151.07536 (100), 123.04406 (41), 182.11756 (16) 
20 123.04406(100), 105.06988(22), 151.07536(14), 133.06479(10) 
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40 
77.03858(100), 123.04406(43), 
51.02293(28), 79.05423(28), 
103.05423(16), 105.06988(13), 
105.03349(10), 65.03858(10) 
4-bromo-2,5-DMMA 
10 257.01717(100), 288.05937(76), 228.98587(14) 
20 228.98587(100), 257.01717(68), 178.09883(63), 241.99369(31) 
40 
135.08044(100), 226.97022(63), 
198.9753(58), 163.07536(52), 
105.06988(46), 105.03349(34), 
91.05423(29), 120.05697(28), 
168.96474(23), 77.03858(23), 
178.09883(17), 122.07262(16), 
90.0464(15), 228.98587(15), 
92.06205(15), 241.99369(15), 
103.05423(14), 148.05188(13), 
79.05423(11) 
para-Methoxymethamphetamine  
10 149.09609(100), 121.06479(38) 
20 121.06479(100), 149.09609(15), 91.05423(11) 
40 
91.05423(100), 121.06479(72), 
77.03858(51), 78.0464(47), 
65.03858(25) 
N,N-DMA  
10 91.05423(100), 164.14338(65), 119.08553(27) 
20 91.05423(100) 
40 91.05423(100), 65.03858(32) 
2C-G  
10 178.09883(100), 193.12231(43), 210.14886(17) 
20 178.09883(100), 163.07536(41) 
40 
163.07536(100), 91.05423(76), 
105.06988(40), 135.08044(30), 
79.05423(28), 107.08553(23), 
115.05423(23), 117.06988(20), 
77.03858(14), 133.06479(10) 
2C-T  
10 211.07873(100) 
20 
211.07873(100), 196.05525(60), 
134.07262(33), 166.04469(28), 
181.03178(23), 164.08318(22) 
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40 
91.05423(100), 119.04914(45), 
121.06479(37), 151.02121(28), 
181.03178(26), 134.07262(22), 
123.0263(21), 77.03858(21), 
147.04406(20), 105.06988(18), 
103.05423(18), 44.97935(18), 
79.05423(16), 104.06205(15), 
136.05188(14), 78.0464(13), 
135.03148(13), 137.05971(12), 
165.03686(12), 133.06479(10), 
149.05971(10)  
2C-T-7  
10 239.11003(100)  
20 
239.11003(100), 197.06308(34), 
224.08655(24), 164.08318(17), 
167.05251(16), 182.0396(15) 
40 
167.01613(100), 91.05423(68), 
134.07262(54), 121.06479(36), 
119.04914(32), 149.05971(28), 
182.0396(27), 152.02904(20), 
125.00556(15), 151.02121(12), 
139.02121(11), 135.03148(11), 
77.03858(11), 164.08318(10) 
2C-TFM  
10 233.07839(100), 250.10494(29), 218.05492(21) 
20 218.05492(100), 233.07839(54), 203.03144(13) 
40 
203.03144(100), 127.03538(34), 
113.03972(26), 133.0448(24), 
218.05492(20), 115.05423(13), 
91.05423(12), 147.04161(11), 
151.03538(10) 
bk-2C-B  
10 
178.06245(100), 177.07843(96), 
274.00733(45), 256.98078(40), 
228.98587(23), 162.05495(17) 
20 
162.05495(100), 178.06245(93), 
177.07843(85), 228.98587(37), 
163.03897(31), 198.9753(24), 
224.97838(14) 
40 
162.05495(100), 163.03897(50), 
134.06004(33), 119.03657(22), 
77.03858(21), 105.03349(20), 
91.05423(16), 181.95999(12), 
209.9549(12), 90.0464(12), 
147.03148(11) 
3C-B-fly  10   
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20 281.01717(100), 202.09883(71), 252.98587(26) 
40 
187.07536(100), 173.05971(54), 
202.09883(36), 159.08044(32), 
174.06753(28), 145.06479(26), 
159.04406(18), 131.08553(14), 
131.04914(13), 252.98587(12), 
201.09101(10) 
3C-P  
10 195.10157(100), 237.14852(52)  
20 
195.10157(100), 107.04914(55), 
163.07536(47), 167.07027(45), 
135.08044(23) 
40 
107.04914(100), 91.05423(37), 
77.03858(37), 79.05423(35), 
103.05423(34), 105.06988(22), 
115.05423(22), 167.07027(16), 
123.04406(12), 147.04406(10) 
N-methyl-2-AI  
10 117.06988(100), 148.11208(42), 115.05423(11) 
20 117.06988(100), 115.05423(54), 91.05423(23) 
40 91.05423(100), 115.05423(97), 65.03858(29) 
Escaline  
10 209.11722(100), 181.08592(91)  
20 
181.08592(100), 121.06479(34), 
91.05423(24), 166.06245(22), 
93.06988(20), 149.05971(16), 
103.05423(13), 77.03858(11) 
40 
91.05423(100), 77.03858(77), 
103.05423(23), 65.03858(20), 
133.02841(20), 78.0464(15), 
123.04406(14), 121.06479(12), 
105.03349(10) 
Mescaline  
10 195.10157(100), 180.0781(16) 
20 
195.10157(100), 180.0781(90), 
165.05462(85), 164.08318(31), 
149.05971(21),133.02841(21), 
150.06753(17), 133.06479(13), 
121.06479(12), 137.05971(11), 
105.06988(10) 
40   
2-Amino-1-phenylbutane  
10 91.05423(100), 133.10118(10) 
20 91.05423(100) 
40 91.05423(100), 65.03858(81) 
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2-Ethylamino-1-phenylbutane  
10 91.05423(100), 178.15903(39), 133.10118(10) 
20 91.05423(100) 
40 91.05423(100), 65.03858(34) 
4-CAB  
10 125.01525(100), 167.0622(12) 
20 125.01525(100) 
40 125.01525(100), 89.03858(57), 98.9996(32), 90.0464(22) 
Cathine 
10 134.09643(100), 117.06988(46), 115.05423(16) 
20 
115.05423(100), 117.06988(85), 
91.05423(53), 134.09643(37), 
56.04948(14) 
40 
91.05423(100), 115.05423(66), 
65.03858(37), 118.06513(16), 
77.03858(11) 
(R)-(−)-MT-45  
10 349.26383(100), 181.10118(11) 
20 181.10118(100), 169.16993(34), 349.26383(26) 
40 
166.0777(100), 181.10118(79), 
103.05423(67), 165.06988(43), 
179.08553(22), 87.09167(19), 
153.06988(11) 
(S)-(+)-MT-45  
10 349.26383(100), 181.10118(11) 
20 181.10118(100), 169.16993(34), 349.26383(25) 
40 
166.0777(100), 181.10118(78), 
103.05423(69), 165.06988(44), 
179.08553(23), 87.09167(20), 
153.06988(11) 
2,3-Dichlorophenylpiperazine  
10 231.04503(100), 188.00283(11) 
20 
188.00283(100), 231.04503(81), 
153.03398(42), 44.04948(15), 
152.02615(15) 
40 
152.02615(100), 117.0573(59), 
153.03398(43), 118.06513(39), 
44.04948(18), 91.05423(15), 
188.00283(14) 
MBZP  
10 191.15428(100), 91.05423(43), 99.09167(15) 
20 91.05423(100), 99.09167(12), 191.15428(12) 
40 91.05423(100), 65.03858(27), 58.06513(10) 
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MT-45  
10 349.26383(100), 181.10118(11) 
20 181.10118(100), 169.16993(35), 349.26383(25) 
40 
166.0777(100), 181.10118(77), 
103.05423(68), 165.06988(44), 
179.08553(23), 87.09167(19), 
153.06988(10) 
Mepirapim  
10 214.12264(100), 314.22269(11) 
20 214.12264(100) 
40 144.04439(100), 214.12264(35), 43.05423(19), 116.04948(12) 
2-Fluoroisocathinone  
10 123.06045(100), 151.05537(76), 103.05423(30), 168.08192(23) 
20 103.05423(100), 123.06045(77), 77.03858(25) 
40 77.03858(100), 103.05423(25), 51.02293(17) 
3,4-Dimethylethcathinone  
10 
188.14338(100), 206.15394(59), 
159.10425(16), 173.1199(14), 
160.11208(12) 
20 
188.14338(100), 159.10425(95), 
173.1199(90), 158.09643(62), 
160.11208(45), 133.10118(28), 
145.0886(25), 144.08078(17), 
105.06988(10) 
40 
158.09643(100), 144.08078(47), 
105.06988(22), 91.05423(21), 
115.05423(18), 143.07295(18), 
145.0886(11), 117.06988(11) 
4-methoxy-N,N-
Dimethylcathinone  
10 208.13321(100), 72.08078(47), 163.07536(29), 135.08044(19) 
20 72.08078(100), 135.08044(76), 163.07536(28), 105.06988(14) 
40 
72.08078(100), 77.03858(42), 
79.05423(32), 105.06988(31), 
103.05423(29), 91.05423(15), 
135.08044(12) 
4-Methylethcathinone 
metabolite  ((±)-Ephedrine 
stereochemistry) 
10 176.14338(100), 194.15394(16)  
20 
176.14338(100), 131.08553(43), 
91.05423(28), 147.10425(22), 
161.1199(21), 146.09643(15), 
105.06988(13), 148.11208(12) 
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40 
91.05423(100), 115.05423(45), 
116.06205(36), 131.07295(26), 
146.09643(20), 105.06988(19), 
130.06513(19), 129.06988(18), 
144.08078(16), 43.01784(12), 
42.03383(10), 128.06205(10) 
N-ethyl-N-Methylcathinone  
10 192.13829(100), 133.06479(20), 105.06988(19), 86.09643(11) 
20 
105.06988(100), 86.09643(62), 
133.06479(29), 192.13829(26), 
58.06513(12) 
40 
77.03858(100), 105.06988(49), 
58.06513(49), 86.09643(47), 
79.05423(39), 103.05423(26), 
105.03349(12), 44.04948(12), 
130.06513(10) 
Isopentedrone  
10 
91.05423(100), 192.13829(70),  
161.09609(62), 174.12773(45), 
132.08078(13), 119.04914(12) 
20 91.05423(100)  
40 91.05423(100), 65.03858(17) 
Mephedrone metabolite ((±)-
Ephedrine stereochemistry) 
10 149.09609(100), 121.06479(38)  
20 121.06479(100), 149.09609(15), 91.05423(11) 
40 
91.05423(100), 121.06479(72), 
77.03858(51), 78.0464(47), 
65.03858(25) 
Mephedrone metabolite ((±)-
Pseudoephedrine 
stereochemistry) 
10 162.12773(100) 
20 
162.12773(100), 147.10425(72), 
91.05423(39), 131.08553(37), 
105.06988(20), 116.06205(16), 
70.06513(13), 146.09643(12), 
129.06988(12), 56.04948(11), 
132.08078(11) 
40 
91.05423(100), 115.05423(67), 
105.06988(63), 116.06205(34), 
77.03858(28), 146.09643(25), 
56.04948(22), 131.07295(21), 
132.08078(20), 79.05423(19), 
103.05423(15), 42.03383(14), 
65.03858(14), 128.06205(13), 
129.06988(12), 130.06513(12) 
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NRG-3  
10 
224.14338(100), 242.15394(84), 
211.11174(30), 182.09643(26), 
141.06988(16), 181.0886(12) 
20 
182.09643(100), 181.0886(84), 
141.06988(60), 224.14338(57), 
167.07295(16), 211.11174(15), 
180.08078(13), 194.09643(10) 
40 
180.08078(100), 181.0886(80), 
141.06988(76), 127.05423(43), 
167.07295(42), 194.09643(40), 
115.05423(20), 166.06513(13) 
Pentedrone metabolite ((±)-
Ephedrine stereochemistry) 
10 176.14338(100), 194.15394(20) 
20 
176.14338(100), 133.0886(61), 
91.05423(38), 117.06988(18), 
134.09643(17), 145.10118(14), 
132.08078(14), 120.08078(12) 
40 
91.05423(100), 132.08078(33), 
77.03858(20), 56.04948(19), 
115.05423(18), 79.05423(17), 
104.06205(16), 118.06513(16), 
43.05423(14), 133.0886(13), 
103.05423(12), 42.03383(12), 
65.03858(10) 
Pentedrone metabolite ((±)-
Pseudoephedrine 
stereochemistry) 
10 176.14338(100) 
20 
176.14338(100), 133.0886(68), 
91.05423(35), 134.09643(19), 
117.06988(17), 132.08078(16), 
145.10118(14), 120.08078(12), 
119.07295(12) 
40 
91.05423(100), 132.08078(40), 
56.04948(21), 104.06205(20), 
118.06513(20), 117.0573(16), 
133.0886(16), 115.05423(16), 
42.03383(13), 103.05423(12), 
130.06513(12), 119.07295(11) 
Benzedrone  
10 254.15394(100), 91.05423(69), 236.14338(20) 
20 91.05423(100) 
40 91.05423(100) 
(−)-(S)-Cathinone  
10 
132.08078(100), 133.06479(20), 
105.06988(20), 117.0573(18), 
150.09134(12) 
20 117.0573(100), 105.06988(46), 132.08078(44) 
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40 
77.03858(100), 90.0464(81), 
117.0573(80), 89.03858(53), 
51.02293(27), 79.05423(22), 
103.05423(14), 130.06513(11) 
2,3-Dimethylethcathinone  
10 
188.14338(100), 206.15394(46), 
159.10425(11), 173.1199(10), 
160.11208(10) 
20 
173.1199(100), 159.10425(99), 
188.14338(71), 158.09643(53), 
160.11208(46), 145.0886(23), 
133.10118(21), 144.08078(14) 
40 
158.09643(100), 144.08078(51), 
143.07295(18), 105.06988(17), 
91.05423(15), 115.05423(12), 
145.0886(10) 
2,4-Dimethylethcathinone  
10 188.14338(100), 206.15394(37) 
20 
173.1199(100), 159.10425(99), 
188.14338(79), 158.09643(48), 
160.11208(45), 145.0886(22), 
133.10118(22), 72.08078(20), 
144.08078(12) 
40 
158.09643(100), 144.08078(45), 
105.06988(17), 143.07295(16), 
91.05423(16), 115.05423(13), 
128.06205(10) 
Diethylcathinone  
10 
188.14338(100), 206.15394(59), 
159.10425(16), 173.1199(14), 
160.11208(12) 
20 
188.14338(100), 159.10425(95), 
173.1199(90), 158.09643(62), 
160.11208(45), 133.10118(28), 
145.0886(25), 144.08078(17), 
105.06988(10) 
40 
158.09643(100), 144.08078(47), 
105.06988(22), 91.05423(21), 
115.05423(18), 143.07295(18), 
145.0886(11), 117.06988(11) 
2,3-Dimethylmethcathinone  
10 161.09609(100), 133.06479(15) 
20 133.06479(100), 161.09609(50) 
40 
133.06479(100), 105.06988(69), 
77.03858(67), 79.05423(62), 
103.05423(47), 91.05423(40), 
117.06988(23), 115.05423(20), 
128.06205(17), 146.07262(14), 
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55.01784(11), 131.04914(11), 
120.05697(10) 
2,4-Dimethylmethcathinone  
10 
174.12773(100), 192.13829(26), 
161.09609(21), 145.0886(14), 
146.09643(13) 
20 
145.0886(100), 105.06988(45), 
174.12773(35), 146.09643(35), 
144.08078(35), 159.10425(21) 
40 144.08078(100), 105.06988(18), 91.05423(18) 
3,4-Dimethylmethcathinone 
metabolite ((±)-Ephedrine 
stereochemistry) 
10 176.14338(100) 
20 
176.14338(100), 161.1199(49), 
145.10118(28), 130.0777(15), 
105.06988(14), 56.04948(13), 
70.06513(13) 
40 
105.06988(100), 129.06988(84), 
115.05423(78), 56.04948(66), 
91.05423(57), 119.08553(57), 
146.09643(47), 131.07295(46), 
130.0777(44), 128.06205(41), 
160.11208(35), 117.06988(29), 
77.03858(25), 79.05423(25), 
145.0886(24), 42.03383(23), 
103.05423(17), 161.1199(14), 
43.01784(14), 144.08078(12), 
127.05423(12) 
3,4-Dimethylmethcathinone 
metabolite ((±)-Pseudoephedrine 
stereochemistry) 
10 176.14338(100)  
20 
176.14338(100), 161.1199(51), 
145.10118(25), 70.06513(15), 
130.0777(14), 56.04948(13), 
105.06988(12) 
40   
3-Bromomethcathinone  
10 145.0886(100), 242.0175(74) 
20 145.0886(100), 144.08078(23) 
40 144.08078(100) 
4-Bromomethcathinone  
10 145.0886(100), 242.0175(74) 
20 145.0886(100), 144.08078(23) 
40 144.08078(100) 
10 166.10265(100) 
167 
   
4-Fluoromethcathinone 
metabolite ((±)-Ephedrine 
stereochemistry) 
20 
166.10265(100), 151.07918(70), 
135.06045(55), 115.05423(29), 
109.0448(19), 133.0448(12), 
70.06513(11) 
40 
109.0448(100), 133.0448(52), 
115.05423(46), 150.07135(16), 
122.05263(15), 83.02915(14), 
43.01784(10) 
4-Fluoromethcathinone 
metabolite ((±)-Pseudoephedrine 
stereochemistry) 
10 166.10265(100) 
20 
166.10265(100), 151.07918(70), 
135.06045(55), 115.05423(29), 
109.0448(19), 133.0448(12), 
70.06513(11) 
40 
109.0448(100), 133.0448(52), 
115.05423(46), 150.07135(16), 
122.05263(15), 83.02915(14), 
43.01784(10) 
(−)-3,4-Methylenedioxy 
Pyrovalerone  
10 276.15942(100) 
20 
276.15942(100), 175.07536(63), 
205.08592(62), 126.12773(62), 
135.04406(49), 149.02332(26) 
40 
126.12773(100), 135.04406(82), 
149.02332(70), 84.08078(34), 
121.02841(31), 65.03858(15), 
175.07536(14), 133.02841(10) 
(+)-3,4-Methylenedioxy 
Pyrovalerone  
10 276.15942(100) 
20 
276.15942(100), 205.08592(61), 
126.12773(60), 175.07536(60), 
135.04406(49), 149.02332(25) 
40 
126.12773(100), 135.04406(81), 
149.02332(70), 84.08078(33), 
121.02841(32), 65.03858(15), 
175.07536(15), 133.02841(11) 
2,3-MDA  
10 
163.07536(100), 135.04406(71), 
133.06479(16), 105.06988(15), 
180.10191(11) 
20 135.04406(100), 105.06988(69), 133.06479(20), 79.05423(12) 
40 
77.03858(100), 79.05423(40), 
105.06988(21), 51.02293(19), 
103.05423(19) 
2,3-MDMA  10 163.07536(100), 194.11756(53), 135.04406(52), 133.06479(11) 
168 
   
20 135.04406(100), 105.06988(48), 133.06479(20), 163.07536(15) 
40 
77.03858(100), 79.05423(54), 
105.06988(39), 103.05423(24), 
135.04406(24), 51.02293(14), 
105.03349(11) 
3,4-MDMA  
10 163.07536(100), 194.11756(19), 135.04406(12), 133.06479(11) 
20 
105.06988(100), 135.04406(91), 
133.06479(77), 163.07536(58), 
58.06513(12), 79.05423(10) 
40 
77.03858(100), 79.05423(62), 
105.06988(43), 103.05423(36), 
135.04406(26), 51.02293(11) 
3,4-Methylenedioxy-5-
methylethcathinone  
10 236.12812(100), 188.10699(69), 218.11756(68), 72.08078(18) 
20 
188.10699(100), 189.07843(15), 
218.11756(15), 160.11208(13), 
72.08078(13) 
40 
105.06988(100), 145.0886(95), 
160.1094(77), 173.08352(72), 
188.0706(68),130.06513(63), 
144.08078(59), 132.08078(56), 
115.05423(55), 79.05423(54), 
133.06479(48),72.08078(41), 
77.03858(39), 154.06513(39), 
103.05423(39), 91.05423(37), 
131.07295(35), 155.07295(22), 
128.06205(22), 44.04948(21), 
189.07843(17), 172.07569(14), 
163.07536(11), 149.05971(11), 
161.05971(10), 158.09375(10) 
3,4-Methylenedioxy-N-
benzylcathinone  
10 284.12812(100), 91.05423(26), 266.11756(15) 
20 91.05423(100) 
40 91.05423(100) 
Methylenedioxy Pyrovalerone  
10 276.15942(100) 
20 
276.15942(100), 126.12773(65), 
175.07536(65), 205.08592(64), 
135.04406(53), 149.02332(26) 
40 
126.12773(100), 135.04406(81), 
149.02332(69), 84.08078(32), 
121.02841(32), 65.03858(14), 
175.07536(14), 133.02841(10) 
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Methylenedioxy Pyrovalerone 
Metabolite 1  
10 278.17507(100) 
20 
175.07536(100), 278.17507(95), 
126.12773(83), 72.08078(38), 
207.10157(30), 137.05971(30), 
151.03897(30) 
40   
Methylenedioxy Pyrovalerone 
metabolite 2  
10 264.15942(100) 
20 
264.15942(100), 72.08078(97), 
126.12773(69), 123.04406(69), 
193.08592(42), 137.02332(30), 
175.07536(29) 
40 
123.04406(100), 126.12773(93), 
137.02332(67), 72.08078(41), 
84.08078(39), 109.02841(36), 
81.03349(17), 97.0886(10) 
N-acetyl-3,4-
Methylenedioxymethcathinone 
10 208.09682(100), 250.10738(49), 190.08626(13), 160.07569(12) 
20 160.07569(100), 190.08626(61), 208.09682(48), 58.06513(21) 
40 
132.08078(100), 160.07569(82), 
58.06513(21), 117.0573(19), 
91.05423(13) 
N-hydroxy MDA  
10 163.07536(100), 135.04406(16), 133.06479(14) 
20 
105.06988(100), 135.04406(87), 
133.06479(78), 163.07536(43), 
79.05423(15) 
40 
77.03858(100), 79.05423(72), 
103.05423(41), 105.06988(32), 
135.04406(22), 51.02293(17) 
25C-NBOMe  
10 336.1361(100), 121.06479(51) 
20 121.06479(100), 91.05423(11) 
40 91.05423(100), 121.06479(23), 93.06988(12) 
25D-NBOMe  
10 316.19072(100), 121.06479(26) 
20 121.06479(100), 91.05423(12) 
40 91.05423(100), 121.06479(19), 93.06988(11) 
25E-NBOMe  
10 330.20637(100), 121.06479(20)  
20 121.06479(100), 193.12231(12), 91.05423(10) 
40 91.05423(100), 121.06479(25), 93.06988(13) 
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25G-NBOMe  
10 330.20637(100), 121.06479(20)  
20 121.06479(100), 193.12231(12), 91.05423(10) 
40 91.05423(100), 121.06479(25), 93.06988(13) 
25H-NBOMe  
10 302.17507(100), 121.06479(45) 
20 121.06479(100), 91.05423(14) 
40 91.05423(100), 121.06479(15) 
25I-NBF  
10 416.05173(100) 
20 290.98765(100), 275.96417(26), 416.05173(23) 
40 
275.96417(100), 260.9407(54), 
109.0448(53), 149.05971(30), 
134.07262(26), 164.08318(19), 
290.98765(19), 104.06205(15), 
121.06479(13), 91.05423(10) 
25I-NBOMe 3-methoxy isomer  
10 121.06479(100), 428.07171(32) 
20 121.06479(100) 
40 121.06479(100) 
25I-NBOMe 4-methoxy isomer  
10 428.07171(100), 290.98765(11) 
20 
121.06479(100), 290.98765(72), 
272.1407(47), 428.07171(44), 
275.96417(16) 
40 121.06479(100), 275.96417(23), 91.05423(22) 
25I-NBOMe imine analog 
10 426.05606(100) 
20 426.05606(100), 290.98765(65), 275.96417(21) 
40 
275.96417(100), 260.9407(46), 
149.05971(28), 290.98765(24), 
134.07262(24), 164.08318(20), 
121.06479(12) 
25T2-NBOMe  
10 348.16279(100), 121.06479(21) 
20 121.06479(100), 211.07536(13) 
40 91.05423(100), 121.06479(33), 93.06988(15) 
30C-NBOMe  
10 181.08592(100) 
20 181.08592(100) 
40 181.08592(100), 148.05188(29) 
3-methoxy PCP  
10 86.09643(100), 189.12739(60) 
20 86.09643(100), 121.06479(80), 189.12739(36), 81.06988(19) 
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40 121.06479(100), 86.09643(57), 91.05423(24), 81.06988(16) 
4-methoxy PCP  
10 189.12739(100), 86.09643(23), 121.06479(12) 
20 121.06479(100), 189.12739(62), 86.09643(23) 
40 121.06479(100) 
PCEEA  
10 159.11683(100), 90.09134(84), 91.05423(20) 
20 
91.05423(100), 159.11683(32), 
90.09134(23), 44.04948(19), 
81.06988(19) 
40 91.05423(100), 44.04948(10) 
PCMPA  
10 90.09134(100), 159.11683(99), 91.05423(17), 248.20089(11) 
20 
91.05423(100), 159.11683(45), 
90.09134(42), 81.06988(19), 
58.06513(17) 
40 91.05423(100) 
PCPr  
10 159.11683(100), 60.08078(44), 91.05423(32), 81.06988(11) 
20 91.05423(100), 60.08078(18), 159.11683(14), 81.06988(13) 
40 91.05423(100) 
Benocyclidine 
10 215.0889(100), 86.09643(39) 
20 215.0889(100), 147.0263(86), 86.09643(49), 81.06988(11) 
40 147.0263(100), 86.09643(17) 
2-methyl-α-
Pyrrolidinopropiophenone  
10 218.15394(100) 
20 
119.08553(100), 218.15394(83), 
147.08044(65), 98.09643(56), 
70.06513(19) 
40 
98.09643(100), 91.05423(99), 
119.08553(55), 117.06988(36), 
56.04948(27), 70.06513(17), 
84.08078(15), 103.05423(14), 
55.05423(13), 77.03858(13), 
104.06205(10) 
3,4-dimethoxy-α-
Pyrrolidinopentiophenone  
10 292.19072(100) 
20 
221.11722(100), 151.07536(87), 
292.19072(83), 126.12773(82), 
165.05462(25), 193.12231(12) 
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40 
151.07536(100), 126.12773(80), 
165.05462(32), 84.08078(23), 
137.05971(12) 
3'-fluoro-α-
Pyrrolidinopropiophenone  
10 222.12887(100) 
20 
222.12887(100), 98.09643(69), 
123.06045(57), 70.06513(27), 
151.05537(26) 
40 
98.09643(100), 103.05423(68), 
77.03858(28), 70.06513(27), 
95.02915(27), 56.04948(24), 
123.06045(21), 84.08078(17), 
123.02407(14), 55.05423(11) 
3-methyl-α-
Pyrrolidinopropiophenone  
10 218.15394(100) 
20 
119.08553(100), 218.15394(83), 
147.08044(65), 98.09643(56), 
70.06513(19) 
40 
98.09643(100), 91.05423(99), 
119.08553(55), 117.06988(36), 
56.04948(27), 70.06513(17), 
84.08078(15), 103.05423(14), 
55.05423(13), 77.03858(13), 
104.06205(10) 
4’-Methyl-N-
methylhexanophenone  
10 
202.15903(100), 220.16959(54), 
189.12739(29), 146.09643(18), 
105.06988(13) 
20 
146.09643(100), 105.06988(63), 
145.0886(53), 202.15903(49), 
131.07295(16), 144.08078(14), 
119.04914(13), 158.09643(13), 
159.10425(12) 
40 
144.08078(100), 105.06988(50), 
158.09643(45), 91.05423(38), 
145.0886(31), 131.07295(30), 
130.06513(18), 77.03858(11), 
79.05423(11) 
4-fluoro-α-
Pyrrolidinobutiophenone  
10 236.14452(100) 
20 
109.0448(100), 236.14452(85), 
165.07102(56), 112.11208(51), 
137.0761(40), 123.02407(26), 
70.06513(20) 
40 
109.0448(100), 112.11208(60), 
95.02915(46), 123.02407(45), 
84.08078(27), 70.06513(17) 
10 250.16017(100) 
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4-fluoro-α-
Pyrrolidinopentiophenone  
20 
109.0448(100), 250.16017(79), 
126.12773(40), 179.08667(39), 
123.02407(23), 70.06513(14) 
40 
109.0448(100), 126.12773(57), 
123.02407(53), 95.02915(48), 
84.08078(33), 70.06513(11) 
4'-fluoro-α-
Pyrrolidinopropiophenone  
10 222.12887(100) 
20 
222.12887(100), 123.06045(85), 
98.09643(82), 151.05537(64), 
70.06513(19) 
40 
98.09643(100), 103.05423(85), 
123.06045(34), 77.03858(30), 
56.04948(27), 70.06513(18), 
95.02915(17), 123.02293(14), 
84.08078(14), 55.05423(11) 
4-Methyl-α-
ethylaminobutiophenone  
10 
188.14338(100), 206.15394(72), 
161.09609(20), 160.11208(16), 
159.10425(13) 
20 
159.10425(100), 105.06988(68), 
144.08078(62), 188.14338(55), 
160.11208(54), 132.08078(24), 
131.07295(11), 158.09643(10) 
40 
144.08078(100), 105.06988(40), 
91.05423(33), 130.06513(18), 
143.07295(12), 158.09643(11) 
4-Methyl-α-
ethylaminopentiophenone  
10 
202.15903(100), 220.16959(79), 
175.11174(27), 160.11208(12), 
105.06988(12) 
20 
105.06988(100), 202.15903(81), 
160.11208(81), 159.10425(69), 
144.08078(58), 132.08078(50), 
173.1199(33), 174.12773(27), 
119.04914(20), 131.07295(14), 
175.11174(14), 158.09643(14), 
145.0886(11) 
40 
144.08078(100), 105.06988(39), 
91.05423(31), 130.06513(14), 
158.09643(12), 117.0573(10) 
α-Ethylaminopentiophenone  10 
188.14338(100), 206.15394(99), 
146.09643(21), 161.09609(18), 
91.05423(15) 
174 
   
20 
91.05423(100), 146.09643(83), 
118.06513(67), 188.14338(49), 
130.06513(48), 145.0886(38), 
159.10425(24), 105.03349(23), 
160.11208(21), 117.0573(12), 
131.07295(11) 
40 
130.06513(100), 91.05423(82), 
77.03858(53), 117.0573(21), 
118.06513(17), 105.03349(11) 
α-Pyrrolidinobutiothiophenone  
10 224.11036(100), 112.11208(20) 
20 
112.11208(100), 125.04195(33), 
224.11036(19), 153.03686(16), 
97.01065(10) 
40 
112.11208(100), 97.01065(45), 
110.98991(42), 70.06513(22), 
84.08078(16), 55.05423(15) 
α-Pyrrolidinopentiophenone 
metabolite 1   
10 234.18524(100), 216.17468(23), 72.08078(14) 
20 
72.08078(100), 216.17468(76), 
173.1199(26), 234.18524(19), 
91.05423(16), 145.10118(15) 
40 
72.08078(100), 91.05423(69), 
79.05423(43), 43.05423(38), 
172.11208(20), 103.05423(17), 
104.06205(14), 117.06988(13), 
77.03858(13), 41.03858(12), 
105.06988(11) 
α-Pyrrolidinopentiothiophenone  
10 238.12601(100), 126.12773(17) 
20 126.12773(100), 97.01065(43), 238.12601(22), 167.05251(12) 
40 
126.12773(100), 97.01065(60), 
110.98991(41), 84.08078(33), 
97.0886(20), 55.05423(10) 
4-fluoro PV8  
10 278.19147(100) 
20 
278.19147(100), 109.0448(69), 
154.15903(24), 207.11683(16), 
123.02407(12), 70.06513(11) 
40 
109.0448(100), 154.15903(48), 
123.02407(47), 84.08078(29), 
95.02915(25) 
4-fluoro PV9  
10 292.20712(100) 
20 292.20712(100), 109.0448(49), 168.17468(16) 
175 
   
40 
109.0448(100), 168.17468(49), 
123.02407(43), 84.08078(26), 
95.02915(17) 
4-methoxy PV8  
10 290.21146(100) 
20 
121.06479(100), 219.13796(98), 
290.21146(96), 154.15903(76), 
135.04406(25) 
40 
121.06479(100), 154.15903(56), 
135.04406(40), 84.08078(24), 
77.03858(15) 
4-methoxy PV9  
10 304.22711(100) 
20 
304.22711(100), 233.15361(73), 
121.06479(71), 168.17468(54), 
135.04406(17) 
40 
121.06479(100), 168.17468(59), 
135.04406(41), 84.08078(22), 
77.03858(11) 
PV8  
10 260.20089(100) 
20 
260.20089(100), 91.05423(75), 
154.15903(21), 70.06513(17), 
189.12739(15), 119.04914(14), 
105.03349(14) 
40 
91.05423(100), 77.03858(37), 
105.03349(35), 154.15903(35), 
84.08078(28) 
PV9  
10 274.21654(100) 
20 274.21654(100), 91.05423(50), 168.17468(14), 70.06513(12) 
40 
91.05423(100), 105.03349(37), 
168.17468(35), 77.03858(28), 
84.08078(25), 70.06513(10) 
4-APB  
10 159.08044(100), 131.04914(73) 
20 131.04914(100), 91.05423(20) 
40 
91.05423(100), 77.03858(99), 
131.04914(80), 115.05423(42), 
103.05423(23), 116.06205(20), 
65.03858(19), 128.06205(11) 
4-APDB  
10 161.09609(100), 133.06479(61) 
20 133.06479(100), 161.09609(14), 120.05697(11) 
40 
77.03858(100), 91.05423(64), 
79.05423(56), 103.05423(44), 
105.06988(38), 133.06479(33), 
176 
   
115.05423(20), 117.06988(14), 
128.06205(11) 
5-APDB  
10 161.09616(100), 178.12288(10) 
20 
161.09609(100), 105.06997(55), 
146.07258(42), 131.07957(18), 
91.05413(14) 
40 
103.05423(100), 131.04918(51), 
91.05425(41), 77.03853(40), 
115.05446(36) 
5-EAPB  
10 159.08044(100), 131.04914(35), 204.13829(29) 
20 131.04914(100), 159.08044(19) 
40 
131.04914(100), 91.05423(60), 
77.03858(29), 116.06205(17), 
115.05423(15), 103.05423(15) 
5-MAPB  
10 159.08044(100), 131.04914(45), 190.12264(19) 
20 131.04914(100), 159.08044(13), 91.05423(11) 
40 
131.04914(100), 91.05423(77), 
77.03858(51), 115.05423(25), 
116.06205(20), 103.05423(20) 
5-MAPDB  
10 161.09609(100), 133.06479(15) 
20 133.06479(100), 161.09609(50) 
40 
133.06479(100), 105.06988(69), 
77.03858(67), 79.05423(62), 
103.05423(47), 91.05423(40), 
117.06988(23), 115.05423(20), 
128.06205(17), 146.07262(14), 
55.01784(11), 131.04914(11), 
120.05697(10) 
6-APB  
10 159.08044(100), 131.04914(68) 
20 131.04914(100), 91.05423(19) 
40 
91.05423(100), 77.03858(87), 
131.04914(78), 115.05423(48), 
103.05423(23), 116.06205(23), 
65.03858(16) 
6-APDB  10 161.09609(100), 133.06479(56) 20 133.06479(100), 161.09609(16) 
177 
   
40 
77.03858(100), 79.05423(64), 
91.05423(52), 103.05423(52), 
105.06988(50), 133.06479(48), 
115.05423(21), 117.06988(18), 
128.06205(15), 55.01784(10) 
7-APB  
10 131.04914(100), 159.08044(75) 
20 131.04914(100) 
40 
77.03858(100), 131.04914(70), 
91.05423(53), 115.05423(27), 
103.05423(25), 116.06205(12) 
3-Methylbuphedrone  
10 
174.12773(100), 192.13829(42), 
161.09609(20), 145.0886(15), 
146.09643(14), 105.06988(10) 
20 
145.0886(100), 105.06988(46), 
146.09643(36), 144.08078(35), 
174.12773(33), 159.10425(22), 
131.07295(10) 
40 144.08078(100), 91.05423(20), 105.06988(20) 
4-Fluorobuphedrone  
10 
178.10265(100), 196.11322(37), 
165.07102(19), 150.07135(18), 
149.06353(13) 
20 
149.06353(100), 150.07135(51), 
109.0448(49), 178.10265(37), 
148.0557(15), 163.07918(12) 
40 
148.0557(100), 109.0448(65), 
149.06353(37), 95.02915(33), 
108.03698(16), 135.04788(15), 
162.07135(12), 83.02915(11) 
4-Methylbuphedrone  
10 
174.12773(100), 192.13829(26), 
161.09609(21), 145.0886(14), 
146.09643(13) 
20 
145.0886(100), 105.06988(45), 
174.12773(35), 146.09643(35), 
144.08078(35), 159.10425(21) 
40 144.08078(100), 105.06988(18), 91.05423(18) 
4-methyl-N-Methylbuphedrone  
10 206.15394(100), 161.09609(56), 105.06988(17), 133.10118(11) 
20 
105.06988(100), 86.09643(37), 
119.04914(35), 161.09609(27), 
133.10118(17) 
178 
   
40 
91.05423(100), 105.06988(78), 
86.09643(53), 71.07295(26), 
119.04914(21), 65.03858(16), 
79.05423(14), 77.03858(12) 
N-Ethylbuphedrone  
10 
174.12773(100), 192.13829(60), 
146.09643(25), 147.08044(16), 
91.05423(14), 145.0886(13) 
20 
145.0886(100), 91.05423(99), 
130.06513(82), 146.09643(76), 
174.12773(53), 118.06513(50), 
105.03349(17), 117.0573(15) 
40 130.06513(100), 91.05423(72), 77.03858(45), 117.0573(19) 
Dimethocaine  
10 279.2067(100), 120.04439(12), 142.15903(11) 
20 120.04439(100), 142.15903(47), 86.09643(31), 279.2067(14) 
40 120.04439(100), 86.09643(53), 92.04948(36) 
(±)-Cannabichromene 
10 
315.23186(100), 193.12231(55), 
259.16926(44), 81.06988(32), 
233.15361(30), 135.11683(14), 
231.13796(10), 219.13796(10) 
20   
40   
(±)-ORG 28611 
10 270.14886(100), 384.26455(37) 
20 270.14886(100) 
40 174.05495(100), 270.14886(33), 55.05423(19) 
5-fluoro NNEI 
10 375.18672(100), 232.11322(23) 
20 232.11322(100) 
40 232.11208(100), 144.04439(86) 
5-fluoro NNEI 2'-naphthyl 
isomer 
10 375.18672(100), 232.11322(31) 
20 232.11322(100) 
40 232.11322(100), 144.04439(86) 
5-fluoro SDB-005 
10 233.10847(100) 
20 233.10847(100), 213.10224(26) 
40 145.03964(100), 213.10224(24), 69.06988(18), 177.04587(16) 
5-fluoro SDB-006 
10 339.18672(100) 
20 232.11322(100), 339.18672(89), 206.13395(71), 91.05423(40) 
179 
   
40 91.05423(100), 144.04439(25), 232.11322(16), 118.06513(15) 
A-796260 
10 355.238(100), 125.09609(14) 
20 125.09609(100), 114.09134(32), 355.238(32) 
40 
114.09134(100), 125.09609(51), 
55.05423(39), 97.10118(26), 
70.06513(21), 57.06988(19), 
69.06988(12) 
A-836339 
10 311.17878(100), 187.08996(63) 
20 187.08996(100), 125.09609(18) 
40 
187.08996(100), 59.04914(71), 
55.05423(56), 129.0481(42), 
125.09609(37), 57.06988(32), 
155.06375(32), 97.10118(23), 
69.06988(14) 
JW 618 
10 393.10322(100) 
20 393.10322(100) 
40 169.0886(100), 393.10322(79), 197.10732(26) 
JW 642 
10 463.14509(100), 183.08044(24) 
20 183.08044(100), 463.14509(30) 
40 183.08044(100), 155.08553(15), 165.06988(12), 168.05697(11) 
MN-25 
10 440.29077(100) 
20 440.29077(100), 261.15975(34), 114.09134(14) 
40 114.09134(100), 81.06988(26), 176.10699(12), 261.15975(10) 
MN-25-2-methyl derivative 
10 454.30642(100), 275.1754(12) 
20 275.1754(100), 454.30642(96), 114.09134(47) 
40 114.09134(100) 
NNEI 
10 357.19614(100), 214.12264(29) 
20 214.12264(100) 
40 144.04439(100), 214.12264(86), 43.05423(14) 
NNEI 2'-naphthyl isomer 
10 357.19614(100), 214.12264(38) 
20 214.12264(100) 
40 144.04439(100), 214.12264(82), 43.05423(13) 
SDB-005 10 215.11789(100) 
180 
   
20 215.11789(100) 
40 145.03964(100), 215.11789(17) 
SDB-006 
10 321.19614(100) 
20 
214.12264(100), 188.14338(63), 
321.19614(51), 91.05423(43), 
132.08078(16) 
40 91.05423(100), 144.04439(24), 118.06513(13), 132.08078(10) 
Δ8-THC 
10 315.23186(100) 
20 
315.23186(100), 193.12231(72), 
259.16926(44), 135.11683(40), 
93.06988(31), 233.15361(18), 
181.12231(15), 235.16926(13), 
231.13796(13), 247.16926(13), 
207.13796(11), 107.08553(10), 
109.10118(10) 
40   
Δ9-THC 
10 315.23186(100) 
20 
315.23186(100), 193.12231(90), 
259.16926(47), 135.11683(42), 
93.06988(30), 221.15361(21), 
235.16926(21), 233.15361(18), 
81.06988(17), 181.12231(16), 
109.10118(12), 123.04406(11), 
107.08553(11), 207.13796(11) 
40   
AM1248 azepane isomer 
10 391.27439(100) 
20 391.27439(100), 112.11208(58), 135.11683(23) 
40 112.11208(100), 135.11683(51), 58.06513(13) 
AM2201 benzimidazole analog 
10 361.17107(100) 
20 
361.17107(100), 233.10847(24), 
177.04587(17), 155.04914(15), 
273.10224(13) 
40 
155.04914(100), 127.05423(65), 
177.04587(27), 145.03964(25), 
129.04472(14) 
KM 233 
10 363.23186(100), 119.08553(37) 
20 119.08553(100), 363.23186(10) 
40 91.05423(100), 119.08553(84) 
LY2183240 10 280.14444(100), 72.04439(48), 167.08553(29), 87.05529(20) 
181 
   
20 72.04439(100), 167.08553(84), 87.05529(13) 
40 72.04439(100), 167.08553(37) 
LY2183240 2’-isomer 
10 280.14444(100), 72.04439(54), 167.08553(32), 87.05529(19) 
20 72.04439(100), 167.08553(84), 87.05529(16) 
40 72.04439(100), 167.08553(39) 
SER-601 
10 435.3006(100) 
20 435.3006(100), 135.11683(70), 284.16451(25) 
40 135.11683(100), 284.16451(20) 
Tetrahydrocannabivarin 
10 287.20056(100) 
20   
40   
Yangonin 
10 259.09649(100), 231.10157(14) 
20 
161.05971(100), 231.10157(53), 
259.09649(40), 
216.0781(31),199.07536(31), 
171.08044(28), 209.05971(24), 
198.06753(15), 203.10666(13), 
185.05971(13), 133.06479(10), 
213.09101(10) 
40 
133.06479(100), 128.06205(67), 
68.99711(48), 118.04132(33), 
151.05423(31), 161.05971(29), 
139.05423(28), 115.05423(24), 
140.06205(23), 103.05423(22), 
171.08044(22), 79.05423(22), 
127.05423(21), 77.03858(20), 
141.06988(20), 155.04914(18), 
152.06205(18), 90.0464(18), 
156.05697(17), 157.06479(16), 
145.06479(15), 184.05188(13), 
129.06988(13), 144.05697(12), 
173.05971(12), 142.04132(12), 
183.04406(12),  168.05697(11) 
Cannabidiolic Acid 
10 341.21112(100) 
20 341.21112(100) 
40   
Cannabigerol 
10 193.12231(100), 317.24751(15) 
20 193.12231(100) 
40   
182 
   
EG-018 
10 392.20089(100), 155.04914(11) 
20 155.04914(100), 392.20089(55), 264.13829(12) 
40 155.04914(100), 127.05423(85) 
(±)-JWH 018 N-(2-
hydroxypentyl) metabolite 
10 358.18041(100) 
20 358.17982(100), 155.04864(92), 230.11689(20) 
40 127.05377(100), 155.04848(86), 160.03941(16) 
(±)-JWH 018 N-(3-
hydroxypentyl) metabolite 
10 358.18016(100), 155.04914(20) 
20 155.04914(100), 358.18016(18) 
40 127.05423(100), 155.04914(89) 
(±)-JWH 018 N-(4-
hydroxypentyl) metabolite 
10 358.1799(100), 155.04864(10) 
20 155.0487(100), 358.18016(46) 
40 127.05391(100), 155.04858(83) 
(R)-(−)-JWH 018 N-(4-
hydroxypentyl) metabolite 
10 358.18016(100), 155.04914(20) 
20 155.04914(100), 358.18016(18) 
40 127.05423(100), 155.04914(89) 
(S)-(+)-JWH 018 N-(4-
hydroxypentyl) metabolite 
10 358.18016(100), 155.04914(20) 
20 155.04914(100), 358.18016(18) 
40 127.05423(100), 155.04914(89) 
5-fluoro JWH 018 adamantyl 
analog 
10 368.23842(100) 
20 368.23842(100), 135.11683(22) 
40 135.11683(100), 93.06988(13), 107.08553(11) 
JWH 018 2-hydroxyindole 
metabolite 
10 358.18041(100) 
20 358.17982(100), 155.04864(92), 230.11689(20) 
40   
JWH 018 4-hydroxyindole 
metabolite 
10 358.18016(100) 
20 358.18016(100), 155.04914(43), 230.11756(26) 
40 127.05423(100), 155.04914(86), 160.0393(42), 230.11756(24) 
JWH 018 5-hydroxyindole 
metabolite 
10 358.18041(100) 
20 358.17982(100), 155.04864(92), 230.11689(20) 
40 127.05377(100), 155.04848(86), 160.03941(16) 
JWH 018 6-hydroxyindole 
metabolite 
10 358.17987(100) 
20 155.04841(100), 358.17954(66) 
40 127.05384(100), 155.04844(85) 
183 
   
JWH 018 7-hydroxyindole 
metabolite 
10 358.18031(100), 155.04876(31) 
20 155.04881(100), 358.18008(14) 
40 127.05397(100), 155.0488(91), 144.04422(12) 
JWH 018 8-quinolinyl 
carboxamide 
10 214.1224(100), 358.19139(25) 
20 214.12235(100) 
40 144.04403(100), 214.12243(75), 43.05417(16) 
JWH 018 benzimidazole analog 
10 343.18056(100) 
20 343.18089(100), 215.11756(46), 273.10216(30), 155.04888(18) 
40 155.04889(100), 127.05411(70), 145.03937(30), 131.05994(16) 
JWH 018 N-(1-ethylpropyl) 
isomer 
10 342.18495(100) 
20 155.04897(100), 342.18524(99), 214.12262(12), 144.04442(11) 
40 127.05428(100), 155.04894(91), 144.04412(48) 
JWH 018 N-(4-oxo-pentyl) 
metabolite 
10 356.16468(100), 155.04894(24) 
20 155.04899(100), 356.16464(17) 
40 127.05414(100), 155.04895(83), 85.06484(13), 43.01812(12) 
JWH 018 N-(5-hydroxypentyl) 
metabolite 
10 358.18031(100), 155.04876(31) 
20 155.04881(100), 358.18008(14) 
40 127.05397(100), 155.0488(91), 144.04422(12) 
JWH 018 N-(5-hydroxypentyl) 
β-D-Glucuronide 
10 358.17854(100), 534.21023(75), 155.04867(21) 
20 358.17916(100), 155.04793(59) 
40 155.04839(100), 127.05485(12) 
JWH 018 N-pentanoic acid β-D-
Glucuronide 
10 372.1595(100), 548.18965(26) 
20 372.15923(100), 155.04822(30) 
40 155.04922(100), 372.15997(16), 127.05253(12) 
JWH 018 N-propanoic acid 
metabolite 
10 344.12759(100) 
20 155.04863(100), 344.12812(61), 216.0651(25) 
40 127.05395(100), 155.04838(58), 216.06493(18) 
JWH 019 5-hydroxyindole 
metabolite 
10 372.19623(100) 
20 372.19547(100), 155.04901(70), 244.13285(17) 
184 
   
40 155.04867(100), 127.05409(99), 160.03885(14) 
JWH 019 N-(2-fluorohexyl) 
isomer 
10 374.19147(100) 
20 374.19151(100), 155.04866(75), 246.12832(21) 
40 155.04884(100), 127.05404(97), 246.12835(21), 144.04371(13) 
JWH 019 N-(3-fluorohexyl) 
isomer 
10 374.19142(100) 
20 374.19107(100), 155.04886(70), 246.12872(19) 
40 155.04842(100), 127.05395(90), 246.12956(16), 144.04406(11) 
JWH 019 N-(4-fluorohexyl) 
isomer 
10 374.19147(100) 
20 374.19129(100), 155.04898(78), 246.12871(14) 
40 155.04915(100), 127.05429(82), 144.0434(13) 
JWH 019 N-(5-fluorohexyl) 
isomer 
10 374.19129(100) 
20 374.19135(100), 155.0488(89), 354.18542(17), 246.1283(14) 
40 155.04852(100), 127.05384(86), 144.04367(12) 
JWH 019 N-(5-hydroxyhexyl) 
metabolite 
10 372.1955(100), 155.04848(47) 
20 155.04868(100) 
40 155.0487(100), 127.05403(86) 
JWH 019 N-(6-fluorohexyl) 
isomer 
10 374.19162(100) 
20 374.19113(100), 155.04903(61), 246.12808(15) 
40 155.04871(100), 127.05394(87), 144.04347(19), 246.12794(11) 
JWH 019 N-(6-hydroxyhexyl) 
metabolite 
10 372.19583(100), 155.04883(46) 
20 155.04886(100) 
40 155.04866(100), 127.0541(83) 
JWH 019 N-(6-hydroxyhexyl) 
β-D-Glucuronide 
10 372.19554(100), 548.22603(54), 155.04802(22) 
20 372.19577(100), 155.04842(69) 
40 155.04837(100) 
JWH 030 2-naphthoyl isomer 
10 292.16976(100), 155.04879(47) 
20 155.0489(100), 164.10682(14) 
40 127.05413(100), 155.04861(24) 
JWH 031 2'-isomer 10 306.18494(100), 155.0487(35) 20 155.0488(100), 178.12241(12) 
185 
   
40 127.05391(100), 155.04869(34)  
JWH 071 
10 300.13787(100), 155.04898(11) 
20 155.04872(100), 300.13813(30), 172.07525(25) 
40 127.05391(100), 155.04876(26), 172.07504(11) 
JWH 073 4-hydroxyindole 
metabolite 
10 344.16411(100) 
20 155.04832(100), 344.16347(87), 216.10097(21) 
40 127.05398(100), 155.04852(67), 160.03883(17) 
JWH 073 5-hydroxyindole 
metabolite 
10 344.16411(100) 
20 155.04832(100), 344.16347(87), 216.10097(21) 
40 127.05398(100), 155.04852(67), 160.03883(17) 
JWH 073 6-hydroxyindole 
metabolite 
10 344.16452(100) 
20 155.04885(100), 344.16474(48) 
40 127.05409(100), 155.04854(64) 
JWH 073 6-methoxyindole 
analog 
10 358.1799(100), 155.04864(10) 
20 155.0487(100), 358.18016(46) 
40 127.05391(100), 155.04858(83) 
JWH 073 7-hydroxyindole 
metabolite 
10 344.16439(100) 
20 155.04853(100), 344.16436(94), 216.1013(24) 
40 127.0539(100), 155.04866(67), 160.03896(24) 
JWH 073 N-(2-hydroxybutyl) 
metabolite 
10 344.16451(100) 
20 155.04887(100), 344.16454(81), 216.10148(16) 
40 127.05405(100), 155.04869(72), 144.04405(18) 
JWH 073 N-(4-hydroxybutyl) 
metabolite 
10 344.1641(100), 155.04872(19) 
20 155.04864(100), 344.16374(24) 
40 127.05388(100), 155.0486(74), 144.04396(13) 
JWH 073 N-(4-hydroxybutyl) β-
D-Glucuronide 
10 520.19659(100), 344.16451(83), 155.04914(23) 
20 344.16451(100), 155.04914(53), 520.19659(10) 
40 155.04914(100), 127.05423(13) 
JWH 073 N-butanoic acid 
metabolite 
10 358.14334(100), 155.04805(13) 
20 155.04888(100), 358.14371(44) 
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40 127.05405(100), 155.04903(79), 144.04354(13) 
(±)-JWH 073 N-(3-
hydroxybutyl) metabolite 
10 344.16438(100), 155.04816(14) 
20 155.04863(100), 344.16415(37) 
40 127.05398(100), 155.04881(74) 
(R)-(−)-JWH 073 N-(3-
hydroxybutyl) metabolite 
10 344.16432(100), 155.04874(14) 
20 155.04872(100), 344.16417(37) 
40 127.05389(100), 155.04855(73) 
(S)-(+)-JWH 073 N-(3-
hydroxybutyl) metabolite 
10 344.16432(100), 155.04874(14) 
20 155.04872(100), 344.16417(37) 
40 127.05389(100), 155.04855(73) 
JWH 080 
10 358.18025(100) 
20 185.05942(100), 358.18007(76), 200.10638(33) 
40 
185.0594(100), 157.06449(59), 
144.04404(29), 200.10645(20), 
127.05422(13) 
JWH 081 4-hydroxynaphthyl 
metabolite 
10 358.17969(100) 
20 171.04385(100), 358.17981(90), 214.12166(23) 
40 171.04365(100), 143.04898(43), 115.05384(17), 144.04501(17) 
JWH 081 N-(4-hydroxypentyl) 
metabolite 
10 388.19072(100), 185.05924(19) 
20 185.05945(100), 388.19091(35) 
40 185.05943(100), 157.06412(36), 144.04417(12) 
JWH 081 N-(5-hydroxypentyl) 
metabolite 
10   
20 185.05941(100), 388.19067(28) 
40 185.05947(100), 157.06447(37), 144.04444(15) 
JWH 081 N-pentanoic acid 
metabolite 
10 402.17045(100), 185.05877(13)  
20 185.05911(100), 402.17062(70), 244.09684(15) 
40 185.05907(100), 157.06425(34), 144.04445(15) 
JWH 081-N-(cyclohexylmethyl) 
analog 
10 398.21153(100) 
20 398.21162(100), 185.05946(46), 240.13795(14) 
40 185.05949(100), 157.06436(25), 144.04405(18) 
JWH 116 10 370.21647(100) 
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20 370.21645(100), 183.08009(55), 214.12216(42) 
40 
144.04422(100), 155.08497(84), 
183.07978(81), 214.12217(64), 
141.06957(51) 
JWH 122 N-(4-hydroxypentyl) 
metabolite 
10 372.1955(100), 155.04848(47) 
20 155.04868(100) 
40 155.0487(100), 127.05403(86) 
JWH 122 N-(5-hydroxypentyl) 
metabolite 
10 372.19587(100), 169.06461(27) 
20 169.06454(100), 372.19622(22) 
40 169.06471(100), 141.06976(83), 144.04373(17) 
JWH 145 2-phenyl isomer 
10 368.20084(100), 155.04879(28) 
20 155.04883(100), 368.20129(11) 
40 127.05407(100), 155.04899(90) 
JWH 146 
10 396.23189(100), 155.04867(40) 
20 155.04889(100) 
40 155.04887(100), 127.05399(80) 
JWH 149 
10 370.21591(100) 
20 370.21622(100), 169.06418(97), 228.13783(22) 
40 169.06417(100), 141.06956(87), 158.05945(19), 228.13735(14) 
JWH 167 
10 306.18524(100) 
20 91.05412(100), 306.18506(95), 214.12257(64), 188.14263(26) 
40 91.05425(100), 144.04423(50), 214.12246(19) 
JWH 176 
10 255.11683(100), 325.19508(86), 141.06988(11), 324.18725(11) 
20 255.11683(100), 141.06988(24), 253.10118(18), 254.109(13) 
40   
JWH 193 
10 399.20638(100), 169.0642(18) 
20 169.06439(100), 399.2067(38), 114.09134(31) 
40 169.0643(100), 114.09129(75), 141.06936(52), 70.06525(12) 
JWH 198 
10 415.20157(100), 185.05911(19) 
20 185.05938(100), 415.20162(41), 114.09124(25) 
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40 185.05946(100), 114.09142(55), 157.06473(23) 
JWH 200 4-hydroxyindole 
metabolite 
10 401.1854(100) 
20 155.04869(100), 401.18597(90), 114.09131(74) 
40 114.09126(100), 155.04888(64), 127.05435(34), 70.06478(15) 
JWH 200 5-hydroxyindole 
metabolite 
10 401.18602(100), 155.04887(15) 
20 155.04907(100), 114.09171(30), 401.18662(29) 
40 155.04905(100), 114.09131(94), 127.05448(58), 70.06499(16) 
JWH 200 6-hydroxyindole 
metabolite 
10 401.18588(100), 155.04891(24) 
20 155.04921(100), 401.18635(24), 114.09095(21) 
40 155.04876(100), 127.05407(70), 114.09171(50), 70.06396(11) 
JWH 200 7-hydroxyindole 
metabolite 
10 401.18597(100) 
20 155.04842(100), 401.18571(90), 114.0911(77) 
40 114.09121(100), 155.04868(66), 127.05338(34), 70.06431(17) 
JWH 203 
10 340.14619(100) 
20 340.14596(100), 125.01508(90), 188.14249(23), 214.12275(11) 
40 125.01519(100), 144.04449(10) 
JWH 203 N-(4-hydroxypentyl) 
metabolite 
10 356.14118(100), 186.12737(26) 
20 
125.01534(100), 186.12747(84), 
356.14075(19), 130.06503(16), 
282.0681(10) 
40 125.01529(100) 
JWH 203 N-(5-hydroxypentyl) 
metabolite 
10 356.14058(100), 186.12701(11) 
20 125.01503(100), 186.12714(36), 204.13768(30), 356.1395(18) 
40 125.01507(100) 
JWH 203 N-pentanoic acid 
metabolite 
10 370.12015(100), 200.10631(12) 
20 125.01478(100), 200.10624(54), 370.12045(37), 218.11713(24) 
40 125.01491(100) 
JWH 210 2-ethylnaphthyl 
isomer 
10 370.21647(100) 
20 370.21645(100), 183.08009(55), 214.12216(42) 
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40 
144.04422(100), 155.08497(84), 
183.07978(81), 214.12217(64), 
141.06957(51) 
JWH 210 5-hydroxyindole 
metabolite 
10 386.21146(100) 
20 386.21164(100), 183.0799(62), 230.11634(17) 
40 
183.08055(100), 155.08506(50), 
230.11714(24), 160.03803(23), 
153.06916(20) 
JWH 210 N-(4-hydroxypentyl) 
metabolite 
10 386.21146(100), 183.07986(16) 
20 183.07995(100), 386.21091(39) 
40 183.07987(100), 155.08505(45), 153.06853(18), 144.0433(15) 
JWH 210 N-(5-hydroxypentyl) 
metabolite 
10 386.21122(100), 183.08002(23) 
20 183.08012(100), 386.21097(28) 
40 183.0799(100), 155.08475(48), 153.06952(19), 144.04371(17) 
JWH 210 N-pentanoic acid 
metabolite 
10 400.19072(100), 183.08025(12) 
20 183.08044(100), 400.1908(73), 244.09647(13) 
40 183.07985(100), 155.0847(43), 144.04433(16), 153.06926(16) 
JWH 213 
10 384.23191(100) 
20 384.23188(100), 183.08006(79), 228.13773(21) 
40 
183.07984(100), 155.08492(47), 
153.06982(20), 158.05948(19), 
228.13742(19) 
JWH 250 5-hydroxyindole 
metabolite 
10   
20 121.06479(100), 352.19072(18) 
40 
91.05423(100), 121.06479(82), 
93.06988(24), 146.06004(14), 
160.07569(14), 131.04914(11) 
JWH 250 N-(4-hydroxypentyl) 
metabolite 
10 352.19072(100), 121.06479(14), 186.12773(12) 
20 121.06479(100), 186.12773(18), 352.19072(14) 
40 
91.05423(100), 121.06479(89), 
93.06988(26), 130.06513(20), 
69.06988(12) 
JWH 250 N-(5-hydroxypentyl) 
metabolite 
10 352.19072(100), 121.06479(20) 
20 121.06479(100) 
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40 91.05423(100), 121.06479(87), 93.06988(25), 130.06513(20) 
JWH 250 N-pentanoic acid 
metabolite 
10 366.16998(100), 121.06479(17) 
20 121.06479(100), 366.16998(18) 
40 
121.06479(100), 91.05423(92), 
93.06988(24), 130.06513(18), 
55.05423(12) 
JWH 309 5'-isomer 
10 418.21654(100), 155.04914(23) 
20 155.04914(100), 418.21654(27) 
40 155.04914(100), 127.05423(64) 
JWH 387 
10 420.09575(100) 
20 420.09575(100), 232.95965(90), 214.12264(10) 
40 232.95965(100), 204.96474(69), 126.0464(12) 
JWH 398 N-(4-hydroxypentyl) 
metabolite 
10 392.14118(100), 189.01017(24) 
20 189.01017(100), 392.14118(22) 
40 189.01017(100), 161.01525(58) 
JWH 398 N-(5-hydroxypentyl) 
metabolite 
10 392.14118(100), 189.01017(36) 
20 189.01017(100), 392.14118(15) 
40 189.01017(100), 161.01525(55) 
JWH 398 N-pentanoic acid 
metabolite 
10 406.12045(100), 189.01017(18) 
20 189.01017(100), 406.12045(30) 
40 189.01017(100), 161.01525(51) 
JWH 412 
10 360.17582(100) 
20 173.03972(100), 360.17582(85) 
40 173.03972(100), 145.0448(67) 
CP 47,497-C8-homolog C-8-
hydroxy metabolite 
10 
175.11174(100), 331.26316, (70), 
83.08553(37), 157.15869(25), 
81.06988(11), 251.20056(11), 
97.10118(11) 
20   
40   
RCS-4 4-hydroxyphenyl 
metabolite 
10 308.16451(100), 121.02841(12) 
20 121.02841(100), 308.16451(30) 
40 121.02841(100), 93.03349(37), 65.03858(17) 
RCS-4 M10 metabolite 
10 324.15942(100), 121.02841(54) 
20 121.02841(100) 
40 121.02841(100), 93.03349(30), 65.03858(14) 
RCS-4 M11 metabolite 10 322.14377(100), 121.02841(47) 
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20 121.02841(100) 
40 121.02841(100), 93.03349(34), 65.03858(13) 
RCS-4 M9 metabolite 
10 324.15942(100), 121.02841(36), 186.12773(11) 
20 121.02841(100) 
40 121.02841(100), 93.03349(29), 65.03858(12) 
RCS-4 N-(4-hydroxypentyl) 
metabolite 
10 338.17507(100), 135.04406(36) 
20 135.04406(100) 
40 135.04406(100), 77.03858(23), 107.04914(17) 
RCS-4 N-(5-carboxypentyl) 
metabolite 
10 352.15433(100), 135.04406(22) 
20 135.04406(100), 352.15433(21) 
40 135.04406(100), 77.03858(18), 107.04914(16) 
RCS-4 N-(5-hydroxypentyl) 
metabolite 
10 338.17507(100), 135.04406(55) 
20   
40   
5-fluoro NPB-22 
10 233.10836(100), 378.1612(80) 
20 233.10814(100), 213.10145(21) 
40 
145.03926(100), 213.10242(33), 
177.04546(21), 69.06945(20), 
41.03849(10) 
5-fluoro PB-22 
10 232.11323(100) 
20 232.11315(100) 
40 144.04429(100), 232.11317(90) 
5-fluoro PB-22 3-carboxyindole 
metabolite 
10 250.12378(100), 206.13395(40), 118.06513(11) 
20 
118.06513(100), 132.08078(59), 
206.13395(57), 
174.05495(27),130.06513(24), 
232.11322(18), 69.06988(13), 
41.03858(11) 
40   
5-fluoro PB-22 3-
hydroxyquinoline isomer 
10 377.16596(100), 232.11309(34) 
20 232.11315(100) 
40 232.11304(100), 144.04431(90) 
5-fluoro PB-22 4-
hydroxyisoquinoline isomer 
10 377.16711(100), 232.11374(67) 
20 232.11318(100) 
40 232.1138(100), 144.04445(95) 
10 232.11243(100) 
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5-fluoro PB-22 4-
hydroxyquinoline isomer 
20 232.11232(100) 
40 144.04412(100), 232.11246(76) 
5-fluoro PB-22 5-
hydroxyquinoline isomer 
10 377.16595(100), 232.1125(11) 
20 232.11321(100), 377.16592(43) 
40 232.11289(100), 144.04419(85) 
5-fluoro PB-22 6-
hydroxyisoquinoline isomer 
10 377.16711(100), 232.11374(67) 
20 232.11318(100) 
40 232.1138(100), 144.04445(95) 
5-fluoro PB-22 6-
hydroxyquinoline isomer 
10 377.16595(100), 232.1125(11) 
20 232.11321(100), 377.16592(43) 
40 232.11289(100), 144.04419(85) 
5-fluoro PB-22 7-
hydroxyisoquinoline isomer 
10 377.16698(100), 232.11358(51) 
20 232.11358(100) 
40 232.11372(100), 144.0445(86) 
5-fluoro PB-22 7-
hydroxyquinoline isomer 
10 232.11329(100) 
20 232.11319(100) 
40 144.04415(100), 232.11325(96), 212.10664(33), 69.06999(11) 
5-fluoro PB-22 8-
hydroxyisoquinoline isomer 
10 377.16698(100), 232.11358(51) 
20 232.11358(100) 
40 232.11372(100), 144.0445(86) 
5-fluoro PB-22 N-(2-
fluoropentyl) isomer 
10 232.11352(100) 
20 232.11323(100) 
40 232.1137(100), 144.04443(47), 212.10724(14) 
5-fluoro PB-22 N-(3-
fluoropentyl) isomer 
10 232.11355(100) 
20 232.1136(100) 
40 232.11376(100), 144.04443(51), 212.10733(25), 69.06988(14) 
5-fluoro PB-22 N-(4-
fluoropentyl) isomer 
10 232.11329(100) 
20 232.11319(100) 
40 144.04415(100), 232.11325(96), 212.10664(33), 69.06999(11) 
FDU-PB-22 
10 252.08152(100) 
20 252.08145(100), 109.04474(30) 
40 109.04453(100) 
FUB-PB-22 
10 252.08213(100) 
20 252.08184(100), 109.04477(28) 
40 109.0448(100) 
NPB-22 10 215.11752(100), 360.17002(38) 
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20 215.11747(100) 
40 145.03919(100), 215.11746(21) 
PB-22 
10 359.17519(100), 214.12217(12) 
20 214.12233(100), 359.17484(29) 
40 144.04408(100), 214.12205(96), 43.05453(13) 
PB-22 3-carboxyindole 
metabolite 
10 
232.13321(100), 188.14338(53), 
132.08078(28), 118.06513(20), 
231.12538(11) 
20 
118.06513(100), 132.08078(81), 
43.05423(37), 174.05495(29), 
188.14338(25), 214.12264(16), 
130.06513(13), 144.04439(13) 
40   
PB-22 3-hydroxyquinoline 
isomer 
10 359.17547(100), 214.12239(36)  
20 214.12241(100) 
40 144.04418(100), 214.1223(80), 43.0542(14) 
PB-22 4-hydroxyisoquinoline 
isomer 
10 214.1223(100), 359.17495(81) 
20 214.12248(100) 
40 144.04412(100), 214.1222(73), 43.05459(14) 
PB-22 5-hydroxyisoquinoline 
isomer 
10 359.17519(100), 214.12217(12) 
20 214.12233(100), 359.17484(29) 
40 144.04408(100), 214.12205(96), 43.05453(13) 
PB-22 5-hydroxyquinoline 
isomer 
10 359.1754(100), 214.12227(61) 
20 214.12233(100) 
40 144.04407(100), 214.12229(77), 43.05435(15) 
PB-22 6-hydroxyisoquinoline 
isomer 
10 359.17556(100), 214.12238(85) 
20 214.12205(100) 
40 144.04423(100), 214.12237(77), 43.05439(16) 
PB-22 6-hydroxyquinoline 
isomer 
10 359.17514(100), 214.12194(12) 
20 214.12224(100), 359.17481(30) 
40 144.04403(100), 214.12223(90), 43.05439(12) 
PB-22 7-hydroxyisoquinoline 
isomer 
10 359.17523(100), 214.12192(10) 
20 214.12241(100), 359.17512(39) 
40 144.04412(100), 214.12234(90), 43.05456(13) 
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PB-22 7-hydroxyquinoline 
isomer 
10 359.17532(100), 214.12257(97) 
20 214.12234(100) 
40 144.04429(100), 214.12219(79), 43.05455(14) 
PB-22 8-hydroxyisoquinoline 
isomer 
10 359.17532(100), 214.12257(97) 
20 214.12234(100) 
40 144.04429(100), 214.12219(79), 43.05455(14) 
PB-22 N-(4-hydroxypentyl) 
metabolite 
10 230.1175(100) 
20 230.11738(100), 144.04415(12) 
40 144.0441(100), 69.06993(47), 230.11744(15) 
PB-22 N-(5-hydroxypentyl) 
metabolite 
10 230.11732(100) 
20 230.11733(100) 
40 144.04419(100), 230.11707(52), 69.06979(21) 
PB-22 N-pentanoic acid 
metabolite 
10 244.09659(100) 
20 244.09686(100) 
40 
144.04411(100), 244.09588(40), 
55.05422(38), 101.05968(19), 
83.04914(17) 
PB-22 N-pentanoic acid-3-
carboxyindole metabolite 
10 244.09682(100), 200.10699(17) 
20 
244.09682(100), 144.04439(47), 
200.10699(34), 172.11208(32), 
156.08078(26), 55.05423(21), 
101.05971(21), 83.04914(14), 
118.06513(13) 
40   
AM2201 8-quinolinyl 
carboxamide 
10 232.11281(100), 376.18197(34) 
20 232.11268(100) 
40 232.11298(100), 144.04378(97) 
BB-22 
10 240.13795(100) 
20 240.13811(100) 
40 144.04399(100), 240.13784(68), 55.05441(33), 97.10104(11) 
BB-22 3-carboxyindole 
metabolite 
10 258.1487(100), 214.15839(12) 
20 
118.06476(100), 55.05426(74), 
132.08022(51), 176.07002(47), 
214.1601(32) 
40 55.05452(100), 118.06426(41), 91.0538(19) 
10 385.19081(100), 240.13766(23) 
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BB-22 3-hydroxyquinoline 
isomer 
20 240.13806(100), 385.19072(15) 
40   
BB-22 4-hydroxyisoquinoline 
isomer 
10 385.19061(100), 240.13759(71) 
20 240.13787(100) 
40 144.0439(100), 240.13754(83), 55.05427(33), 97.10078(13) 
BB-22 5-hydroxyisoquinoline 
isomer 
10 385.19022(100) 
20 240.13758(100), 385.19022(73) 
40 144.04375(100), 240.13759(95), 55.05409(30), 97.10075(11) 
BB-22 5-hydroxyquinoline 
isomer 
10 385.19058(100), 240.13757(57) 
20 240.13766(100) 
40 144.04389(100), 240.13771(84), 55.05412(33), 97.10106(11) 
BB-22 6-hydroxyisoquinoline 
isomer 
10 385.19059(100), 240.13772(47) 
20 240.13712(100) 
40 144.04395(100), 240.13749(84), 55.05407(31), 97.10096(11) 
BB-22 6-hydroxyquinoline 
isomer 
10 385.1904(100) 
20 385.19046(100), 240.13764(99) 
40 144.04374(100), 240.13785(97), 55.05416(26), 97.10072(11) 
BB-22 7-hydroxyisoquinoline 
isomer 
10 385.1904(100) 
20 385.19046(100), 240.13764(99) 
40 144.04374(100), 240.13785(97), 55.05416(26), 97.10072(11) 
BB-22 7-hydroxyquinoline 
isomer 
10 385.19058(100), 240.13757(57) 
20 240.13766(100) 
40 144.04389(100), 240.13771(84), 55.05412(33), 97.10106(11) 
BB-22 8-hydroxyisoquinoline 
isomer 
10 385.1909(100), 240.13799(54) 
20 240.13781(100) 
40 144.04402(100), 240.138(84), 55.05416(31), 97.10108(13) 
AM2201 2-hydroxyindole 
metabolite 
10 376.17073(100) 
20 
270.09134(100), 358.16017(98), 
376.17073(94), 155.04914(26), 
282.09134(17), 252.08078(16), 
338.15508(12), 172.0393(11) 
196 
   
40 
252.08078(100), 270.09134(59), 
155.04914(13), 172.0393(12), 
127.05423(10), 41.03858(10) 
AM2201 5-hydroxyindole 
metabolite 
10 376.17011(100) 
20 376.17073(100), 155.0486(70), 248.10677(16) 
40 155.04842(100), 127.05373(95), 160.03877(17), 248.10863(14) 
AM2201 6-hydroxyindole 
metabolite 
10 376.16995(100) 
20 155.0484(100), 376.17001(86) 
40 155.04842(100), 127.05364(98) 
AM2201 7-hydroxyindole 
metabolite 
10 232.11279(100) 
20 232.11267(100) 
40 144.04382(100), 232.11275(71) 
AM2201 N-(4-hydroxypentyl) 
metabolite 
10 376.17047(100), 155.04854(11) 
20 155.0488(100), 376.16991(68) 
40 155.04874(100), 127.05393(86), 144.04407(16) 
EAM2201 
10 388.20657(100) 
20 388.20703(100), 183.07974(53), 232.11256(21) 
40 
183.07995(100), 155.08479(48), 
232.11249(30), 144.04395(29), 
153.06945(21) 
NM2201 
10 232.11279(100) 
20 232.11267(100) 
40 144.04382(100), 232.11275(71) 
AM2201 N-(3-chloropentyl) 
isomer 
10 376.14584(100) 
20 376.14585(100), 155.04856(73), 248.08291(18) 
40 155.04848(100), 127.05385(94), 144.04371(11), 212.10635(10) 
MAM2201 N-(2-fluoropentyl) 
isomer 
10 374.19092(100) 
20 374.19136(100), 169.06436(74), 232.11316(32) 
40 169.06435(100), 141.06934(93), 232.11267(32), 144.04394(17) 
MAM2201 N-(3-fluoropentyl) 
isomer 
10 374.19058(100) 
20 374.19113(100), 169.06408(73), 232.11293(25) 
40 169.06415(100), 141.06949(86), 232.11261(25), 144.04376(15) 
197 
   
MAM2201 N-(4-hydroxypentyl) 
metabolite 
10 390.18588(100) 
20 169.06401(100), 390.18626(92), 248.10786(14) 
40 169.06397(100), 141.06913(71), 144.04338(23) 
MAM2201 N-(5-chloropentyl) 
analog 
10 390.16182(100) 
20 390.16184(100), 169.0643(57), 248.08311(21) 
40 169.0643(100), 141.06948(77), 248.08329(21), 144.04415(20) 
MAM2201 N-(5-chloropentyl) 
analog-d5 
10 395.19306(100) 
20 395.19318(100), 169.06417(42), 253.11452(12), 170.07067(11) 
40 
169.0642(100), 141.0695(69), 
170.07058(26), 253.11489(16), 
142.07587(15) 
MAM2201 N-pentanoic acid 
metabolite 
10 386.17497(100), 169.06486(12) 
20 169.06409(100), 386.17501(59), 244.09626(10) 
40 169.06401(100), 141.06942(74), 144.04331(15) 
(±)-UR-144 N-(4-
hydroxypentyl) metabolite 
10 328.22697(100), 125.09588(18) 
20 125.09583(100), 328.22643(24) 
40 
55.05414(100), 125.09539(66), 
57.06983(52), 69.0697(48), 
97.10102(43) 
UR-144 Degradant 
10 312.23111(100), 214.12199(21) 
20 214.12167(100), 312.23172(19) 
40 144.044(100), 214.12215(47), 43.05436(18), 116.04933(11) 
UR-144 Degradant N-pentanoic 
acid metabolite 
10 342.20616(100), 244.09637(15) 
20 244.09646(100), 342.20644(29) 
40 
144.04413(100), 55.05408(52), 
244.09673(36), 101.05909(20), 
83.04897(19) 
UR-144 N-(2-chloropentyl) 
analog 
10 346.19287(100) 
20 346.19308(100), 125.0959(45), 248.08341(19), 328.18257(11) 
40 
55.05415(100), 144.04412(69), 
125.09582(63), 97.10111(42), 
57.06971(40) 
10 328.22705(100) 
198 
   
UR-144 N-(2-hydroxypentyl) 
metabolite 
20 328.22711(100), 125.09568(62), 230.11697(17), 310.21609(12) 
40 
55.05424(100), 144.04439(53), 
125.09598(51), 57.06973(41), 
97.10065(39) 
UR-144 N-(3-chloropentyl) 
analog 
10 346.19293(100) 
20 346.19274(100), 125.09581(43), 248.08341(16) 
40 
55.05419(100), 125.09577(73), 
69.06952(52), 97.10066(46), 
57.07002(43) 
UR-144 N-(4-chloropentyl) 
analog 
10 346.19319(100) 
20 346.19326(100), 125.09576(43), 248.08309(14) 
40 55.05427(100), 125.09559(75), 69.06957(59), 97.101(46), 57.06979(41) 
UR-144 N-(5-bromopentyl) 
analog 
10 390.14256(100) 
20 390.14259(100), 125.09586(31), 292.03295(13) 
40 
55.05432(100), 125.09593(88), 
69.06954(52), 97.10085(50), 
292.03236(44) 
UR-144 N-(5-chloropentyl) 
analog 
10 346.19251(100) 
20 346.19311(100), 125.09577(42), 248.0839(16) 
40 
55.05428(100), 125.09563(65), 
144.04417(44), 97.1009(44), 
57.06973(42) 
UR-144 N-(5-hydroxypentyl) 
metabolite 
10 328.22691(100), 125.09596(27) 
20 125.09581(100), 328.22682(17) 
40 
55.05412(100), 125.09583(69), 
57.06974(48), 97.10075(41), 
69.06929(39) 
UR-144 N-(5-hydroxypentyl) β-
D-Glucuronide 
10 504.25802(100), 328.22683(31), 125.09491(12) 
20   
40   
UR-144 N-pentanoic acid 
metabolite 
10 342.2062(100), 125.09622(11) 
20 125.09588(100), 342.20637(55), 244.09565(13) 
40 
55.05408(100), 125.09563(66), 
97.10091(39), 57.06983(33), 
144.04386(32) 
199 
   
UR-144 N-(5-methylhexyl) 
analog 
10 340.26263(100) 
20 340.26329(100), 125.09567(36), 242.15289(13) 
40 
55.0542(100), 125.09579(79), 
57.06972(61), 144.04445(50), 
97.10105(48) 
UR-144 N-heptyl analog 
10 340.26232(100) 
20 340.26306(100), 125.0958(42), 242.15301(15) 
40 
55.05411(100), 125.0956(73), 
57.06961(61), 144.04446(48), 
97.10088(43) 
FUB-144 
10 350.19059(100) 
20 350.19098(100), 125.09571(51), 109.04444(17), 252.08119(16) 
40 109.04452(100), 55.05414(20), 125.0953(13) 
XLR11 6-hydroxyindole 
metabolite 
10 346.21725(100) 
20 346.21741(100), 125.09575(85), 248.10762(11) 
40 
55.05391(100), 125.09544(68), 
97.10079(44), 57.06956(39), 
69.06901(28) 
XLR11 Degradant 
10 330.22234(100) 
20 330.22269(100), 125.09581(55), 232.11312(26), 312.21194(13) 
40 
55.05432(100), 232.1134(55), 
125.09591(50), 57.06977(43), 
97.10095(35) 
XLR11 N-(2-fluoropentyl) 
isomer 
10 330.22234(100) 
20 330.22269(100), 125.09581(55), 232.11312(26) ,312.21194(13) 
40 
55.05432(100), 232.1134(55), 
125.09591(50), 57.06977(43), 
97.10095(35) 
XLR11 N-(3-fluoropentyl) 
isomer 
10 330.2216(100) 
20 330.2227(100), 125.09588(52), 232.11311(22), 312.21146(11) 
40 
55.05416(100), 125.09562(54), 
232.11309(45), 57.06985(44), 
97.1008(37) 
10 330.22193(100) 
200 
   
XLR11 N-(4-fluoropentyl) 
isomer 
20 330.22271(100), 125.09573(55), 232.11296(19) 
40 
55.05408(100), 125.09551(59), 
144.04421(47), 57.06976(45), 
97.10081(39) 
XLR11 N-(4-hydroxypentyl) 
metabolite 
10 346.21768(100), 248.10834(12) 
20 248.10778(100), 346.21761(41) 
40 144.04379(100), 248.10792(30), 67.05413(19), 87.06026(12) 
XLR11 N-(4-pentenyl) analog 
10 310.21594(100) 
20 
310.21638(100), 125.09583(98), 
212.10656(35), 292.20574(14), 
97.10107(12) 
40 
55.05428(100), 57.07(45), 
125.09567(34),144.04478(34), 
97.10083(31) 
XLR12 
10 352.18872(100) 
20 352.18845(100), 125.09588(34), 254.07835(19), 334.17718(12) 
40 
254.07881(100), 55.05415(90), 
125.09597(61), 144.04426(45), 
97.10076(40) 
Acetyl fentanyl  
10 323.21099(100) 
20 188.14277(100), 323.21137(84), 105.06997(11) 
40 105.06983(100), 188.14296(18) 
Acetyl norfentanyl  
10 219.1482(100), 84.08043(44) 
20 84.08044(100), 56.04947(20), 55.05437(11) 
40 
55.05443(100), 56.04949(55), 
84.08061(25), 42.03397(15), 
94.06508(14) 
Butyryl fentanyl  
10 351.24227(100) 
20 351.24284(100), 188.14289(95) 
40 105.06976(100), 188.14324(33) 
para-Fluorofentanyl  
10 355.21752(100) 
20 355.21766(100), 188.14321(78) 
40 105.06974(100), 188.14301(32) 
AH 7921 
10 329.118(100), 284.06034(23) 
20 
284.06043(100), 172.95501(34), 
46.06524(26), 95.08563(18), 
189.98181(18) 
201 
   
40 
172.95528(100), 95.0855(47), 
46.06533(24), 144.96023(21), 
67.05401(18) 
ATM4 4-acetoxy analog 
10 396.18034(100), 378.16981(33), 354.17022(27), 305.11737(12) 
20 
281.11728(100), 354.16972(76), 
305.11693(58), 249.09069(32), 
323.12785(19) 
40 
221.09551(100), 249.09063(40), 
217.06478(19), 234.06732(17), 
266.09372(15) 
3-hydroxy Phenazepam 
10 364.96869(100) 
20   
40   
Bromazepam 
10 316.00793(100) 
20 
316.008(100), 288.01261(27), 
209.09459(18), 261.00239(13), 
182.083(11) 
40 
182.08334(100), 208.08578(40), 
209.09353(38), 259.99373(30), 
183.97511(19) 
Delorazepam 
10 305.02429(100), 304.28364(10) 
20 305.02423(100) 
40 
140.02671(100), 206.08231(41), 
165.02068(29), 241.05169(26), 
228.0446(26) 
Diclazepam 
10 319.03997(100) 
20 319.03975(100) 
40 
227.04904(100), 154.04173(68), 
125.01521(28), 275.01344(28), 
220.09816(26) 
Etizolam 
10 343.07775(100) 
20 343.07742(100), 314.03804(26) 
40 
314.03875(100), 259.02108(47), 
138.03513(25), 295.07326(23), 
224.05003(23) 
Flubromazepam 
10 333.00333(100) 
20 333.00333(100) 
40 
226.09008(100), 183.97564(86), 
206.08385(47), 105.0573(35), 
179.07295(26), 208.97089(23), 
109.0448(17), 257.99129(17), 
333.00333(16), 104.04948(15), 
202 
   
225.08225(15) ,198.07135(15), 
205.07602(13), 130.05255(12), 
211.07918(10) 
Pyrazolam 
10 354.03416(100), 230.13916(38) 
20 354.03429(100), 230.13921(41) 
40   
1'-naphthoyl-2-methylindole 
10 286.12244(100), 155.04888(18) 
20 155.0491(100), 158.05984(36), 286.12264(18), 127.05433(10) 
40 127.05423(100), 158.05972(19), 155.04895(17) 
5-IT 
10 158.09626(100), 130.065(22) 
20 130.0651(100), 117.05753(47), 158.09621(36), 143.07208(12) 
40 
130.06497(100), 117.05727(81), 
77.03861(48), 103.05426(40), 
115.05401(31) 
6-IT 
10 158.09626(100), 130.065(22) 
20 130.0651(100), 117.05753(47), 158.09621(36), 143.07208(12) 
40 
130.06497(100), 117.05727(81), 
77.03861(48), 103.05426(40), 
115.05401(31) 
A-834735 
10 340.22671(100) 
20 125.09588(100), 340.22724(89) 
40 
55.05402(100), 125.09563(94), 
97.10079(50), 69.06952(47), 
57.06966(41) 
A-834735 degredant  
10 340.22761(100), 242.11781(11) 
20 242.1176(100), 340.22727(54) 
40 
99.08037(100), 242.1172(72), 
69.06995(64), 144.04399(36), 
81.0696(36) 
methyl-1-(5-fluoropentyl)-1H-
indole-3-Carboxylate 
10 264.13943(100), 232.11383(27) 
20 232.1138(100), 144.04486(21), 132.08066(20), 264.13996(12) 
40 
144.0446(100), 130.06485(99), 
117.05733(68), 116.04948(55), 
129.05739(31) 
10 272.16343(100) 
203 
   
methyl-1-(cyclohexylmethyl)-
1H-indole-3-carboxylate 
20 
240.13756(100), 144.04427(71), 
272.16492(64), 190.08472(57), 
176.06989(39) 
40 
55.05439(100), 144.04452(49), 
117.05779(26), 116.04914(25), 
130.06373(22) 
methyl-1-pentyl-1H-indole-3-
Carboxylate 
10 246.14886(100), 214.12264(38) 
20 214.12264(100), 144.04439(36), 132.08078(22), 43.05423(11) 
40   
ADBICA 
10 327.2067(100), 214.12264(69) 
20 214.12264(100) 
40 214.12264(100), 144.04439(85), 43.05423(13) 
ADBICA N-(4-hydroxypentyl) 
metabolite 
10 343.20122(100), 230.11742(67), 360.32389(53) 
20 230.11747(100) 
40 144.04396(100), 69.06932(39), 230.11599(35) 
ADBICA N-(5-hydroxypentyl) 
metabolite 
10 343.20168(100), 230.11757(56), 360.32318(42) 
20 230.11703(100) 
40 144.04409(100), 230.11737(93), 69.0699(21) 
ADBICA N-pentanoic acid 
metabolite 
10 357.18088(100), 244.09682(53) 
20 244.09682(100) 
40 
144.04439(100), 244.09682(95), 
55.05423(33), 101.05971(23), 
83.04914(16) 
AM694 N-(5-hydroxypentyl) 
metabolite 
10 434.0607(100), 230.92931(54) 
20 230.92991(100), 434.06091(12) 
40 230.93002(100), 202.93537(47) 
AM694 N-pentanoic acid 
metabolite  
10 448.03976(100), 230.9297(35) 
20 230.92933(100), 448.03941(25) 
40 230.92981(100), 202.93487(39) 
tetrahydro-Harmine 
10 188.10729(100), 200.10736(72), 217.13204(10) 
20 188.10712(100), 200.10748(38), 173.08421(23),185.08318(12) 
40 
158.06068(100), 145.08847(95), 
130.06534(94), 173.0838(84), 
156.081(54) 
204 
   
5-chloro AB-PINACA 
10 320.152(100), 348.1475(59), 249.07871(10) 
20 249.07813(100), 320.15247(90) 
40 
213.10183(100), 145.0396(67), 
249.07836(46), 69.06954(16), 
193.01531(10) 
5-fluoro ABICA 
10 232.11377(100), 331.18298(91) 
20 232.11365(100) 
40 144.044(100), 232.11323(99) 
5-fluoro AB-PINACA 
10 304.18197(100), 332.17688(66) 
20 233.10847(100), 304.18197(74) 
40 
145.03964(100), 213.10224(77), 
233.10847(56), 177.04587(31), 
69.06988(30), 41.03858(10) 
5-fluoro AB-PINACA N-(4-
hydroxypentyl) metabolite 
10 320.1788(100), 348.17199(71) 
20 249.10329(100), 320.17775(69) 
40   
5-fluoro ADBICA 
10 345.19866(100), 232.11447(55) 
20 232.11392(100) 
40 232.11437(100), 144.0446(56) 
5-fluoro ADB-PINACA 
10 318.19782(100), 346.19342(82) 
20 233.10885(100), 318.19848(94) 
40 
213.10263(100), 233.10929(99), 
145.03971(85), 69.06982(35), 
177.04638(34) 
5-fluoro AMB 
10 364.20455(100), 304.18299(73), 233.10906(27), 332.17759(15) 
20 233.10919(100), 304.18314(41), 213.10265(12) 
40 
145.03985(100), 213.10293(49), 
233.10884(26), 69.06996(24), 
177.04607(23) 
5-fluoro MN-18 
10 233.10904(100), 376.18315(86) 
20 233.1089(100), 213.10218(19) 
40 
145.03998(100), 213.10267(29), 
69.06989(19), 177.04602(19), 
41.03896(11) 
5-fluoro-AKB48 N-(4-
hydroxypentyl) metabolite 
10 400.24064(100), 135.11715(46) 
20 135.11713(100) 
40 135.11701(100) 
5-fluoro-THJ 10 377.1785(100) 
205 
   
20 233.10886(100), 377.17824(39), 359.16801(34), 213.10224(16) 
40 
145.03996(100), 213.10207(41), 
69.06995(20), 177.04614(20), 
359.16849(19) 
AB-005 
10 353.25935(100) 
20 
112.11227(100), 353.25947(84), 
125.09627(56), 98.09656(54), 
256.16996(36) 
40 
98.09672(100), 112.11252(49), 
125.09617(15), 58.0654(14), 
55.05447(11) 
AB-005 azepane isomer 
10 353.25874(100), 112.11208(27) 
20 112.11208(100) 
40 112.11208(100), 58.06513(27) 
AB-CHMINACA 
10 340.20319(100), 312.20749(92), 241.13421(11) 
20 241.13399(100), 312.20783(83) 
40 241.13399(100), 145.03959(97), 55.05414(12) 
AB-FUBINACA 
10 324.15153(100), 352.14816(50), 253.07882(12) 
20 253.07806(100), 324.1513(69) 
40 109.04533(100), 253.07734(26) 
AB-FUBINACA 2-fluorobenzyl 
isomer 
10 324.15178(100), 352.14623(69), 253.07786(14) 
20 253.0776(100), 324.15151(47) 
40 109.04479(100), 253.07769(25) 
AB-FUBINACA 3-fluorobenzyl 
isomer 
10 324.15178(100), 352.14623(69), 253.07786(14) 
20 253.0776(100), 324.15151(47) 
40 109.04479(100), 253.07769(25) 
AB-FUBINACA isomer 1 
10 324.15185(100), 352.14689(48), 253.07617(18) 
20 253.07734(100), 324.15149(33) 
40 109.04494(100), 253.07802(18) 
AB-FUBINACA isomer 2 
10 324.15178(100), 352.14623(69), 253.07786(14) 
20 253.0776(100), 324.15151(47) 
40 109.04479(100), 253.07769(25) 
AB-FUBINACA isomer 5 10 
352.14558(100), 324.15067(29), 
253.07717(15) 
20 253.07717(100), 324.15067(26) 
206 
   
40 109.0448(100), 253.07717(21) 
AB-PINACA 
10 286.19185(100), 314.187(46), 215.11826(16) 
20 215.11781(100), 286.19223(37) 
40 145.03994(100), 215.1182(76) 
AB-PINACA N-(2-
fluoropentyl) isomer 
10 304.18241(100), 332.17836(49), 233.10847(10) 
20 233.10894(100), 304.18257(65) 
40 233.10887(100), 145.03961(39) 
AB-PINACA N-(4-
fluoropentyl) isomer 
10 304.18228(100), 332.17763(56) 
20 233.1088(100), 304.1823(57) 
40 
145.03964(100), 213.10229(90), 
233.10886(80), 69.06993(47), 
177.0455(34) 
AB-PINACA N-(4-
hydroxypentyl) metabolite 
10 302.18699(100), 330.18267(86) 
20 302.18674(100), 231.11332(72), 213.10217(57) 
40 213.1022(100), 145.04073(65), 69.06983(25), 175.04903(18) 
AB-PINACA N-(5-
hydroxypentyl) metabolite 
10 302.18699(100), 330.18267(86) 
20 302.18674(100), 231.11332(72), 213.10217(57) 
40 213.1022(100), 145.04073(65), 69.06983(25), 175.04903(18) 
AB-PINACA pentanoic acid 
metabolite 
10 316.16624(100), 344.16098(71), 360.32446(66) 
20 
316.16593(100), 245.09243(81), 
298.15558(69), 217.0968(38), 
227.07955(21) 
40 
217.09748(100), 227.08192(88), 
199.08861(19), 145.03973(18), 
175.05113(12) 
AKB48 N-(5-fluoropentyl) 
analog 
10 384.24534(100), 135.11694(53) 
20 135.11696(100) 
40 135.11701(100), 93.06999(12) 
MN-18 
10 215.11827(100), 358.19236(52) 
20 215.11816(100) 
40 145.03972(100), 215.11867(23) 
THJ 
10 359.18772(100), 215.1181(15) 
20 215.11811(100), 341.17679(23), 359.18734(18) 
207 
   
40 145.03971(100), 215.1183(33), 341.17646(11) 
THJ 018 
10 215.11829(100), 343.18154(87) 
20 215.11774(100) 
40 145.03956(100), 215.11782(11) 
THJ 2201 
10 361.17225(100), 233.10866(78) 
20 233.10873(100), 213.10228(29) 
40 
145.03963(100), 213.10312(17), 
69.07009(14), 177.04602(13), 
41.03897(12) 
ADB-FUBINACA 
10 338.16723(100), 366.1627(65), 253.07688(11) 
20 253.07754(100), 338.16796(90) 
40 109.04492(100), 253.07694(35) 
ADB-PINACA 
10 300.20752(100), 328.20255(67), 215.11832(11) 
20 215.11821(100), 300.20782(56) 
40 215.11819(100), 145.03969(92) 
ADB-PINACA isomer 1 
10 300.20778(100), 328.20252(82), 215.11795(11) 
20 215.11785(100), 300.20765(58) 
40 215.11816(100), 145.03973(89) 
ADB-PINACA isomer 2 
10 300.20751(100), 328.20283(45), 215.11827(10) 
20 215.11813(100), 300.20756(45) 
40 145.03922(100), 215.11823(90) 
ADB-PINACA isomer 3 
10 300.20769(100), 328.20257(48), 215.11754(17) 
20 215.11823(100), 300.20699(23) 
40 145.03974(100), 215.11786(82) 
ADB-PINACA N-(4-
hydroxypentyl) metabolite 
10 344.19823(100), 316.20279(99) 
20 316.20225(100), 231.11382(90), 213.10295(33) 
40 213.10198(100), 145.03946(64), 69.06984(38), 175.0488(12) 
ADB-PINACA N-(5-
hydroxypentyl) metabolite 
10 344.19704(100), 316.2023(83) 
20 316.20226(100), 231.11287(73), 213.10263(41) 
40 213.10193(100), 145.03951(37), 69.07013(16), 175.05033(13) 
10 330.1825(100), 358.17585(87) 
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ADB-PINACA pentanoic acid 
metabolite 
20 330.18171(100), 245.09227(54), 217.09701(18) 
40 217.09694(100), 227.08119(77), 145.03884(14), 199.08577(13) 
AKB48 N-(4-fluorobenzyl) 
analog 
10 404.21327(100), 135.11683(90) 
20 135.11663(100) 
40 135.11683(100), 93.06988(11) 
AKB48 N-(4-hydroxypentyl) 
metabolite 
10 382.25027(100), 135.11709(39) 
20 135.11698(100) 
40 135.11713(100), 93.07001(12) 
AKB48 N-(5-hydroxypentyl) 
metabolite 
10 382.25008(100), 135.11694(33) 
20 135.1169(100), 382.25017(12) 
40 135.117(100) 
AKB48 N-pentanoic acid 
metabolite 
10 396.22964(100), 135.11735(39) 
20 135.11701(100), 396.22989(10) 
40 135.11694(100), 93.06995(11) 
AMB 
10 346.21373(100), 286.19223(87), 215.11817(48), 314.18695(19) 
20 215.11811(100), 286.1922(19) 
40 145.0399(100), 215.11807(44) 
4-acetoxy DiPT (hydrochloride) 
10 303.2067(100), 114.12773(24), 202.08626(10) 
20 114.12773(100), 160.07569(63), 202.08626(52), 102.12773(10) 
40 
160.07569(100), 132.08078(17), 
72.08078(16), 115.05423(13), 
114.12773(12) 
4-acetoxy DMT (hydrochloride) 
10 247.14467(100), 58.0653(97), 202.08648(32), 160.07558(10) 
20 58.0653(100), 160.07575(53), 202.08604(12) 
40 
58.0653(100), 160.07562(35), 
115.05413(27), 132.08089(14), 
117.05807(11) 
4-hydroxy DET 
10 86.09633(100), 233.16548(40), 160.07596(25) 
20 86.09633(100), 160.07553(63) 
40 
115.05453(100), 86.09669(80), 
160.0759(30), 58.0653(29), 
117.05774(29) 
4-hydroxy DiPT (hydrochloride) 10 261.19643(100), 114.12793(74), 160.07606(34) 
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20 160.07544(100), 114.1279(71) 
40 
115.05463(100), 160.07583(86), 
132.08089(37), 117.05785(30), 
72.08096(20) 
4-hydroxy MET 
10 72.08056(100), 219.14957(30), 160.07585(26) 
20 72.08054(100), 160.07577(54) 
40 
115.05454(100), 72.08087(86), 
44.04976(37), 117.0576(27), 
160.07585(17) 
4-hydroxy MiPT 
10 86.09639(100), 233.16535(55), 160.0758(29) 
20 86.09634(100), 160.07562(77), 44.04969(12) 
40 
115.05444(100), 44.04969(57), 
160.0758(32), 117.05757(28), 
132.08095(22) 
4-methyl-α-Ethyltryptamine 
10 186.12803(100), 144.08101(82), 146.09652(13) 
20 144.08104(100) 
40 
144.08101(100), 143.07364(35), 
115.05462(21), 91.05421(16), 
142.06532(14) 
5-methoxy-α-Ethyltryptamine 
10 202.12275(100), 160.07585(68) 
20 160.07585(100) 
40 117.05757(100), 145.05235(88), 160.07578(42), 130.06483(16) 
DiPT 
10 114.12776(100), 245.20164(80), 144.08122(49) 
20 144.08069(100), 114.12788(59) 
40 
144.08077(100), 117.06917(36), 
143.07304(34), 127.05445(21), 
115.05447(18) 
DPT (hydrochloride) 
10 114.1274(100), 245.20177(41), 144.0808(24) 
20 114.12757(100), 144.08075(80), 86.09646(12) 
40 
144.08086(100), 117.06898(39), 
143.0728(36), 86.09649(28), 
127.05426(23) 
N-Methyltryptamine 
10 144.08056(100), 132.08092(21) 
20 144.08053(100), 132.08102(17), 117.06839(11) 
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40 
115.05437(100), 117.06115(79), 
143.07301(69), 91.05434(65), 
77.03856(32) 
AMT (hydrochloride) 
10 131.06375(100) 
20 
55.0544(100), 131.06379(89), 
59.99032(26), 89.01698(21), 
77.01687(18) 
40 59.99027(100), 55.05438(25), 71.99048(22) 
Methylphenidate 
(hydrochloride) 
10 234.14846(100), 84.08066(62) 
20 84.08044(100) 
40 84.08049(100), 56.04966(21) 
MMAI (hydrochloride) 
10 161.09616(100), 178.12288(10) 
20 
161.09609(100), 105.06997(55), 
146.07258(42), 131.07957(18), 
91.05413(14) 
40 
103.05423(100), 131.04918(51), 
91.05425(41), 77.03853(40), 
115.05446(35) 
Etaqualone 
10 265.13323(100) 
20 265.13338(100), 146.09647(11) 
40 
131.07315(100), 146.09651(97), 
118.06529(44), 130.06553(41), 
105.07006(33) 
Hydroxy Bupropion 
10 238.09923(100) 
20 
238.09962(100), 167.04886(28), 
139.03111(20), 166.04196(19), 
131.07325(14) 
40 
131.07319(100), 103.05449(96), 
130.06542(83), 139.03103(78), 
166.04195(47) 
Levamisole  
10 205.07886(100) 
20 205.07919(100), 178.06849(61) 
40 
91.05434(100), 123.02655(29), 
128.06108(18), 117.06299(17), 
77.03874(16) 
Loperamide  
10 477.23075(100), 266.15462(34) 
20 266.15383(100), 477.23181(21) 
40 266.1543(100), 210.12803(36) 
N-Phenylacetyl-L-prolylglycine 
ethyl ester 
10 188.10741(100), 216.10233(82), 70.06521(34) 
20 70.06517(100), 188.10711(23) 
40 70.06517(100), 91.0545(22) 
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Phenylpiracetam 
10 174.09098(100), 202.08589(24) 
20 174.09129(100), 145.06486(61), 129.06994(46), 117.06928(13) 
40 
117.06935(100), 127.05441(83), 
91.0543(62), 115.05414(46), 
129.07019(45) 
Sildenafil 
10 475.21351(100) 
20 475.2122(100) 
40 58.06502(100), 283.11827(28), 100.09952(22), 99.09134(20.00593) 
Sildenafil Citrate 
10 475.2122(100) 
20 475.2122(100) 
40 58.06513(100), 283.11895(22), 100.0995(20), 99.09167(20) 
Thiosildenafil 
10 491.19018(100) 
20 491.1908(100) 
40 
58.06521(100), 299.09722(47), 
99.09142(29), 100.09958(24), 
341.14216(14) 
Acetildenafil 
10 467.27705(100) 
20 467.27718(100) 
40 
111.092(100), 127.12303(77), 
297.13534(69), 84.08075(66), 
72.08079(57) 
Benzydamine 
10 310.19154(100), 86.09635(48) 
20 86.09617(100) 
40 86.09651(100), 58.06544(76) 
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